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A B S T R A C T
Methods for the determination of the hydroxylation 
of biphenyl in rat liver and the glucuronidation of 
4-methylumbelliferone in rat and rabbit liver preparations 
have been developed by the modification of existing 
methods.
Using these methods, the activities of biphenyl- 
hydroxylase and 4-methylumbelliferone glucuronyl 
transferase and £-nitrobenzoic acid nitroreductase and 
cytochrome P450 have been determined in normal and pregnant 
rats. When expressed per gram o f 'liver,bipheny1-4- 
hydroxylase, 4-methylumbelliferone glucuronyl transferase 
and cytochrome P450 were found to be decreased in the 
livers of 19-20 day, but not 15-16 day, pregnant rats. 
However, liver weight also increased so that the total 
liver content of these parameters was similar to that of 
non-pregnant animals; total microsomal protein and nitro­
reductase activity were increased. Pregnancy did not 
prevent the induction of these parameters with pheno- 
barbitone.
None of these parameters is altered in the full-term 
pregnant rabbit, although the hydroxylation of coumarin 
is decreased.
The action of hexobarbitone in full-term pregnant 
rats is prolonged, confirming the in vitro studies.
The effects of pregnancy on hepatic microsomal 
enzymes could not be reproduced by pretreatment with 
progesterone or oestradiol, alone or combined, though 
both of these endogenous steroids, and also oral contra­
ceptive steroids, inhibited the hydroxylation and 
nitroreductiori in vitro. Pretreatment with high doses 
of chlormadinone, norgestrel, norethynodrel, ethynodiol 
or mestranol for eighteen days, did not alter any of the 
liver parameters, though a single dose of norethynodrel
caused inhibition of biphenyl-4-hydroxylation at one and 
twenty-four hours after dosing. Eighteen days treatment 
with ethynodiol and mestranol combined, increased the 
hydroxylation. Long-term oral administration of a low 
dose of chlormadinone or ethynodiol, but not norethynodrel, 
decreased the hydroxylation but none of the other parameters. 
Pretreatment of rats with oral contraceptive steroids, 
except chlormadinone, decreased the duration of action 
of hexobarbitone in vivo.
A me.thod for the determination of the urinary 
metabolites of phenacetin by gas chromatography has been 
developed by modification of previous methods. ■ The 
pattern of excretion in pregnant and non-pregnant rats 
is similar. Humans on the "pill" possibly excrete more 
unchanged phenacetin and less conjugated U-acetyl-j)- 
aminophenol than controls.
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CHAPTER I
INTRODUCTION
•A. General.Principles of Drug Metabolism
Drugs are compounds that are generally of little 
or no nutritive value to the body, since they cannot 
be utilized for the production of energy or for the 
build up of tissue. They are "foreign" to the major 
metabolic pathways of the body, which are concerned 
with the metabolism of nutrients, and are therefore 
classed as "foreign compounds". They are distinguished 
from other foreign compounds by the fact that they 
produce a pharmacological effect, but as far as the 
body is concerned they are treated the same as all 
other foreign compounds. Since these compounds are 
alien to the body it is necessary for the animal to 
eliminate them as rapidly as possible, otherwise if 
allowed to remain they will accumulate and eventually 
lead to the poisoning of the animal. The body thus 
possesses a defence system which transforms these 
anutrients (as they are otherwise called) so that they 
can be readily excreted. The term "drug metabolism" 
is applied to these transformations that occur. The 
site of these transformations is generally the liver, 
and as a result of them the activity and/or toxicity 
of a compound may be altered.
Apart from drugs, there are present in our 
environment today many foreign compounds which can 
get into the body b y ‘various means. These include 
food additives, such as preservatives, antioxidants, 
sweeteners, flavours and colours, cosmetics, detergents, 
pesticides and industrial chemicals. As far as the body 
and its defence system are concerned, drugs and these 
other classes of compound are treated similarly, and 
therefore the principles of drug metabolism can be 
applied to most foreign substances. Moreover, the
administration of one compound may affect the metabolism 
of another (Fouts, 1964), so it is important to know 
the metabolic interactions of these different classes of 
compound.
The study of drug metabolism and of factors 
affecting it are therefore important since they help to 
understand "what the body does to the drug" as opposed 
to pharmacology which is concerned with "what the drug 
does to the body". (Williams, 1967). Much information 
on this subject prior to 1958 has been covered by 
Williams, R.T., in his book "Detoxication Mechanisms" 
(1959), while more recent information is covered by 
Parke, D.V. in his book "The Biochemistry of Foreign 
Compounds" (1968p.). There have also been numerous 
reviews on the subject, (Williams, I960, 1964, 1965: 
Maynert, 1961: Parke, 1962, 1968 b::Boyland and Booth,1962:
Shuster, 1964: Williams and Parke, 1964).
Metabolic reactions of Drugs and Foreign Compounds
Metabolic reactions of drugs and foreign compounds 
have been classified into two types - Phase I and 
Phase II (Williams, I960). In the first the compound 
undergoes one or more of a variety of oxidations, 
reductions or hydrolyses which result in the introduction 
or unmasking of functional groups which increase the 
polarity of the compound and therefore render it more 
readily excretable. These groups often act as a
centre for the second phase of metabolism in which a
synthetic step occurs so that the compound is conjugated 
with an endogenous molecule. The products of the second 
phase, so-called conjugation products, are usually water 
soluble acids which are easily excreted. The majority 
of phase two conjugations involve glucuronic and 
sulphuric acids, but conjugation with amino acids and 
methyl or other alkyl groups also occurs.
The majority of compounds are metabolised by 
both phases of reaction, for example benzene is chiefly 
metabolized as follows
oxidation conjugation
Benzene -------- >> Phenol ---------- Phenyl glucuronide
phase I phase II
When a compound already possesses a polar group 
it often only undergoes phase two metabolism. Benzoic 
acid is therefore primarily conjugated with glycine and 
glucuronic acid to form hippuric acid and benzoylglucu- 
ronide respectively and only undergoes oxidation to give 
l^drox^benzoic acid to a small extent.
These transformations can influence the pharma­
cological activity and the toxicity of the compounds.
Phase one metabolism may activate or deactivate a drug, 
or alter its toxicity so that it becomes either more 
toxic (intoxication) or less toxic (.detoxication).
Phase two metabolism generally results in deactivation 
of a drug and usually a decrease in toxicity. Examples 
of some of these processes are shown below:-
Phase I Phase II
Phenacetin  **■ p-Acetamido--------- ;— »• p-Acet ami do phenol
Activa- phenol heactiva- ~Grlucuronide 
tion (.active) tion (inactive excretory
product)
Phase I Phase II
Pheno- Hydroxypheno- Hydroxypheno-
barbitone -------- >- barbitone   +- barbitone
Deactiva- glucuronide
(active) tion (inactive) (inactive excretory
product)
However, phase two metabolism can lead to toxic metabolites 
and such a process is termed "lethal synthesis" (Peters 
1952).
Microsomal Drug-metabolizing Enzymes
The metabolic changes described above are, in 
general, brought about by enzymes located in the endo­
plasmic reticulum of the liver, and, to a lesser extent,
other organs such as the lungs, gastrointestinal tract
and kidneys. These enzymes are referred to as
"microsomal" enzymes and they play a major role in the
oxidation and reduction of foreign compounds. There 
are also other enzymes associated with the metabolism 
of foreign compounds which are not associated with 
endoplasmic reticulum. These "non-microsomal" enzymes, 
however, have only a minor role in drug metabolism. 
k  few foreign compounds may also be metabolized by 
some of the normal enzymes of intermediary metabolism 
such as alcohol dehydrogenase and xanthine oxidase.
The endoplasmic reticulum is a lipoprotein, 
tubular network extending throughout the whole of the 
cytoplasm of a cell, and comprises two. major components, 
the rough endoplasmic reticulum (RER) and the smooth 
endoplasmic reticulum (SER). The surface of the former 
is studded with ribosomes which are sites of protein 
synthesis: the latter has no ribosomes. Many, but not 
all, drug-metabolizing enzyme systems are preferentially 
concentrated in the smooth endoplasmic reticulum 
(Orrenius and Ernster, 1964; Gram and Eouts 1967).
Solubilization of the microsomal drug-metabolizing 
enzyme system, necessary for a comprehensive study of 
its characteristics and components, has proved excep­
tionally difficult. However, it is possible to under­
take a preliminary study of the characteristics of these 
systems using homogenized tissue. Centrifugation of 
homogenized tissue in isotonic solution at 10,000 x/:;g 
for ten minutes deposits cell debris, mitochondria 
and nuclei, leaving the endoplasmic reticulum which is 
now broken up into small vesicles and therefore called
microsoraes, in the supernatant.. Further centrifugation 
of this supernatant at 105,000 x/gfor one hour deposits 
the nmicrosomes”, and leaves the soluble fraction as 
supernatant (Mitoma et___al 1956). Dallner (1963) has 
described a method for separating the HER and SER by 
centrifugation. Since the microsomal enzymes have a 
requirement for certain factors (see later) present in 
this soluble fraction, investigations of the enzyme 
activity are usually carried out on the 10,000 x/gsuper­
natant fraction.
The microsomal enzymes do not metabolize endogenous 
compounds such as phenylalanine, 1-t.ryptophan and kynu- 
renine (Mitoma et al 1956) which are hydroxylated by 
specific enzymes in other parts of the cell. They 
generally metabolize lipid-soluble foreign compounds 
(G-audette and Brodie 1959) forming more polar compounds, 
but the latter type compounds themselves can also be 
metabolized by these enzymes (Mazel and Henderson 1965). 
They catalyze reactions involving both oxidation and 
reduction.
Drug Oxidations
All drug oxidations, and that covers a wide range of
reactions, may be classed as hydroxylations (Parke 1968$).
Aromatic hydroxylation
E - c6h5 e - c6h4oh
Acyclic oxidation
E - OH, ___03: R - CHo0H
n  «— — —  I     IftTW
U - dealkylation
R - HHCH, fOl R - NHCHo0H _ RNH„ + HCH05---  S®- c.  s® c.
0 - dealkylation
E - 0 - OH, fOlt E - OCH2OH  EOH + HCH0
Deamination
e"chhh„ foj: En o (oh)eHo e'co + n h ,^   ^ J
R A R
Sulphoxidation o
E - S - R g)K E - S+ (0H)-R   R - S - R + HH
All these reactions have the paradoxical requirement 
for both reduced coenzyme NADPH2 and oxygen (Brodie 
et al 1958). Experiments with ^802 and H ^ O  have 
shown that the oxygen of the hydroxyl group intro­
duced into the foreign compound is derived from 
molecular oxygen and not from water (Mason 1957; 
Hayaishi 1962). It is for this reason that the 
microsomal hydroxylating enzymes have been termed 
"mixed function oxidases", (Mason 1957; 1965).
It has also been shown that the liver microsomes 
contain BADPH2-dependent enzymel. systems which 
hydroxylate various steroid hormones (Conney and 
Klutch 1963; Kuntzman et al 1964). Many similarities 
exist between these enzyme systems and those respon­
sible for drug oxidations (Conney et al 1966; 1968; 
Tephly and Mannering 1968), and it has therefore been 
suggested that these reactions are mediated through 
the same enzymes, and that steroid hormones are 
naturally occurring substrates for drug-metabolizing 
enzymes in liver microsomes (Kuntzman et al 1964).
These findings led Gillette (1962) to suggest 
that microsomal hydroxylation occurs by a coupled 
redox reaction in which HADPH2 reduces a coenzyme which 
then combines with oxygen to form "active oxygen".
This finally reacts with the foreign compound in the
presence of various hydroxylases to give the hydroxy­
lated compound. The postulated sequence is shown 
below:-
1. NADPH + H+ + A  ^ AH2 + NADP
2. AH2 + 02  ^  "Active oxygen"
3. "Active oxygen _______  Oxidized drug + A + HpO
+ drug ^
where A represents a reducible coenzyme.
Cytochrome P450
Gillette (1962) suggested that the reducible 
coenzyme "A" was a microsomal flavoprotein. Later Omura ?- 
and Sato (1962; 1964a) suggested that it was a haemoprotein 
and this was confirmed by Omura et al (1965) who named the 
haemoprotein "cytochrome P450". This cytochrome was 
so-called because of its anomalous spectral behaviour in 
combination with carbon monoxide (CO). In such combina­
tion cytochrome P450 in the reduced form gives a Soret 
peak at 450 nm. Such a CO-binding pigment had been 
first observed in liver microsomes in 1958 (Klingberg; 
Garfinkel).
The concept of the involvement of cytochrome P450 
in the liver microsomal hydroxylating process is based 
on the demonstration that the process is inhibited by 
CO (Orrenius et al 1964) and reactivated by light with 
an action spectrum exhibiting a maximum at 450 nm 
(Cooper et al 1965). In addition, the cytochrome P450 
content of liver microsomes increases parallel to the 
increase in hydroxylating activity of liver microsomes 
upon treatment of animals with barbiturates or carcinogens 
(Orrenius and Ernster 1964; Remmer and Merker 1965;
Ernster and Orrenius 1965).
Although the electron transport system of microsomal 
mixed function oxidases has proved too labile for the 
solubilization or separation (Omura and Sato 1964b) of 
its components, the steroid hydroxylating system of 
beef adrenal cortex', mitochondria has been separated 
into a flavoprotein NADPH2 diaphorase, a non-haem iron 
protein and cytochrome P450 (Omura et al 1966). The 
authors therefore suggested the following electron 
transport system for hepatic microsomal hydroxylations 
(Omura et al 1965)*-
Fe++ P450-*. 
Protein (oxid.)
RCENADPH,
P450-0
Fe+++
Protein
(red)
P450(red)
P450 GO
Kato (1966) accumulated much evidence in support of 
this idea.
Remmer et al (1966) showed, however, that it was 
the oxidised form of cytochrome P4-50 that forms the 
complex with the drug, suggesting that P450 first 
reacts with drugs and is then reduced by NADPHg*
Thus the present view is as follows (Brodie 1967):-
Drug + P450 (ox) ------—  Drug - P450, _„nNADPH2 Drug - P450(re
"■ ' 'p?5<5*'
reductase
^2^ Drug - P450 . 0o Oxidised Drug + P450
  (red) 2------ *" (ox)
Thus cytochrome P450 is a key component of the microsomal 
hydroxylase system. A great deal of attention has been 
focussed on cytochrome P450 in the last five years so it 
is worth considering it in more detail.
The haemoprotein referred to as cytochrome P450 on 
the basis of its reaction with CO also combines in the 
reduced form with ethyl isocyanide (Omura and Sato 1962; 
1964a. ;Imai and Sato 1966^ to give Soret peaks at 430 and 
455 nm. This led Imai and Sato (1966$ to suggest that 
cytochrome P450 existed in two forms in microsomes which 
were in pH-dependent equilibrium. The equilibrium 
between the two forms is also affected by ionic strength 
(Imai and Sato 1968). Treatment of rats with pheno- 
barbitone or the polycyclic hydrocarbon, 3-methyleholan- 
threne (3-MC) increases the apparent concentration of
cytochrome P450. present in liver microsomes (Remmer 
and Merker 1965; Ernster and Orrenius 1965). Using 
ethyl isocyanide as liganddifferences were shown in 
the induction by phenobarbitone and 3-MC, and it was 
suggested that 3-MC treatment causes the formation of 
a new haemoprotein called P-]450 (Sladek and Mannering 
1966; Alvares et al 1967). In further support of 
this idea it was found that the haemoprotein induced 
by phenobarbitone is not the same as that induced by
3-MC,when CO was used as ligand. Thus in the 3-MC 
treatadiimicrosomes there was a shift in absorption 
maximum from 450 nm to 448 nm (Alvares et al 1967; 
Kuntzman et al 1968). Recently treatment with 3-MC 
of male rats has been shown to change the Michaelis 
constant for the hydroxylation of 3,4-benzpyrene, and 
it is possible that this effect is due to a greater 
affinity of 3,4-benzpyrene for the haemoprotein 
preferentially formed in 3-MC-treated rats, (Alvares 
et al 1968; Curtoo et al 1968).
The above considerations posed the question of 
whether a single cytochrome P450 existed in two or 
more spectrally distinguishable forms, or whether two 
or more haemoproteins of the type of cytochrome P450 
are present in microsomesv '.These .oculd be induced by 
various agents and could be specific for substrates 
metabolized in hydroxylation reactions.
Much of the early work was carried out on micro­
somal suspensions using the CO and ethyl isocyanide 
difference spectra. Attempts have been made to 
isolate cytochrome P450 in the active form using 
various techniques, but all have resulted in its con­
version to a spectrally modified form called "cyto­
chrome P420" (Omura and Sato 1964 b; Mason et al 1965) 
which has, however, been solubilized and partly 
purified (Omura and Sato 1964 b). However, various 
techniques have been developed for measuring the
absolute spectrum of cytochrome P450 (Kinoshita 
and Horie 1967; Remmer et al 1968; Miyake ;.et al. ;ui 
"1968; Nishibayashi and Sato 1968) and the results 
obtained have been used to provide further data as 
to whether cytochrome P450 is a single haemoprotein 
or not (Hildebrandt et al 1968; Schenkman et al 1969). 
The absorption spectrum of oxidised P450 has been 
shown to possess a peak at 420 nm and the reduced J? 450 
peak at 408 nm.
In investigations of the absolute spectrum of 
cytochrome P450 in animals pretreated with phenobar.bi- 
tone or 3-MC, different types of spectrum are obtained 
(Hildebrandt et al 1968; Schenkmani et al 1969). 
Hildebrandt et al (1968) suggest that two spectrally 
distinct haemoproteins exist which are interconvertible 
forms of a single haemoprotein. Schenkman et al 
(1969) suggest that one of these forms is the native 
haemoprotein, the other the haemoprotein-substrate- 
complex. However, Kuntzman et al (1968) have shown 
that 3-MC added in vitro, or given to a rat immediately 
prior to killing, does not bring about the spectral 
change caused by 3-MC mentioned above, and therefore 
the binding of 3-MC to the haemoprotein is not respon­
sible. for the changes.
The addition of drugs to liver microsomal prepa­
rations causes changes in the absorption spectrum of 
oxidised cytochrome P450. Remmer et al (1966) and 
Imai and Sato (1966 a) showed that drugs could be 
classified into two groups on the basis of the change 
that they brought about and they called them type I 
and type II. The type I spectral change, characterized 
by a difference spectrum with a trough at 420 nm and a 
peak at 385 - 390 nm, is caused by the addition of 
compounds such as hexobarbitone, aminopyrine and 
phenobarbitone to liver microsomes, while the type II
is characterized by a peak at 430 nm and a trough 
at 390 nm and is brought about by compounds such as 
aniline and nicotinamide. Explanations of these 
two types of binding can be given to fit either theory 
as to the number of microsomal haemoproteins that 
exist, (Mannering et al 1969). Thus two binding 
sites could exist on a single haemoprotein,the 
different drugs combining preferentially with one 
site or the other, or two haemoproteins could exist 
which combine selectively with different drugs.
The problem of whether cytochrome P450 is one 
haemoprotein or more has not,therefore, been solved.
Two schools of thought appear to exist. Kuntzman 
and co-workers- who suggest the existence of more than 
one cytochrome responsible for the oxidation of drugs 
as opposed to Remmer and co-workers who suggest that 
only one cytochrome exists. As to which school of 
thought is correct will probably have to await 
solubilization and characterization of the haemo- 
protein(s) found in normal, phenobarbitone and 3-MC 
treated animals (Kuntzman 1969).
Microsomal Reductions
In addition to the oxidative enzymes, the endo­
plasmic reticulum of the liver contains enzymes that 
reduce drugs. These enzymes catalyze the reduction 
of aromatic nitro and azo compounds to amines (Pouts 
and Brodie 1957; Pouts et al 1957)> The system 
responsible for the reduction of nitro groups can use 
either NADH^ or NADPHg as electron donor, and is active 
under anaerobic conditions, but virtually inactive in 
air (Pouts and Brodie 1957). The nitro-reductase 
system is a flavoprotein, having PAD as its prosthetic 
group, and it was originally suggested that microsomal 
enzymes, e.g. NADPHg-eytochrome c reductase or NADHg- 
cytochrome b^ reductase, reduce PAD to PADHg which
then reduce the nitro group non-enzymically 
♦.(Kamrn.and Gillette, • 1963). Recently (Gillette
et al 1968) it has been suggested, however, that the 
reduction of p-nitrobenzoic acid to p-aminobenzoic 
acid by liver microsomes is mediated by cytochrome 
P450.
Other Metabolic Pathways
Drugs and foreign compounds also undergo various 
non-microsomal metabolic transformations. These 
include non-microsomal enzyme systems such as are 
present in mitochondria, e.g. amine oxidases, and in 
the soluble fraction e.g. alcohol dehydrogenases.
There are also enzymes in the blood and in the intes­
tinal micro flora. There are, finally, many metabolic 
transformations that occur for which the enzymes and 
their locations are as yet unknown. A consideration 
of these enzyme systems is of little importance in the 
present context but mention of their existence serves 
to complete this section on metabolic transformations 
(see Parke 1968a).
Conjugation Reactions
Conjugation with glucuronic acid is probably the 
most important conjugation mechanism and this is. also 
brought about by enzymes located on the endoplasmic 
reticulum,.principally of the liver (Dutton and Storey
1954). The formation of glucuronides is a two-stage 
process involving first the biosynthesis of the 
coenzyme donor, UDPGA, and secondly the transfer of 
the glucuronyl moiety from UDPGA to the aglycone. The 
glucuronylation has been well defined and is shown 
below:-
UDPG +. 2 NAD UDPG UDPGA + 2 NADH2
UDPGA + ROH
dehydrogenase
Glucuronyl
Transferase
r o c 6h 9o 6+ UDP
(Glucuronide)
The first stage, involving oxidation of UDPG,is 
brought about by enzymes located in the supernatant 
fraction of the cell (Strominger et al 1957), but the 
glucuronyl transferases (otherwise known as transglucu- 
ronylases) are microsomal enzymes. Unlike the enzymes 
involved in phase I metabolism, those involved in 
phase II metabolism, including glucuronyl transferases, 
are responsible for conjugating’ endogenous substrates 
(e.g. bilirubin, thyroxine) as well as foreign compounds. 
These enzymes occur mainly in the liver, and to a lesser 
extent in the kidney, gastrointestinal tract and the skin, 
and there is probably a multiplicity of liver microsomal 
glucuronyl transferases.
Glucuronides are classified as O-glucuronides, 
N-glucuronides or S-glucuronides, formed from oxygen, 
nitrogen and sulphur containing compounds respectively. 
O-glucuronides are formed from phehols and alcohols 
(ether-type) and carboxylic acids (ester-type); 
N-glucuronides from amines, and S-glucuronides from 
thiols. Much information about glucuronides and the 
enzymes responsible for their synthesis is given in 
"Glucuronic acid, Pree and Combined11 (Dutton 1966).
The other types of conjugation reactions are sulphate 
conjugation, methylation, acetylation, peptide conjugation 
and glutathione conjugation. These reactions are not 
catalyzed specifically by microsomal enzymes and are in 
general relatively minor routes of metabolism compared 
with glucuronide conjugation. They are therefore not 
mentioned in detail here.
Factors affecting drug metabolism
The activity of the hepatic microsomal drug- 
metabolizing enzymes can be affected by a variety of 
factors resulting in altered metabolism of a compound and 
thereby possibly altered activity or toxicity (Conney and 
Burns 1962; Pouts 1963; Parke 1968b). Increased enzyme
activity resulting from stimulation leads to more rapid 
metabolism which can lead to either an increased or 
decreased duration of action depending on whether 
phase I metabolism activates or deactivates the drug. 
Alternatively decreased enzyme activity resulting from 
inhibition will produce the opposite effect. Phase II 
metabolism always deactivates drugs so that stimulation 
or inhibition of this phase leads to decreased or 
increased duration of action respectively. The factors 
that affect drug metabolism may be genetic, physiological 
or environmental in origin. Such factors include species, 
strain, age, sex, the nutritional state of the animal, 
disease, stress, ingestion of other foreign compounds 
and pregnancy.
Species - the difference in drug metabolism 
between species is well known and is of particular 
importance to the pharmacologist who wishes to extra­
polate data from animals to man. It is now common 
practice to investigate the metabolism of any new 
compound in a number of animal species before it is 
considered for human use. As a result the metabolic 
data of a wide variety of foreign compounds are known in 
quite a large variety of species, and the knowledge has 
been.profitably used in the design of new drugs. Some 
species differences in drug metabolism are qualitative, 
for example the enzyme responsible for the 7-hydroxylation 
of coumarin is found in the liver of the rabbit, guinea 
pig, coypou, cat, hamster and hen, but is absent from 
the liver of rat, mouse and ferret (Greaven et al,1965 a). 
However, detoxication by different mechanisms is rare, 
and therefore most species differences in the metabolism 
of drugs are quantitative. Species differences are also 
known in the effects of other factors on drug metabolism. 
For reviews on species differences see Williams (1959 
and 1964).
Strain - heredity seems to play an important role 
in determining rates of drug metabolism. Many investi­
gators have shown differences in drug metabolism in 
different strains of a given species (Quinn et al 1958; 
Cram et al 1965; Vesell 1968).
Age - the activity of drug-metabolizing enzymes 
is markedly affected by age (Kato et al 1964a). Newborn 
mice, guinea pigs, rabbits and rats lack microsomal 
enzymes, including cytochrome P450 (Kato 1966), which 
oxidatively metabolize drugs. In rats these enzymes 
increase progressively up to the age of thirty days 
and then gradually decrease. Of particular interest 
is the observation of Oreaven et al (1965 b) that 
young rabbits and young rats were able to hydroxylate 
biphenyl in the ortho position as well as the para 
but adult animals of both species were only capable of 
para-hydroxylation. Conjugation reactions are also 
low in young animals. In mouse, rabbit, guinea-pig 
and man glucuronyl transferase activity of the liver 
is low at birth and gradually increases to adult levels 
depending on the species and substrates (Dutton 1963). 
However, in rats the glucuronyl transferase activity 
towards.certain substrates is as high in the newborn 
as in the adult liver (Dutton et al 1964).
Sex - it has long been known that the duration 
and intensity of drug action is often greater in the 
adult female rat than in the adult male (Hoick et al 
1937). Quinn et al (1958) showed this difference was 
due to higher drug-metabolizing enzyme activity in the 
male rat liver than the female. Later workers have 
found similar differences (Kato et al 1962; Schenkman
.9.^. 1967). However, not all metabolic reactions
show a sex difference. Kato and Gillette (1965)
have shown that although the aliphatic hydroxylation 
of hexobarbitone and pentobarbitone and the N-demethy- 
lation of aminopyrine and morphine show sex differences,
the aromatic hydroxylation of aniline and zoxazolamine 
show virtually none. It was suggested that the sex 
differences were due to a balance between male and 
female sex hormones since they appear only at puberty 
and may be abolished by castration. Moreover, 
administration of androgens to female rats increases the 
activities of the microsomal enzymes, while in males the 
opposite effect is brought about by oestrogens (Quinn 
et al 1958; Murphy and Dubois 1958). These sex 
differences in the rat are perhaps not surprising since 
the sex hormones are probably endogenous substrates for 
the microsomal drug-metabolizing enzymes (Kuntzman et al 
1964). The influence of sex hormones, particularly 
female ones will be discussed in' more detail in section B. 
The sex differences in drug-metabolizing enzymes seem to 
be confined mainly to the rat since no such differences 
have been observed in guinea-pigs, rabbits, cats and dogs. 
There does seem to be a sex difference in mice with 
respect .to pentobarbitone and hexobarbitone metabolism 
but the effect is the opposit-e to that observed in the 
rat, (Westfall et al 1964; Novick et al 1966).
Nutrition - the nutritional status of an animal 
can markedly affect the activity of its hepatic micro­
somal enzymes. Metabolism of compounds which show a 
sex dependence such as hexobarbitone and aminopyrine, 
is impaired by starvation in male rats, while aniline 
metabolism, which is independent of sex, is enhanced.
In female rats, though, starvation causes an increase in 
all drug-metabolizing enzymes (Kato and Gillette 1965). 
Refeeding of these animals with a standard diet or 
sucrose diet leads to a marked decrease in enzyme 
activity (Kato 1967). Rats fed on a low.protein’diet'^show 
decreased hepatic drug-metabolizing activities (Kato 
et al 1968) and a decrease in microsomal cytochrome P450 
content (Marshall and McLean 1969). Similarly a diet
deficient in calcium leads to diminished enzyme activity 
(Dingell et al 1966).
Disease - the duration of action of carisoprodol, 
zoxazolamine and pentobarbitone are increased in male 
and female rats bearing abdominal carcinosarcomas 
(Kato et al 1968 a) and this has been shown to be due 
to decreased liver microsomal enzyme activity and 
cytochrome P450 (Kato et al 1968 b). The activity of 
microsomal enzymes in various hepatic tumours is also 
impaired or absent (Adamson and Pouts 1961; Gram et al 
1968). In the situations reported rapid liver growth 
is taking place. Similarly in the newborn animal 
where there is rapid growth taking place the microsomal 
enzymes are lower in activity. It therefore seems
that low levels of drug-metabolizing enzymes are found 
in situations of rapid growth (Conney 1967).
Stress - adverse environmental conditions, i.e. 
stresses, have been shown to affect drug metabolism 
(Pranklin 1969). Exposure -to cold appears to increase 
microsomal metabolism; thus the hydroxylation of 
acetanilide by rat liver microsomes is almost doubled 
on exposure to cold, while that of biphenyl is also 
increased. However, Kalsn^r and Kunig (1969) have 
shown that exposure of rats to 5°Cfor up to seven weeks 
does not alter hexobarbitone metabolism, whereas 
similar exposure at 25°C. increases hexobarbitone 
metabolism.
Hepatic microsomal drug metabolism also follows a 
circadian rhythm. Thus Radzialowski and Bousquet 
(1968) showed that the oxidative metabolism of amino- 
pyrine, p-nitroanisole and hexobarbitone was maximal 
in male rats at 0200 hours and minimal at 1400 hours. 
Plasma corticosterone levels were also shown to follow 
circadian rhythm but the maximum and minimum occurred 
at 1400 hours and 0200 hours respectively, i.e. twelve 
hours out of phase with the metabolism.
Other Foreign Compounds - simultaneous administra­
tion of more than one foreign compound or drug can lead 
to either decreased or increased metabolism of one or 
both of those compounds depending on whether the compounds 
inhibit or stimulate drug-metabolizing enzymes. These 
aspects have therefore received much attention during the 
last decade or so because of the great bearings on drug 
action that they confer.
The stimulatory effect of foreign compounds on 
liver microsomal enzyme activity was first observed by 
Brown, Miller and Miller (1954) after administration of 
polycyclic hydrocarbons to rats and mice. The studies 
were developed further by Conney et al (1956, 1957 a & b) 
and the activation was shown to involve an increase in 
synthesis of drug-metabolizing enzymes. Later, two 
independent groups of workers showed that phenobarbitone 
and a number of other common drugs also acted as inducers 
of drug-metabolizing enzymes (Conney & Burns 1959;
Remmer 1959). Many other compounds have since been shown 
to induce drug-metabolizing enzymes, e.g. phenylbutazone, 
the barbiturates, chlorinated insecticides and many 
carcinogenic polycyclic hydrocarbons (see Conney 1967).
The amount of work done has been sizeable and several 
reviews have been .published (Ernster and Orrenius 1965; 
Remmer 1962; Conney 1967; Kuntzman 1969).
Inducers of drug-metabolizing enzymes are of two 
types exemplified by phenobarbitone and methylcholanthrene. 
Phenobarbitone and similar compounds effect a relatively 
non-specific induction of microsomal enzymes, whereas 
polycyclic hydrocarbons produce a more specified induction 
(Conney 1967). .A fine example of the differential 
stimulation by polycyclic hydrocarbons and phenobarbitone 
is afforded by the observation (Creaven and Parke 1966) 
that in rats and mice 3,4-benzypyrene stimulates the
2-hydroxylation of biphenyl but not its 4-hydroxylation, 
whereas phenobarbitone causes a large increase in
4-hydroxylation but only a small increase in
2-hydroxylation. Pretreatment of rats with pheno­
barbitone causes parallel increases in drug- 
metabolizing activity and cytochrome P450 (Remmer and 
Merker 1965; Ernster and Orrenius 1965). However,
3-MC induces the formation of a microsomal haemoprotein 
with spectral characteristics different from those 
observed in liver microsomes obtained from control or 
phenobarbitone treated rats, (Alvares et al 1967; 
Kuntzman et al 196?). Further differences between 
the effects of phenobarbitone and 3-MC on cytochrome 
P450 have already been discussedv
The changes that accompany drug-induced micro­
somal enzyme synthesis have been well reviewed by 
Orrenius et al (1968). The mechanism of the 
induction of microsomal enzymes by foreign compounds, 
however, is not definitely known. Parke (1968a) 
has suggested that activation of the enzymes which 
metabolize foreign compounds may be due to induction 
of one or more genetic systems by de-repression of an 
operator gene(s). By combining with the repressor 
substance the activator would cause de-repression and 
thus stimulation of messenger RNA synthesis and 
induction of the enzyme system (see fig. 1). How 
the different modes of stimulation of phenobarbitone 
and 3-MC occurs has not been suggested, but since 
that produced by both is abolished by simultaneous 
administration of actinomycin I) (Orrenius et al 1965> 
Gelboih and Blackburn 1964) it would seem that 
activation of the microsomal enzyme systems occurs 
at the level of messenger-RHA synthesis in both cases 
(see Parke 1968$).
Regulator Operator Structural Genes
gene gene SG^ SG2 SG^ SG^
XXIX )0OGOOCOCXIXDQCX Chromosome DNA
Actinomycin 3) inhibits
Messenger ERA
Eepressor Proteins
de-represses
Activating compound
Pig.1 Possible mechanism for the induction of the
hepatic microsomal drug-metabolizing enzymes.
* These proteins could be mixed function oxidases or 
components of the electron transport chain involved in 
microsomal hydroxylation.
An observation of extreme practical importance 
was made by Perguson (1966). He found that mice kept 
on red cedar chip bedding exhibited significant 
reductions in sleeping time when administered hexobarbi­
tone or pentobarbitone sodium. Vessell (1967) showed 
that this effect was produced by a factor in the cedar- 
wood which induced liver microsomal enzymes responsible 
for metabolizing hexobarbitone, aniline and ethylmorphine. 
Wade et al (1968) have since shown that the constituents 
of cedarwood oil, cedrol and cedrene, are inducers of 
drug-metabolizing enzymes.
Several drugs and foreign compounds are known which 
inhibit the microsomal metabolism of foreign compounds
e.g. J3-diethylaminoethyldiphenylpropylacetate hydro­
chloride (SKP 525-A), 2,4 - dichloro-6-phenylphenoxy- 
ethyldiethylamine hydrobromide (Lilly 1947),
2,4-dichloro-6-phenylphenoxyethyl. mine (DPEA), 
iproniazid, imipramine and glutethimide. Not all 
microsomal reactions are inhibited, however. SKP 525-A, 
which is typical of these inhibitors (Gillette 1963), 
for example, inhibits the in vitro oxidation of 
barbiturates, the demethylation of ethylmorphine 
(Anders and Mannering 1966), hydroxylation of aniline 
and glucuronide formation (Ikeda et al 1968), but not 
the hydroxylation of acetanilide (Pouts and Brodie
1955), the sulphoxidation of chlorpromazine (Gillette 
and Kamm I960) or the reduction of nitro - and azo - 
compounds (Gillette 1963). These facts would suggest 
that a variety of inhibitory mechanisms may exist.
However, none of these mechanisms is fully understood.
It has been shown that SKP 525-A inhibits the 
N-demethylation of ethylmorphine in rat liver micro- 
somes competitively, suggesting that SKP 525-A 
combines with the active site of the demethylase as an 
alternative substrate (Anders and Mannering 1966^ . In 
contrast Ikeda et al (1968) showed that the inhibition 
of the hydroxylation of aniline and of the glucuroni- 
dation Of o-aminophenol by SKP 525-A was non­
competitive. Remmer et al (1968) have shown that 
SKP 525-A and DEEA have a much greater affinity than have
aniline,' hexobarbitone or aminopyrine for cytochrome 
P 450' , and they therefore suggest that this explains
their inhibitory actions. Rubin et al (1964) have 
shown that many compounds which are substrates, for 
hepatic microsomal enzymes are competitive inhibitors 
of each other’s metabolism in vitro, while certain 
drugs which are not metabolized did not act as 
inhibitors. The inhibition is presumably due to 
the substrates competing for cytochrome P450. However,
these compounds, unlike SKP 525-A and the other 
inhibitors mentioned above, do not act as inhibitors 
of drug metabolism when given in vivo.
Many compounds which initially inhibit hepatic 
microsomal enzyme systems when given in vivo exhibit 
a stimulating phase later (Kato et al 1964$. Thus 
prolonged administration of SKP 525-A induces micro­
somal enzyme activity by the synthesis of new enzyme 
protein, but both the old and the new enzymes are 
inhibited by a further dose of SKP 525-A (Anders and 
Mannering 1966 b). Similarly the steroid norethynodrel 
has been shown to produce such a biphasic effect on hexobarb­
itone metabolism (Juchau-and:-Pouts 1966).The time for
reversal of action to occur varies from drug to drug 
(Kato. et al 1964), so that with potent activators like 
glutethimide reversal occurs after a shorter period.
Thus, the terms "stimulation" and "inhibition" are 
really only relative, determined by the time interval 
after pretreatment.
The inhibitory and stimulatory effects of foreign 
compounds on the metabolism of other foreign compounds 
often results in changes in toxicity and intensity of 
pharmacological activity. The action of a drug may 
thus be affected by the administration of another drug 
simultaneously. This can either lead to synergism 
or tolerance. In the former a synergist is given along 
with a drug, and depending on whether metabolism 
activates or deactivates the drug, the synergist 
stimulates or inhibits its metabolism so that its 
action is prolonged. The latter, i.e. tolerance, can 
be produced where the action of a drug is reduced, due 
to increased metabolism, either by another compound or 
by the drug itself.
Enzymic considerations
I mentioned earlier that the role of cytochrome 
P450 is now firmly established as the terminal oxidase
in drug oxidations by liver microsomes. Is the total 
amount of cytochrome P450 then the rate limiting step 
of a reaction? If so, in view of all the differences 
described above, one would expect to find large 
variations in the cytochrome P450 content of different 
species, strains etc. Several workers have correlated 
changes in cytochrome P450 content with changes in 
hydroxylase activity (Orrenius and Ernster 1964;
Orrenius et al 1965; Remmer and Merker 1965). However 
all the variations and differences in drug metabolism 
described above cannot be explained on the grounds of 
varying amounts of cytochrome P450 (Remmer et al 1968; 
Kuntzman 1969), since the amount of P450 does not vary 
very much. How then can they be explained? Schenkman 
et al (1967) have shown that the sex difference in 
hexobarbitone and aminopyrine oxidation in rat liver 
is due to a difference in substrate affinity for the 
cytochrome P450 and to a greater maximum extent of 
binding of substrate by the microsomes. However, the 
small sex difference in aniline hydroxylation is due 
to the 20ft difference in cytochrome P450 content.
Remmer et al (1968) have extended this idea to cover 
even wider differences in drug metabolism. However, 
Davies et al (1969) were unable to find any correlation 
between the maximum rates of ethylmorphine dernethylation 
by liver microsomes from various species with magnitude 
of the type I spectral change caused by ethylmorphine 
and therefore concluded that at least in the case of 
ethylmorphine the affinity and binding of the drug to 
cytochrome P450 was not the rate limiting step. They 
found that the demethylation was most closely related 
to the rate of reduction of cytochrome P450. This was 
not the case though with the sex difference in rats, 
and Gigon et al (1969) have since shown that the 
limiting step may well be the rate of reduction of the 
cytochrome P450-substrate complex.
Thus, many factors can influence the metabolism 
of drugs by microsomal enzymes, and since this in 
turn can profoundly influence the duration of action 
and even pharmacological action of a drug, an under­
standing of them is extremely important. There are, 
however, two important omissions from the above 
consideration of the factors affecting drug metabolism. 
They are the effect of pregnancy and the effect of oral 
contraceptives. As these topics form the subject of 
this thesis they are considered more fully in sections 
B and C of this chapter.
B. The Effect of Pregnancy on Drug Metabolism
It has been shown in the previous section that many 
factors can influence the metabolism of drugs resulting 
in altered durations of action or in toxicity. Several 
reports have appeared over the last fifteen years which 
suggest that during pregnancy the metabolism of drugs is 
inhibited, although there do not seem to be many reports 
in the literature of increased pharmacological effect of 
drugs during pregnancy, at least in humans. However, 
Crawford and Rudofsky (1966) have commented that there 
is in informed clinical circles a slowly-growing 
impression that pregnancy in the human imposes a 
modification in the woman’s response to drugs, although 
they do not give any evidence for this.
It is known that pregnancy can influence the activity 
of certain enzymes which are not directly concerned with 
drug metabolism. Thus p-glucuronidase activity is 
increased in rat liver and serum (Bernard and Odell,1950) 
and in human serum (Pishman 1947; Pulkinnen and V/illman, 
1968). Other serum enzymes have been shown to decrease 
in activity during pregnancy in women; acetylcholinesterase 
lactic dehydrogenase and succinic dehydrogenase are all 
thus affected (Vasiliu et al, 1967). The enzyme system 
responsible for conjugating bromsulphthalein with 
glutathione, which is present in the soluble fraction of 
liver preparations, is decreased in activity during the 
last trimester of pregnancy in rats (Combes and Stakehem 
1962).
During pregnancy there is a large increase in 
steroid hormones - oestrogens and progestogens - 
circulating in the blood (Brown, 1956; Short, 1961;
et al, 1962; Nicol et al, 1964; Grota and Eik-nes,1967; 
Hashimoto et al, 1968; Yannone et al, 1968). Several 
studies have shown that these steroids are metabolized by 
NADP^-dependent enzyme systems of liver microsomes
(Conney, 1967) which have many similarities with those 
that oxidise drugs from which it may be inferred that 
steroid hormones are naturally occurring substrates 
for drug-metabolizing enzymes in liver microsomes 
(Murphy and Dubois 1958; Kuntzman et al 1964,1965;
Tephly and Mannering 1968; Conney et al 1968; Lange 
and Thun 1969). If this is the case then it would not 
be surprising if steroids, and therefore pregnancy, 
affect drug metabolism.
Conjugations
Cessi (1952) discovered that the conjugation of 
jo-aminophenol with glucuronic acid in the pregnant 
guinea-pig is about 50$ of that in the non-pregnant 
animal. This could be attributed to the fact that the 
in vitro conjugation in the liver and kidney was 
decreased in the pregnant animal. Later Lathe and 
Walker (1958) showed that conjugation of biliibnbin with 
glucuronic acid by rat liver slices was inhibited by 
serum from pregnant women and new-born infants, but not 
by "normal" human seruitu The conjugation by rabbit and 
monkey liver slices was also inhibited, but to a smaller 
extent. On the suggestion that this inhibition might 
be due to high steroid levels in the'blood, Lathe and 
Walker (1958) investigated the effect of adding various 
steroids to liver slices. In the rat (but not rabbit 
or monkey) liver slices,conjugation of bilirubin was 
inhibited by pregnane- ,20oC -diol, progesterone 
.and pregnanolone but not by testosterone, cortisone or 
oestrogens. However, neither pregnant serum nor any 
of the steroids inhibited conjugation of o^-aminophenol 
with glucuronic acid in liver slices. Although these 
authors found an inhibitory effect of various steroids 
or glucuronide conjugation they did not identify the 
inhibitor present in the "pregnant" serum. This was 
achieved by Hsia et al (i960) who showed that the
inhibition was primarily due to pregnane - 3®<■ - 20*- diol 
and also allo-pregnanetriol and pregnanolone. Several 
other physiologically important progestational steroids 
were also shown to inhibit phenolphthalein conjugation 
by rat liver microsomes (Hsia et al I960). These 
authors, unlike Lathe and Walker (1958), obtained 
inhibition of glucuronide conjugation by rat liver 
microsomes by progesterone using £-aminophenol, 
phenolphthalein and bilirubin as substrates.
Later work by Hsia et al (1963) has shown that 
progesterone, pregnanediol and other progestogens 
decrease the activity of guinea-pig liver glucuronyl 
transferase in vitro using £-aminopheno], £-nitrophenol 
and 4-methylumbelliferone as aglycones. Oestriol and 
testosterone produced a similar effect, but neither 
oestradiol nor oestrone had any effect. Pregnanediol 
was the most potent of the inhibitors.
Recently Lauritzen and Lehmann (1967) have shown 
that administration of oestriol, pregnanediol or 
cortisone, but not progesterone, to new-born infants, 
increased the level of unconjugated bilirubin in the 
blood serum. A similar effect on the suckling infant 
is produced when the hormones are given to the nursing 
mother but in this case progesterone does raise the 
blood bilirubin level. Arias and Gartner (1964) 
demonstrated that the presence of pregnane - 3*, 20 ^ — 
diol in mothers! milk led to hyperbilirubinaemia and 
that administration of it to neonates caused raised 
serum bilirubin levels.
Some of the above information was concerned with 
evaluating the cause of hyperbilirubinaemia in the 
new-born infant, but the evidence does seem to suggest 
that steroid hormones, particularly progestogens, are 
capable of producing profound effects on glucuronide 
formation. It would not be surprising, therefore, if
the inhibition of glucuronide formation during 
pregnancy was attributable to high blood levels of 
progestogens. However, several conflicting reports 
have appeared. Pulkkinen and Rauramo (1963) failed to 
find any inhibition of guinea-pig glucuronyl transferase 
by the addition of serum from pregnant women to micro­
somal preparations of the liver. Prolonged administra­
tion of progesterone or oestradiol to female dogs 
dosed with salicylamide does not affect the blood level 
of the glucuronide (Rauramo et al 1963 a) although 
women given salicylamide during pregnancy have lower 
blood levels of the glucuronide than normal (Rauramo 
et al 1963 b). Hartiala et al (1963) noted, however, 
that not only is the blood level of salicylamide glucuronide 
decreased in pregnancy in rabbits, but so is the blood 
level of the salicylamide itself, and they therefore 
suggest that there is an altered resorption as well as 
an altered detoxication function during pregnancy.
Lessel and Cliffe (1964), studying the metabolism of 
aspirin, noted a similar de-crease in salicylate concen­
trations in the blood during pregnancy in rabbits, but 
not in rats, and suggested that this was due to an 
increased rate of metabolism brought about by the maternal 
hormones and cited the work of Booth and Gillette (1962) 
who showed that some steroid hormones increase the 
activity of drug-metabolizing enzymes. In fact the 
steroids used by Booth and Gillette were male sex 
hormones and the effect was demonstrated in rat liver.
Creaven and Parke (1965) have shown that in pregnant 
rats glucuronide conjugation of dl-borneol in vivo is 
lower than in non-pregnant rats. This they attributed 
to the high level of progestogen present in the blood 
during pregnancy since they showed that pretreatment of 
non-pregnant animals with progesterone led to decreased 
in vivo conjugation of dl-borneol and salicylamide in
rats and rabbits respectively. They also demonstrated 
that the £-aminophenol glucuronyl transferase activity 
of pregnant female rabbit liver microsomes was about 
two-thirds that of non-pregnant rabbits.
Sulphate conjugation of £-nitrophenol is lowered 
during pregnancy in the rat (Pulkkinen 1966). This 
author suggests this is possibly due to the high levels 
of oestrogen, since prolonged administration of oestradiol 
to a rat leads to an inhibition of o-aminophenyl 
glucuronide formation in liver slices. Inscoe and 
Axelrod (i960) had previously shown that oestradiol 
administration to male rats decreased conjugation of 
£-aminophenol with glucuronic acid.
All the above considerations have been concerned 
with conjugation reactions and have shown that the effect 
of pregnancy on these reactions, although a little 
confused by the many variable factors used, e.g. different 
species, different substrates, appears to be one of 
inhibition, brought about by inhibition of the glucuronyl 
transferases of the liver by oestrogenic and/or 
progestogenic steroid hormones.
Metabolic Transformations
The hydroxylation of biphenyl and of coumarin and 
the metabolism of phenacetin and of aminopyrine by 
rabbit liver microsomal preparations are all reduced 
to approximately half the normal values during late 
pregnancy, (Creaven and Parke 1965). A similar decrease 
is observed in the hydroxylation of biphenyl (Creaven 
and Parke 1965) by rat liver during pregnancy. In humans 
the metabolism of the drugs pethidine and promazine is 
decreased during pregnancy (Crawford and Rudofsky 1966). 
This conclusion was based on a study of the pattern of 
urinary excretion of these drugs and their metabolites.
The pregnant subjects (and also neonates) excreted a 
preponderance of unchanged drug over metabolized, whereas
the converse applied in the non-pregnant, The results 
therefore suggest that, the metabolism of pethidine and 
promazine is inhibited during pregnancy (and the 
neonatal period) but do not preclude the possibility 
that some other cause(s) is responsible for the altered 
pattern of excretion. It has been suggested, for 
example, that during pregnancy the oestrogens interfere 
with the transport of certain materials (e.g. sulpho- 
bromophthalein) through the liver cell (Mueller and 
Kappasl964). The processes involved in the metabolism 
of these two drugs are demethylation (of pethidine) 
and oxidation or hydroxylation (of promazine); the 
authors suggest that "it would be unreasonable to 
suppose that these are the only processes of detoxication 
and metabolic degradation to be influenced by changes in 
the environmental concentration of progestogen - oestrogen 
type substances". (Crawford and Rudofsky 1966).
An editorial in the Lancet (1966) on "Pregnancy 
and Drug Metabolism" criticises Crawford and Rudofsky 
for using too few subjects, and points out that the 
variation in excretion was too wide to allow any firm 
conclusions to be drawn. The pH of the urine was not 
controlled even though this has been shown to be very 
important in studies of drug excretion (Milne 1964), 
especially of pethidine. The editorial concludes that 
it is not known whether pregnant women are particularly 
susceptible to pethidine or phenothiazines or not.
The in vitro addition of various steroids to
liver preparations has been shown to inhibit several
metabolic•transformation reactions. Thus it was shown
-7that progesterone at concentrations ranging from 10 
to 10"”%  inhibited the metabolism of lysergic acid 
diethylamide in vitro in male rat liver microsomal 
preparations (Bergen et al 1962). Other steroids to 
show this effect included pregnanediol, oestradiol,
cortisol and testosterone. Similarly oestradiol, 
progesterone and testosterone have been shown to inhibit 
competitively the N-dernethylation of ethylmorphine and 
the oxidation of hexobarbitone by male rat liver micro­
somes in vitro, (Tephly and Mannering 1968). These 
steroids also inhibited the in vitro oxidation of 
chlorpromazine but in this case the steroids were less 
potent inhibitors and the inhibition was not competitive0 
Juchau and Fouts (1966) demonstrated that progesterone 
at concentrations of 10”  ^ and 10”%  markedly inhibited 
in vitro the side-chain oxidation of hexobarbitone, 
ring hydroxylation of zoxazolamine and ^-hydroxylation of 
aniline in immature male rat liver microsomal preparations. 
To a lesser degree it also inhibited the ring hydroxylation 
of 3,4-benzpyrene and the N-demethylation of aminopyrine, 
but it did not appreciably alter the reduction of the 
nitro radical of p-nitrobenzoic acid, the reduction of the 
azo linkage of neoprontosil, the O-demethylation of codeine 
or the metabolism of promazine. Moreover, pretreatment 
of immature male rats with a high dose of progesterone 
1 or 2 hours prior to killing the animals led to a 
decrease in in vitro oxidation of hexobarbitone and 
zoxazolamine but had no effect on the other pathways 
mentioned above. A similar inhibition was noted 
twenty-four and thirty-six hours after a high dose of 
progesterone but between two hours and twenty-four hours 
the level of activity returned to normal (Juchau a n d .
Fouts 1966).
It appears then that metabolic transformation 
reactions may also be inhibited by pregnancy, and that 
it is possible that this effect may be produced by high 
levels of steroids in the maternal blood.
Very recently there have been two reports of impaired 
drug metabolism in pregnancy. Halac and Sicignano (1969) 
have shown that conjugation of bilirubin and £-nitrophenol
with glucuronic acid in vitro by dialysed homogenates 
of rat liver gradually decreases below normal during 
pregnancy. As they were using dialysed homogenates 
they concluded that the decreased conjugation was not 
due to the presence of an inhibitor. Moreover, 
phenobarbitone administration during pregnancy increased 
the activity but not quite to the level induced by 
phenobarbitone in non-pregnant rats. The administration 
of phenobarbitone during pregnancy was not without 
deleterious side effects on the foetuses. Feuer and 
Liscio (1969) have demonstrated that the duration of 
action of pentobarbitone is increased in pregnant rats 
above that of non-pregnant rats v/hen dosed on a weight 
basis. This probably indicates a slower rate of 
metabolism. King et al (1963) had previously reported 
a longer duration of action of pentobarbitone in 
pregnant rats. The hydroxylation of 4-methylcoumarin 
and the conjugation of jo-aminophenol with glucuronic 
acid by rat liver homogenates are inhibited during 
pregnancy (Feuer and Liscio 1969). Pretreatment with 
either 4-methylcoumarin, 3-methylcholanthrene or 
phenobarb.itone induces an increase in the pregnant 
animals but the level of activity is not raised to 
that of induced non-pregnant animals. Induction of 
drug-metabolizing enzymes in the livers of pregnant 
animals had been reported previously (Inscoe and 
Axelrod I960; Pantuck et al 1968) although no inhibition 
in the untreated pregnant livers was noted. Kato et al 
(1968 b) have recently reported that the effect of 
phenobarbitone to increase the activities of microsomal 
drug-metabolizing enzymes is greater in pregnant rats 
than in non-pregnant.
These recent observations seem to confirm previous 
suspicions that drug-metabolism is inhibited during 
pregnancy. Some studies have indicated that the 
hormones of pregnancy cause this effect by inhibiting
the drug-metabolizing enzymes in the liver, while one 
or two studies do not find this to be so. Whether 
these findings in different species can be applied to 
humans or not is not known; there certainly do not seem 
to be many reports of altered quantitative pharmacological 
effect in pregnant humans.
Before leaving the topic'of pregnancy the possible 
role of the placenta and the foetal liver in drug 
metabolism should be mentioned. It is known that the 
placenta plays an important role in the biosynthesis, 
degradation and conjugation of hormones (Dixon and 
Willson 1968), and since there is much evidence to 
suggest that steroids are endogenous substrates for drug- 
metabolizing enzymes (Kuntzman et al 1964; Kuntzman 1969), 
it would not be surprising if the placenta was capable of 
drug metabolism. Moreover drug metabolites are found in 
the foetal circulation suggesting that metabolites 
formed in the liver of the mother traverse the placenta, 
that drugs are metabolized in the placenta, or that 
drugs are metabolized in the foetus (Van Petten et al 
1968). If the placenta and foetus can metabolize 
drugs this might have an effect on the overall metabolism : 
of a drug by the mother.
It has been,established for some time now that the 
ability to metabolize and conjugate various drugs is low 
or absent in the livers of foetal and new-born animals 
(Jondorf et al 1958; Pouts and Adamson 1959; Creaven and 
Parke 1965; Pantuck et al 1968) and this is associated 
with a lack of cytochrome P450 (Kato 1966). Until ' .
recently, however, the placenta has not been 
investigated for drug-metabolizing ability. Rabbit 
placentae were ’found to be able to metabolize zoxazolamine 
but not hexobarbitone (Dixon and Willson 1968); similarly 
no hydroxylation of coumarin or biphenyl was detectable 
in rat and rabbit placentae (Creaven and Parke 1965).
Van Petten et al (1968) demonstrated that the human 
placenta was capable of bringing about the oxidation 
of pentobarbitone, the deamination or hydroxylation 
of amphetamine or the metabolism of meperidine (but not 
by demethylation as in the rat liver), but was not 
capable of demethylating aminopyrine or reducing the 
nitro group of jo-nitrobenzoic acid. Juchau (1969) 
also found that the human placenta did not reduce 
jD-nitrobenzoic acid but this was not the case with 
rabbit and rat placentae. It had earlier been reported 
that the human placenta is capable of reducing azo 
linkages (Juchau et al 1968). The presence of 
cytochrome P450 in microsomal and mitrochondrial sub­
fractions of human term placenta has been reported 
(Meigs and Ryan 1968) and would lend credibility to 
reports of placental drug-metabolizing activity.
Dixon and Willson (1968) attempted to stimulate 
placental drug metabolism by treating the pregnant 
mother rabbits with known inducers of metabolism.
Ohlordane but not phenobarbitone treatment induced 
hexobarbitone metabolism in the placentae. Cigarette 
smoking by pregnant women has been shown to induce the 
hydroxylation of 3,4-benzpyrene by human placenta and 
this is attributable to several polycyclic aromatic 
hydrocarbons present in the smoke since pretreatment of 
pregnant rats with these leads to increased benzpyrene hydroxy 
.lation in the placenta (Welch et al 1968). Attempts 
to stimulate foetal liver metabolism by pretreatment 
with inducers have produced variable results, some 
producing stimulation (Pouts and Hart 1965; Pantuck 
et al 1968) others not, (Dixon and Willson 1968; Peuer 
and Liscio 1969).
The metabolism of drugs by the placenta and foetal 
liver at the present time seems to be rather confused.
They appear able to metabolize some drugs and n o t ’others,
and there are also species differences. Such metabolism 
that does exist may supplement the decreased ability of 
the maternal liver to metabolize foreign compounds and 
drugs. It might be argued that this would be a good 
thing since it protects the foetus from the pharmaco­
logical action of the drug as metabolism usually 
deactivates the drug. On the other hand, some metabolites 
are more active ori more toxic so that placental 
metabolism would represent an increased hazard to the 
foetus. Moreover, metabolites are generally more polar 
than the parent drug, so as a result of placental 
metabolism these may get into the foetal tissues and 
build up to toxic levels since transfer of polar 
compounds across the placental barrier is more difficult.
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C. The Effect of Oral Contraceptive Agents on Drug
Metabolism
Gregory Pincus pioneered the development of oral 
contraception. He originally found that progesterone and 
progestational hormones could inhibit ovulation. Since 
that time, and particularly over the last five years, 
much progress has been made, and nowadays most oral 
contraceptive formulations contain a progestogen and an 
oestrogen (the conventional type), although recently 
oestrogens alone (the sequential type) and progestogen 
alone (the "minipill") have been used. A detailed 
review of oral contraception is not warranted in the 
present context, for this see Tyler (1967), Jackson and 
Schieden (1968), Diczfalusy (1968), Kalman (1969).
The conventional type of "pill" contains a progestogen 
and one or other of the two oestrogens, ethinyloestradiol 
or mestranol. The progestogens fall into two main types, 
those derived from 19-nortestosterone which include 
norethynodrel, norethisterone, lynoestrenol, ethynodiol 
diacetate and norgestrel (a new totally synthetic 
progestogen, Roland, 1966; 0 1Roark et al 1966), and those 
derived from 17oc-hydroxyprogesterone which include 
chlormadinone acetate and megestrol acetate. The first 
type are closely related to the male sex hormone 
testosterone, while the second type are more closely 
related to progesterone (Pig. 1.2). The dosage regime 
for this type of pi'll is one daily for three weeks 
followed by one week without medication.
The sequential formulations consist of oestrogen 
alone and a mixture of oestrogen and progestogen. Por 
the first fortnight of the woman’s cycle the oestrogen 
alone is taken, then for the next week the mixture is 
taken, then as with the conventional type medication is 
stopped for a week.
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Fig. 1, 2 . Types of Progestogen
Type I
OH OH
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Testosterone
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Progesterone
c h ^ o h
Chlormadinone
The '’minipillM or continuous progestogen type of 
oral contraceptive contains a small dose of progestogen 
(at present the two on the market both contain chlormadi­
none acetate) and is taken every day, without any 
interruption, even during menstruation.
There is now a wide range of oral contraceptives on 
the market nearly all of which vary slightly in their 
content, particularly in their overall oestrogen/progestogen 
balance. This balance is very important in determining side 
effects. Whether a "pill" is predominantly progestogenic 
or oestrogenic cannot be inferred from the milligram dosage 
since other factors play a part (Today’s Drugs, 1968). A 
list of oral contraceptives currently on the market is 
shown in Table 1.2, and this also classifies each product 
according to its oestrogen/progestogen balance.
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The mode of action of none of the types of formu­
lation is completely understood. There is evidence 
that "both progestogens and oestrogens inhibit ovulation 
by suppressing pituitary gonadotropin secretion,as 
happens during normal pregnancy,and this led Tyler 
(1964 a) to suggest that the use of oral contraceptives 
leads to a state of metabolic pseudopregnancy. However, 
it has. been found that these hormones prevent conception 
in doses which are below the gonadotropin suppressing 
range, so other hypotheses have been suggested but a 
discussion of these is beyond the scope of this 
introduction, (Holmes and Mandl, 1962 5 Diczfalusy,1968).
However conception is prevented, it is apparent 
that the hormones circulating in the blood are 
responsible, so that the situation resembles that of 
the pregnant woman. One might, therefore, find 
similarities between the effect of pregnancy and oral 
contraception on drug metabolism.
One important point with all present forms of oral 
contraception is that they are taken regularly and for 
long periods of time by large numbers of healthy women.
It is, therefore, extremely important that they produce 
very few side effects and are safe to use. Several 
relatively important effects have been attributed to 
the use of the pill, so before considering the effect 
of oral contraceptives on drug metabolism a brief 
mention should be made of their major side effects.
The question of whether the use of oral contraceptives 
is associated with an increased risk of thromboembolic 
disease is very controversial and has not yet been 
resolved, although it does seem that the risk of thrombo­
embolic disease is certainly not as great during oral 
contraception as during pregnancy. (Swyer 1966;tyorld 
Health Organisation 1966; British Medical Research 
Council 1967; British Committee for the Safety of Drugs,
1968; Drill and Calhoun,1968).
Several reports have appeared which suggest that 
oral contraceptives also cause liver damage (Eisalo 
et al 1964? 1965; Palva and Mustala 1964; Cullberg et al 
1965; larsson-Cohn 1965; Stoll et al 1965; Orellana- 
ALcalde and Dominguez 1966). However, many of these 
reports are isolated cases and other investigations 
have found no evidence that the pill causes liver damage 
(Linthorst 1964; Rice-Wray 1964; Tyler 1964 b). Swyer 
and Little (1965) note that all the reports suggesting 
hepatic impairment come from Scandinavian countries 
where they suggest racial, dietetic or other factors may 
be important. Orellana-Alcalde and Dominguez (1966) 
have reported from Chile, however, fifty cases, over a 
two year period, of cholestatic jaundice associated with 
the use of oral contraceptives, and this bore a close 
resemblance to that observed in cholestatic jaundice of 
pregnancy.
So far there have been few reports of any effects 
of oral contraception on drug metabolism. Crawford 
and Rudofsky (1966) at the same time as studying the 
effect of pregnancy on the metabolism of pethidine and 
promazine in humans also investigated their metabolism 
in subjects taking the pill. They found a similar pattern 
(increased urinary concentration of unmetabolized drug) 
of excretion to that found in pregnancy and therefore 
suggested that the metabolism of these drugs is rendered 
deficient in women taking oral contraceptives.
A very interesting case has been reported by Keeler 
et al (1964) of a thirty-year-old woman receiving 
chlorpromazine treatment for schizophrenia who was 
simultaneously treated for suspected endometriosis with 
a progestogen-oestrogen type medication similar to one 
used for oral contraception. Soon after the hormone 
treatment was commenced the response to the chlorpromazine 
improved, but on subsequent withdrawal of the hormone
- 50 -
therapy the psychotic manifestations again worsened.
Prom this case it appears that the hormone treatment 
increased the effectiveness of the chiorpromazine 
possibly by inhibition of its metabolism.
Little appears to have been done on the effect 
of oral contraceptive steroids on drug-metabolizing 
enzyme systems. Following the suggestion of
Kuntzman et al (1964) that the same hepatic microsomal 
enzyme systems are involved in the metabolism of drugs 
and endogenous steroids, and the finding that several 
naturally occurring steroids competitively inhibit the 
N-demethylation of ethylmorphine in vitro (Tephly and 
Mannering 1964* 1968), Juchau and Pouts (1966) 
investigated the effect of the synthetic progestogen, 
norethynodrel, on hepatic microsomal drug-metabolizing 
enzyme systems of immature male rats. They also 
studied the effect of the oral contraceptive, Enovid 
(the American equivalent of Conovid) on the hydrOxylation 
of hexobarbitone by rat liver. Addition in vitro of 
norethynodrel produced similar results to progesterone 
(see section B) in that pathways involving hydroxylation 
or oxidation were inhibited by concentrations of 10~^Fl, 
but little effect was produced on other pathways of 
metabolism. The nature of the inhibition was competi­
tive. Pretreatment of rats with norethynodrel 
indicated that it acted like, certain other inhibitors 
of drug-metabolizing enzymes in that an initial inhibition 
was followed by stimulation (Kato, Chiesara and Vasanelli 
1964) and this stimulation remained during chronic 
treatment. Prolonged treatment with Enovid, however, 
caused an inhibition of hexobarbitone metabolism in vitro. 
It should be noted that these effects were only brought 
about by very high doses of norethynodrel.
Recently it has been shown that the progestogen, 
medroxyprogesterone acetate, either alone or combined
with ethinyloestradiol, when administered chronically 
to female rats increases the in vitro hydroxylation of 
aniline, O-demethylation of £-nitroanisole and 
N-demethylation of aminopyrine by liver microsomal 
preparations (Jori et al, 1969). However, unlike 
Juchau and Pouts (1966),these authors did not find any 
increase produced by norethynodrel alone, nor a decrease 
v/hen given in combination with mestranol.
Rumke and Noordhoek (1969) have also shov/n that a 
single dose of lynoestrenol given alone,48 hours but 
not 24 or 2 hours- beforehand, enhances the elimination 
of phenobarbitone pLus phenytoin from mouse plasma and 
consequently diminishes their anticonvulsive effect.
The hexobarbitone sleeping time is shortened' and the 
in vitro metabolism of hexobarbitone is accelerated by 
the same pretreatment. The authors suggest that these 
effects may be due to accelerated metabolism of these 
drugs after lynoestrenol treatment.
The few reports of effects of oral contraceptive 
agents on drug.metabolism to date thus show no 
consistent trend. One or two reports suggest that, as 
in pregnancy, there is an inhibition of drug metabolism, 
while others show the reverse or none at all. It is 
very likely that the different steroids, particularly 
the two types of progestogens, produce different 
effects depending more on the way they are metabolized 
than on their pharmacological potency as progestogens 
or oestrogens.
Prom this introduction it can be seen that the amount 
of work that has been carried out on the effect of pregnancy 
and oral contraceptives on drug metabolism is very small. 
Most of the investigations described have been concerned 
with the effect of pregnancy on conjugation reactions. The 
aim, therefore, of the work described in this thesis is to 
investigate more fully the effect of pregnancy on drug
metabolism both at the enzymic level and in the whole 
animal. The possible.causes of the effect of pregnancy 
on drug metabolism in the rat are considered, with 
particular reference to the natural steroids of 
pregnancy. The effect of oral contraception on drug 
metabolism has also been investigated in order to 
determine whether this produces a similar effect to 
pregnancy.
CHAPTER II 
MATERIALS AND METHODS
The materials and methods described in this chapter 
are all concerned with the study of hepatic microsomal 
drug-metabolizing enzymes. Separate chapters are devoted 
to two particular systems - the hydroxylation of biphenyl 
and the glucuronidation of 4-methylumbelliferone - as these 
have been studied in more detail. Hexobarbitone sleeping 
times and the gas chromatography of phenacetin and its 
metabolites are dealt with in their respective chapters.
Materials
Substrates:
p-Nitrobenzoic acid, (B.D.H. Analar G-rade) was used 
as supplied. The substrate solution used in the enzyme 
assay was prepared by dissolving 0.835 g. in Tris (Sigma) 
base solution, then adjusting the pH to 7.6 at 23°C 
with dilute hydrochloric acid and the volume to 500 ml, 
such that the concentration of Tris in the final 
solution was 0.05 M.
Coumarin, (B.D.H.) was recrystallized from water (carbon) 
and was used as a solution of 1 yumole/ml. in 1.15$ W/v 
KCl solution, m.p. 68°C.
4-Methoxybiphenyl and 4-Ethoxybiphenyl (P.J.Creaven,gifts). 
Substrate solutions were prepared by dissolving 36.8 and 
39*6 mg respectively in 2 g. Tween 80, and diluting the 
whole to 100 ml with 1.15$ W/v KCl. Crystals that 
deposited on cooling were redissolved by warming before use.
Standards:
p-Aminobenzoic acid, B.D.H., was recrystallized from 
aqueous ethanol, m.p. 187°C.
7-Hydroxy coumarin (IJmbelliferone) Hopkins &
Williams) was recrystallized from water (carbon) 
m.p. 225°C.
Cofactors:
NADP (Sigma), Glucose-6-phosphoric acid, disodium 
salt (Koch-light), Flavinmononucleotide (Sigma), 
all used as supplied.
Other reagents:
Folin & Ciocalteu's reagent (B.D.H.) used as 
supplied.
Potassium chloride (B.D.H. Analar) was used as a 
1.15% w/v solution.
Phosphate buffer, both 0.1 M and 0.2 M were 
prepared as described by Dawson et al (1959) from 
'Analar' grade sodium dihydrogen phosphate and 
disodium hydrogen phosphate.
Carbon monoxide (British Oxygen Company). However, 
for the majority of Cytochrome P4-50 determinations 
'coal gas' used as a source of CO.
Solvents:
All solvents were obtained from B.D.H. and were 
used as supplied.
Steroids: ± 11 were used as supplied.
Progesterone . *1
(Pregn-4— ene-3,20-dione)
Pregnanediol
(5J5-Pregnane-5^ ,20<X -diol)
Oestradiol
(Oestra-1,3 »5(10)-triene-5, 17^-diol) >Sigma
Oestrone
3-Hydroxyoestra-l,3,5(10)-trien-17-one
Oestriol
(Oestra-1,3*5(10)-triene-3* 16<* , 17p-triol)
Testosterone
(l7J3-hydroxyandrost-4— en-3-one) -
Norethynodrel
(17jB-hydroxy-19-nor-17<* -pregn-5(10)-en-20-yn-3-one
Searle.
Ethynodiol
(l9-Nor~17®* -pregn-4— en-20-yne-3p * 17-diol) •
Searle.
Norgestrel
(13 P -Ethyl-17-hydroxy-18,19-dinor-17^ - 
pregn-4-en-20-yn-3-one): Schering.
Chlormadinone
(S-Chloro-l?0  ^-hydroxypregna-4,6-diene- 
3,20-dione): I.C.I.
Mestranol
(17°^ -Ethynyl-3-methoxyoestra-l,3,5(10)- 
trien-17p~ol): Searle 
Norethisterone
(17p“Hydroxy-19~nor-17^ -pregn-4— en-20- 
yn-3-one): Parke-Davis.
Inducing agents:
Bienobarbitone sodium (B.D.H.) Used as supplied 
Methylcholanthrene (Sigma) Used as supplied.
Animals
A. Rats Two strains of rat were used, Wistar albinos 
and Black-hooded. During the first year of this 
work, carried out at St. Mary’s Hospital Medical 
School, only Wistar albino rats were used and they 
originated from two sources, either Oxfordshire 
Laboratory Animal Colonies or Allington Farm. The 
animals were kept in metal boxes with wire mesh 
floors, there being six to eight in a cage. The 
rats were fed on Diet 41B (Oxoid) and water 
ad libitum, and kept in a room on the fifth floor 
of the medical school along with other admals such 
as ferrets, rabbits, guinea-pigs and chickens.
During the second two years of this work, 
carried out at the University of Surrey, both 
Wistar albino and Black-hooded rats were used, 
although the latter strain was only used occasion­
ally. The rats were bred in the University animal
house, at ground floor level under controlled 
heating and lighting conditions. They were all 
specific pathogen free. The mother rats were 
littered on wood chippings and the young reared 
to weaning (4 weeks) on the same bedding before 
being transferred and maintained in plastic cages, 
six to eight to a cage on 'Steralit'. /The rats 
were fed on Spiller's autoclaved small animal diet 
and water ad libitum, and were kept in a room with 
no other species.
B. Rabbits Only one strain of this species was used, 
namely the New Zealand white. At St. Mary's the 
rabbits were obtained from the same source as the 
rats and were maintained under similar conditions.
At Surrey the rabbits were obtained from Westwood 
Hybrid Table Rabbits Ltd., Plymouth. They were 
housed in individual cages in a room with no other 
animals and were fed on a diet of Dixon's rabbit 
pellets and water ad libitum.
Preparation of Liver Fractions
The species, strain, sex, supplier, age and weight 
of the animals used were routinely recorded, and are given 
in the text where relevant.
Animals were killed by a blow on the head at approxi­
mately the same time of day, i.e. 10 a.m. - 1 hour to 
avoid differences due to diurnal variation (Radzialowski 
and Bousquet 1968). The livers were removed rapidly and 
placed in ice-cold potassium chloride solution (in the 
case of rabbits the gall bladder was removed), chopped 
and weighed. The liver, or a portion of it, was then 
homogenised in a glass homogeniser (diameter 2.4 cm) 
using a loose fitting Teflon pestle (Potter and Elvehjem, 
1936). The pestle was driven by a Black & Decker 
electric drill, and three up and three down strokes were 
employed. The homogenate was then diluted to give a
one in four dilution, i.e. 1 ml of KCl solution 
contained • the equivalent of 250 mg of wet weight 
liver. It was then centrifuged in 50 ml plastic 
centrifuge tubes in an M.S.E. 'High Speed 18' 
refrigerated centrifuge at 1°-4°C at 9,500 r.p.m.
(10,000 xg) for ten minutes. The supernatant was 
carefully decanted and used in most enzyme assays 
as the '10,000 x g  supernatant'. At all times the 
homogenates were kept cool in ice-water.
For the preparation of the microsomal fraction 
an aliquot of the 10,000 x g supernatant was centrifuged 
for one hour in an M.S.E. 'Superspeed 50' in a 10 x 
10 ml. angle head at 40,000 r.p.m. giving an average 
of 105,000:xg in the centre of the tube, at a tempera­
ture between 1°-4°C. The supernatant was carefully 
decanted, the pellet was rinsed with a few drops of 
ice-cold 1.15% KOI to remove adhering supernatant 
fraction, and was then resuspended in the same volume 
of 1.15% KCl by gentle homogenisation. This constitu- 
tuted the 'microsomal suspension'. Exceptionally the 
second centrifugation was carried out at 50,000 r.p.m. 
s 160,000 xg, to bring down the "light" microsomes.
Determination of the nitroreduction of p-nitrobenzoic acid
Nitroreductase activity of liver homogenates was 
measured by following the reduction of £-nitrobenzoic 
acid to p-aminobenzoic acid using the method developed 
by Fouts and Brodie (1957) and modified by Gingell 
(Unpublished). The outline of the method is given below 
as it is as yet unpublished. The incubation mixture 
consisted of 10,000 x g  supernatant (1.0 ml), p-nitro­
benzoic acid substrate solution as described under 
'Materials' (2.0 ml), magnesium chloride (25yumoles), 
glucose-6-phosphate (25//umoles), flavinmononucleotide 
(0.125 yumoles) and NADP (0.25 /umoles) in a total volume 
of 5*0 ml, made up with 1.15% KCl solution.
The incubation was carried out under nitrogen in 
wide side arm glass tubes, stoppered with rubber bungs. 
Oxygen-free nitrogen was fed into the tubes by a needle 
inserted through the rubber stopper, and flowed out to 
the next tube via the side arm. The incubation tubes 
were cooled in iced-water, evacuated and then pre­
flushed with nitrogen for ten minutes, after which time 
they were moved to a Mickel shaking incubator at 37°0 
and incubated for 30 minutes.
The reaction was terminated by immersing the tubes 
in ice-cold water and flushing the system with oxygen for 
one. minute, then adding 1.0 ml of 25% w/v trichloracetic 
acid solution to precipitate the protein. The tubes 
were centrifuged at 2,000 r.p.m. for ten minutes in an 
M.S.E. 'Super Magnum' centrifuge at room temperature.
4.0 ml of the supernatant was taken and used in the 
Bratton and -Marshall (1939) test as follows: 0.5 ml of 0.1% 
freshly prepared sodium nitrite solution was added, the 
tubes were shaken and allowed to stand three minutes, 
after which time 0.5 ml of a 0.5% ammonium sulphamate 
solution was added and the shaking repeated. After a 
further three minutes, shaking was repeated with 0.5 ml 
of 0.1% Bratton-Marshall (1939) reagent (N-(naphthyl)- 
ethylenediamine dihydrochloride). The volume was 
adjusted to 10 ml with water and after standing for 30 
minutes to allow the colour to develop, the optical 
density was measured in a Unicam SP 500 at 5^6 nm.
All tubes were run in triplicate; a blank was run 
adding the substrate after incubation, while standards 
were run in a similar fashion adding both substrate;.and 
standard solution of p-aminobenzoic acid after incubation. 
Recovery of p-aminobenzoic acid was essentially complete 
(98- 4%). The calibration curve for the standards is 
shown in Fig. 2.1.
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Fig, 2. 1. Standard curve for the determination
of p-aminobenzoic acid
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Determination of aromatic hydroxylation
The hydroxylating activity of liver homogenates was 
measured using two systems, namely the hydroxylation of 
coumarin and of hiphenyl. Both systems are found in the 
rabbit, but only the latter is found in the rat. (Creaven 
et al 1965a, 1965b).
A. The coumarin-7-hydroxylase activity of rabbit liver
10.000 x g preparations was determined essentially as 
described by Creaven et al (1965a). The differences were 
as follows: nicotinamide was not added to homogenates;
NADP concentration in each incubation was raised to 0.5 
pnoles; the disodium glucose-6-phosphate was omitted from 
the incubation; and the incubation was carried out in 15 ml 
glass-stoppered test tubes (unstoppered whilst incubating).
B. The biphenyl-4-hydroxylase activity of rabbit liver
10.000 x g supernatant preparations was determined as 
described by Creaven et al (1965b). However, for the 
determination of the activity in rat liver homogenates 
the method described by Creaven et al had to be modified 
quite appreciably, with consequent reappraisal of many 
factors. These are described in chapter three; thus only 
the final method adopted is described here.
Tissue fractions were prepared as described by 
Creaven et al (1965a) except that nicotinamide was not 
added. The incubation mixture consisted of liver
10.000 x g supernatant 0.5 ml. (h 125 mg. of liver), 
biphenyl 3*0yumoles (in 10$ Tween 80), 0.05 M Tris HC1 
buffer pH 8.1, 0.5 ml., magnesium chloride 10 /imoles,
HADP 1.5 yumoles in a total incubation volume of 2.0 ml. 
made up with 1.15$ KCl solution.
The incubation time was 20 minutes. The method 
used for the extraction and estimation of 2- and 4- 
hydroxybiphenyls was similar to that described by
Creaven et al (1965b), the fluorescence being 
measured in a Baird-Atomic Spectrophotofluori meter 
with excitation and fluorescence wavelengths of 511 
and 4-00 nm respectively.
Determination of OTdealkylatipn__ of alkox.ybiphenyls
The dealkylating activity of rat and rabbit liver 
preparations was measured by following the dealkylation 
of 4— methoxybiphenyl and 4— ethoxybiphenyl to 4— hydroxy- 
biphenyl (Creaven et al 1966), which was then extracted 
and estimated as described by Creaven et al. (1965b).
The incubation conditions used for both 4— methoxy 
and 4— exothy biphenyl were as follows: liver 10,000 x g
supernatant 0.5 ml., substrate 1 . 0 /imoles, 0.05 M Tris 
HC1 buffer pH 8.1, 0.5 ml., magnesium chloride 10 pmoles, 
NADP 0.25 yumole.in a total incubation volume of 2.0 ml. 
made up with 1.15% KCl solution. Incubation time was 
20 minutes. The effect of varying substrate concentration 
was determined as this was not stated before (Creaven et al 
1966), and is shown in Fig. 2. 2 and Fig 2. 3*
The extraction and estimation of the 4— hydroxybiphenyl 
was as described by Creaven (1965 b).
Cytochrome P4-50 determination
The following method for the estimation of cytochrome 
P4-50 is based on that described by Sladek and Mannering 
(1966). 6.0 ml. of 0.2 IT phosphate buffer pH 7*^ and a
few crystals of sodium dithionite were added to 3*0 ml. 
of '’microsomal suspension” . After mixing by inversion, 
the mixture was poured into each of two cuvettes, and 
carbon monoxide or coal gas was bubbled through one (the 
sample) for 30 seconds. The second cell was used as 
reference. The difference spectra between the two was 
then traced between 500 and 4-00 nm. using the dual-beam 
Pye-Unicam SP 800 spectrophotometer. The difference in 
absorbance between 4-90 nm and 4-50 nm was measured and the 
cytochrome P4-50 content calculated using the molar
Fig.2. 3- The 'effect of .substrate 'concentration on
,§ the de-ethylation of 4-ethoxy biphenyl by
g rat Oliver 'preparations.
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extinction coefficient of 91 cm”*1' mM”1 as determined 
by Omura and Sato (1964a). A typical trace is shown 
in Fig.2 4. It was found that there was no difference 
obtained between the difference spectrum produced 
whether carbon monoxide or coal gas was used, Pig. 2. 5*
Coal gas was therefore used routinely for the determina­
tion.
Determination of the glucuronidation of 4- meth.ylumbelliferone
The glucuronyl transferase activity of rat and 
rabbit liver preparations was measured using 4-methyl- 
umbelliferone as aglycone. The method was developed 
from that described by Arias et al~ (1958) and the development 
is described in Chapter four. Only the final method 
adopted is described here.
The primary incubation system was as follows:
4— methylumbelliferone 0.6 /umoles, 0.1 M Tris HC1 buffer 
pH 7*6 0.3 ml, UDPGA 2.0yumoles, liver 10,000 x g
supernatant, diluted 1 in 20 immediately before use,
0.2 ml,made up to a total volume of 1.0 ml with 1.15%
KCl.
The incubation was carried out in 20 ml glass- 
stoppered test tubes (unstoppered for incubation) in 
a Mickel shaking incubator, 60 oscillations per minute, 
stroke 3", for 30 minutes. The reaction was terminated 
by placing the tubes in iced-water and adding 2.0 ml 
of ice-cold distilled water. 10 ml of chloroform was 
then added and the tubes shaken in a mechanical shaker 
for 5 minutes. The tubes were then centrifuged* in an 
M.S.E. Super Magnum centrifuge at 2,000 r.p.m. for ten 
minutes at room temperature. The aqueous layer was 
then transferred to a further 10 ml of chloroform - 
and the shaking and centrifuging repeated. Aliquots 
of 0.5 ml of the aqueous layer were then incubated 
for 30 minutes at 37°C in test tubes in a Mickle 
shaking incubator with 1.0 ml of 0.1 M acetate buffer,
pH 5*0 and 500 units of .p-glucuronidase in a total 
volume of 2.0 ml. Similar aliquots were carried 
through the same procedure without■the p-glucuronidase. 
After incubation 5*0 ml of 0.5 M glycine buffer pH 
10.4, was added to each tube and the fluorescence 
determined in an Aminco-Bowman Spectrophotofluorimeter 
or Baird-Atomic Spectrophotofluorimeter, excitation 
wavelengths being 353 hM and 368 nm respectively, and 
fluorescence wavelengths 442 and 450 respectively, all 
wavelengths being instrumental and uncorrected.
The increase in fluorescence following incubation 
with p-glucuronidase was considered to indicate the 
amount of 4-methyl-umb.elliferone conjugated with 
glucuronic acid, in the initial incubation.
Tubes were run in triplicate. Blanks, comprising 
substrate added after the initial incubation, and 
standards of 4-methylumbelliferone glucuronide and 
4-methylumbelliferone were run through the procedure. 
Recoveries and calibration curves are given in Chapter 
four.
Protein determination
The protein concentration of 10,000 £g supernatant 
and microsomal suspensions were determined using a 
modification of the method described by Lowry et al 
(1951). In the case of the 10,000 x g  supernatant,
0.2 ml was diluted to 10 ml with distilled water, while 
with the microsomal suspension 0.5 ml was diluted to 10 ml.
1.0 ml of the diluted solution was then taken for protein 
estimation. Pour reagents were required as follows:-
A. 2.0% v'/v Ua2C0, in 0.1N NaOH
B. 2.0% w/v NaK tartrate
0. 1 %  w/v CuS04 , 5H20
Pig. 2. 6. Standard serum bovine aLbumen curve •
for pTotein determinations
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1.0 ml each of B and C were mixed immediately prior 
to use,with 100 ml of A, and 10 ml of mixture was added to
1.0 ml of diluted protein solution.
After mixing and standing for 15 minutes, 0.5 ml 
of Folin and Ciocalteu’s reagent was added and the 
solutions mixed immediately. After standing 40 minutes 
the optical densities were read at 750 nm in a Pye- 
Unicam SP 500. All samples were run in triplicate.
A blank of distilled water was used together with 
standards (1 ml) of serum bovine albumin containing 
between 50 ^ ig and 500 ^ g. The standard curve for albumen 
is shown in Pig. 2. 6.
Statistics
+All results are expressed.as the mean - standard error 
of the mean. Significance levels were evaluated using the 
Student’s t test.
CHAPTER III
REAPPRAISAL OP THE METHOD FOR 
THE DETERMINATION 
OF BIPHENYL HYDROXYLATION IN
RAT LIVER PREPARATIONS
Introduction
Creaven et al (1965 b) have described a method for 
studying the enzymic hydroxylation of biphenyl by liver 
microsomal preparations from eleven species, using a 
fluorescence method for the estimation of the hydroxy­
lation products 2- and 4-hydroxybiphenyl. The method 
was developed using rabbit liver preparations, and 
while it has been found to be satisfactory for that 
species, I have found that several modifications 
have had to be made to obtain optimal conditions for 
ia vitro hydroxylation of biphenyl by rat liver 
preparations. It was therefore necessary to reappraise 
the method for the determination of bipheny1-4-hydroxy­
lase with rat liver, and these investigations are 
described in this chapter.
Materials
Biphenyl
2-hydroxybipheny1 
4-hy d r oxy b iphp ny1
Succinic acid
Nicotinamide
NA.DP
Disodium glucose- 
6-phosphate
m.p,
m.p
70°c
57 °C
) All purified as 
) described by Bridges 
) et al (1965).Solutions 
) prepared as described 
m.p. 167 C ) by Creaven et al(l965b)
(B.D.H.) recrystallized from water
(B.D.H.) )
)
(Sigma) ) use(j as purchased
)
)(Sigma)
Tween 80, polyoxyethylene sorbitan mono-oleate
(Koch-Light) used as purchased.
Experimental
The original incubation conditions described by 
Creaven were as follows:
0.05 M Tris HC1 buffer pH 8.6 1.0 ml
25% Liver 10,000 x gsupernatant
(containing 10 ^ umoles nicotinamide)1.0 ml 
NADP (0.25.yumole) 0.25-ml
Biphenyl substrate solution 0.5 ml
In a total volume of 2.7 ml.
This incubation was carried out in 25 ml beakers 
for 50 minutes at 37°C in a shaking incubator.
These conditions were at first modified to give 
a total incubation volume of 5*0 ml to allow for the 
additions of various other factors to the incubation.
20 ml glass-stoppered test tubes (unstoppered during 
incubation) were then substituted for 25 ml beakers, 
so that the first extraction into n-heptane could be 
done directly from the incubation container. Neither 
of these modifications produced any significant 
difference in activity to the original conditions.
The remaining modifications involved changing the 
incubation conditions to obtain the optimal conditions 
for rat liver preparations. The following conditions 
were studied: co-factor requirements, optimal period of 
incubation, substrate concentration, enzyme (homogenate) 
concentration and pH of the incubation mixture.
Throughout these experiments the termination and 
extraction procedure used was that used by Creaven et al 
(1965b).
Co-factor Requirements
A • Effect of NADP concentration
Using the original incubation conditions described 
by Creaven et al (1965 b)9and shown under the experimental 
section of this chapter, the variation of biphenyl hydroxy­
lation by female rat liver with increasing NADP coneen-
tration was determined (Table 3 l.A). In order 
effectively to increase the concentration of NADP 
without increasing the amount used, the incubation 
volume was reduced to 2.0 ml, and the effect of 
varying the NADP concentration on biphenyl hydroxy­
lation again determined (Table 3 l.B).
The 2.0 ml incubation conditions used were as 
follows:
0.05 M Tris-HCl buffer pH 8.6 0.5 ml
25% liver 10,000 x :g supernatant 0.5 nil
MgClg solution (50 ^ umoles/ml) 0.2 ml
Biphenyl substrate solution (3 yumoles) 0.25 ml 
NADP (varying amounts) in 1.15% KCl 0.2 ml
1.15% KCl to a total volume of 2.0 ml
The results are shown in Table 3* 1 and are 
illustrated graphically in Pig. 3* 1-
Table 3. 1 
The effect of NADP concentration on the 
the hydroxylation of biphenyl by rat 
liver preparations
NADP added 
^umoles)
Hydroxylase activity in^moles 
product formed/g. liver/hour
A B
0.0 0.15 0.34
0.25 0.40 0.99
0.5 0.70 1.82
0.75 - 2.76
1.00 1.42 3.46
1.5 2.25 3.54
3.0 3.53 3.32
5.0 3-36 3.14—
10.0
_____
1.62 —
A - Original 3*0 ml incubation conditions 
B - 2.0 ml incubation conditions
The same liver homogenate was used in both experiments.
The results are the means of two experiments 
which did not show an y .significant differences.
The results show that the optimum level of 
activity of bipheny1-4— hydroxylase in rat liver 10,000 x g 
supernatant is reached when the concentration of NADP 
in the incubation is in the order of 0.75 mMolar,
i.e. 1.5yumole in a 2.0 ml incubation. A concentra­
tion of 1.5yumoles per incubation was therefore chosen 
to be added routinely.
B. Effect of Glucose-6-Phosphate and Mg4"*'
G-6-P is oxidized by G-6-P dehydrogenase with 
the concomitant reduction of NADP to NADPHg in the prepa­
ration, '‘G-6-P may thus act as a co-factor for the 
hydroxylation of biphenyl; Creaven et al (1965b) 
found, in fact, that activity could be restored to 
rabbit liver microsomes by the addition of G-6-P,
NADP and G-6-P dehydrogenase.
Mg++ is a known stimulator of many enzyme systems 
(Terriere and Chan 1969), so the effect of adding this 
alone and in combination with the G-6-P was tried.
The incubation conditions were as follows:-
0.05 M Tris HC1 buffer pH 8.6 1.0 ml
25% rat liver 10,000 x g  supernatant 1.0 ml
Biphenyl substrate solution (3*0 yumoles) 0.5 ml
NADP (where indicated) 2.5 yumoles in
1.15% KCl 0.2 ml
G-6-P (0.0, 1.0 or 5*0 yumoles)in )
1.15% KCl ' )
MgClp (0.0, 5*0 or 10.0 yumoles)in )
* 1.15 KCl )
ml
Total 3.0 ml
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Fig 3. 1. The effect of NADP concentration on the 
hydroxylation of biphenyl by rat liver 
preparations
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The results of adding G-6-P and lig++ both in the 
absence and presence of NADP are shown in Shble 3* 2.
Table 3. 2
Effect of G-6-P and on the .~bydrox,ylat ion of
hi phenyl b.y rat liver preparations
Additions Yield of 4— hydroxybiphenyl 
(yumol es/g. liv er/hour )
Mg++
(yuatoms)
G-6-P
(yumoles)
NADP
(absent)
NADP 
(present, 2.5 
/umoles)
i
0 0 0.23 3.53
0 1 0.34 3.79
0 5 0.36 3.85
5 0 0.33 3.85
10 0 0.38 4.02
15 0 0.35 3.97
5 1 0.41 3.87
10 . 1 0.45 4.05
The results are the means of three animals, and did not 
differ'by more than - 0.02.
The results show, both in the absence and presence 
of NADP, that G-6-P produces a slight increase in 
hydroxylating activity, and Mg++ produces a slightly 
greater increase. The effects are not additive, the 
increase produced by I1g++ in the presence of G-6-P 
being the same as that of I1g++ alone. It was decided 
therefore to add 10 yumoles of magnesium chloride 
routinely to the standard incubation, but not to add 
any G-6-P.
C. Effect of Nicotinamide
Nicotinamide has been added in many in vitro 
studies of liver microsomal mixed function oxidase 
reactions (Schenkman et al 1967a) to inhibit pyridine 
nucleotidases (Mann and Quastel, 1941) which break 
down NADP (Zatrnan et al 1953) but it does not inhibit 
the pyrophosphatase which destroys NADPH (Gillette, 
1963, Gillette et al 1963). However, in the presence 
of non-limiting concentrations of NADPH, nicotinamide 
has been shown to inhibit several rat liver microsomal 
mixed function oxidases (Schenkman et al 1967a). 
Creaven et al (1965b) added nicotinamide routinely to 
liver homogenates before determining biphenyl 
hydroxylase activity. It was decided, therefore, to 
investigate the effect of varying NADP concentration 
in the absence and presence of nicotinamide.
The incubation conditions employed were as 
follows
0.05 M Tris HC1 buffer pH 8.6 0.5 ml.
25% Hat liver 10,000 x g supernatant 0.5 ml
• Biphenyl substrate solution (3.0 yumoles)0.25 nil.
NADP 1.5 yumoles in 1.15% KCl 0.25. ml.
M g C ^  solution (50yumoles/ml.) 0.2 ml.
1.15% KCl to Total of 2.0 ml.
Nicotinamide where Used was added to the homogenate 
immediately after homogenisation,at a concentration of 
either 1 or 2 mg./ml. homogenate, as indicated.
The results are shown in Table 3*3, and are 
illustrated in Fig. 3*2.
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TabJe 3. 3
Effect of laicotinamide and NADP on the 
.'hydrox.ylation of biphenyl b.y rat liver 
.preparations
Nicotinamide 
added to 
homogenate
I
Hydroxylating activity Qumoles 4- 
hydroxybiphenyl/g.liver/hour) in the 
presence of the following amounts 
^umoles) of NADP
0.0 0.25 0.5 0.75 1*3 4.0
0
1 mg./ml.
2 mg./ml.
0.34
1.58
0.99
2.4-1
2.20
1.54
2.61
2.76
2.71
3*54
2.22
2.04
3*22
1.82
1.63
The results are the mean of three experiments, with 
no significant experimental differences.
The results show that nicotinamide can both enhance 
or inhibit the hydroxylating activity depending on the 
concentration of NADP used. At low concentrations of 
the latter, nicotinamide increases the activity, whereas 
at high NADP concentrations it inhibits the activity.
Because of the possible unpredictable effect of 
nicotinamide it was decided not to add it routinely to 
homogenates, but rather to use higher NADP concentrations.
Optimal Period of Incubation
The rate of production of 4-hydroxybiphenyl was 
determined under various conditions at incubation times 
of 10, 20 and $0 minutes. The results are shown in 
Pig* 3*3 in which A* and 4" represent the original 3 ml. 
incubation conditions but using 1 and 2 yumoles of NADP 
respectively, and represents the revised 2 ml. 
conditions using 4- /umoles of NADP per incubation.
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,Fig. 3*3* Effect of .period of incubation on the 
rate of hydroxylation of biphenyl by rat
liver preparations.
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Effect of Substrate Concentration
The following incubation conditions were employed for 
the investigation of this parameter:
0.05 M Tris HC1 buffer pH 8.6
25% Hat liver 10,000 x g supernatant
NADP, 4 yumoles in 1.15% KOI.
£01, 1.15% solution
Biphenyl solution in Tween 80 in 
1.15% KOI (0.25 - 4. 0 yumoles)
Total
The incubation time was 20 minutes.
The results,shown in 3?able 5*4, indicate that the 
percentage of substrate hydroxylated was maximal at the 
lowest substrate concentrations (0.25 /imole/2 ml. of 
incubation mixture) used, but the maximum yield of 
4-hydroxybiphenyl was obtained with 3*0 yumoles of sub­
strate per incubation. This concentration was, therefore, 
added in the standard procedure.
Table 314.
The effect of substrate concentration on the rate of 
formation of 4-hydrox,ybiphen,yl by rat .liver 10,000 x g
preparations
0.5 nil* 
0.5 ml. 
0.25 ml. 
0.5 ml.
0.25 ml. 
2.0 ml.
Substrate Concen­
tration fyumoles/
2 ml.incubation)
Rate of formation 
of 4-hydroxybiphenyl 
^umoles/g.liver/hr.)
% of Substrate 
Hydroxylated
0.25 0.67 22
0.5 0.92 15
1.0 1.28 11
2.0 1.52 6
3.0 1.92 5
4.0 1.90 4
6.0 1*95 3
The results are the means (S.E.Ii.= 0.05) of three 
experiments.
Effect of Enzyme Concentration
The incubation conditions used for this investi­
gation were the revised 2.0 ml. ones described under the , 
effect of NADP using 1.5 /umoles of NADP per incubation.
The volume of 25% w/v 10,000 x g rat liver supernatant 
added to the incubation mixture was varied and the 
volume made up with 1.15% w/v KC1. The results, 
illustrated in Pig. 3*4, show that the hydroxylating 
activity is linearly related to the amount of 10,000 x:g 
liver supernatant added, up to a volume of 0.75 ml. A 
volume of 0.5 ml. was, therefore, added in the procedure 
finally adopted; this is equivalent to 125 mg. of liver.
Effect of pH
The conditions for incubation used were similar to 
those described in the preceding section, the pH of the 
Tris buffer being varied between 7*7 and 8.7 at 20° C.
The results,illustrated in Pig.3.5,show that the highest 
activity is obtained in the region of pH 8.0 - 8.2.
0.05 M Tris pH 8.1 was therefore used in the standard 
procedure.
The Recovery of 4-H,ydrox.ybiphen,yli_ from Enzymic Incubations
Since the incubation conditions had been altered to 
give an increased production of 4-hydroxybiphenyl, it 
was thought advisable to check the recovery of the product. 
Por this the final 2 ml. incubation conditions were used 
omitting the substrate; 1.0 ml. of standard 4-hydroxy­
biphenyl solution (30/ug/ml. in 5% ethanol) was added 
to the incubation mixture either before or after 
incubation. 0.5 ml. of 2N HC1 and 0.25 ml. of biphenyl 
substrate solution were added at the end of the 20-minute 
incubation period. The comparison of recovery, as 
indicated by fluorimeter reading, of standard added 
before and after the incubation is shown in Table 3*5- 
This also shows the effectyon both the standard and 
'on tlie enzyme incubation, of refluxing in 3N HC1 for 
30 minutes after incubation.
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Table 3. 5
The Recovery of 4-h.ydrox,ybiphenyl from the incubation
medium
Conditions Fluorimete r Reading
Not refluxed Refluxed 
with 3N HC1
Standard added
before
incubation
2.13 3.38
Standard added
after
incubation
3.43 3.43
Normal enzyme 
incubation with 
biphenyl substiate
3.15 2.94
The results show that the recovery of 4-hydroxy- 
biphenyl, added before the incubation is started, is 
less than that added after incubation, and that acid 
hydrolysis restores the recovery to normal. These" results 
suggest that the 4-hydroxybiphenyl is being conjugated, 
and since bacterial ^-glucuronidase added to the 
incubation prevents the decreased recovery (Franklin 
1969) it is suggested that the glucuronide is formed.
The results also show that acid hydrolysis of a normal 
enzyme incubation does not lead to greater amounts of 
free 4-hydroxybiphenyl indicating that 4-hydroxybiphenyl 
formed during the normal enzyme incubation is not 
further metabolized by conjugation. Franklin (1969) 
has similarly shown that addition of bacterial 
^-glucuronidase to the enzyme incubation does not lead 
to an increased production of 4-hydroxybiphenyl. The 
recovery of 4-hydroxybiphenyl from incubations carried 
out under the revised conditions is no different from
that found by Creaven et al (1965b), and is therefore 
satisfactory.
Summary of revised conditions for assay of liver activity
The revised assay procedure for rat liver biphenyl- 
4-hydroxylase activity is, therefore, as follows:-
The incubation conditions:
0.05 M Tris buffer pH 8.1 0.5 ml.
25% liver 10,000 x g supernatant
fraction - no nicotinamide 0.5 ml.
ligCl2 10 /imoles
NADP 1.5 /imoles
Biphenyl 5 /imoles
Tween 80 10 mg.
in 1.15$ 
KOI
1.0 ml.
In a total incubation volume of 2.0 ml.
Incubation period was for 20 minutes at 37°C.
The termination of reaction’and extraction and determi­
nation of 4-hydroxybiphenyl was carried out as described 
by Creaven et al (1965b).
Comparison between Creaven1s method and that devised here.
It has been.shown here that the bipheny1-4- 
hydroxylase activity of rat liver preparations has different 
optimum requirements to that of rabbit liver (Creaven et al 
:(1965b).
The optimum concentration of NADP required for rat 
liver in the incubation medium is 0.75 mM. Thus the 
concentration of NADP (0.1 mM) used by Creaven et al 
(1965b), when studying the activity of rat liver 
preparations was far below optimal. These authors were, 
however, adding nicotinamide routinely to the homogenate, 
even though in fresh rabbit liver preparations the 
nicotinamide produced an inhibiting effect. However, in 
the rat I have shown that at low NADP concentrations
(i.e. the NADP is a limiting factor) nicotinamide 
has a stimulating effect. However, when the NADP 
concentrations are high, such that they are no longer 
limiting, the effect of nicotinamide is inhibiting.
This agrees with the findings of Schenkman et al (1967a) 
on the effect of nicotinamide on aminopyrine demethylation. 
Although nicotinamide stimulated hydroxylation of biphenyl 
at sub-optimal NADP concentrations, it was not possible to 
obtain maximal activity with a mixture of nicotinamide 
and NADP. Maximal activity was. obtained with a minimum 
NADP concentration of 0.75 mM. These findings could thus 
account for the higher activity obtained by Creaven et al 
for rat liver, using 0.25 /amoles NADP, which was 1.2/umoles 
per gm. liver per hour, compared to the 0.4/imoles per 
gm. liver per hour found here for 0.25 /imoles NADP and 
3.5/imoles per gm. liver per hour for 3.0 yumoles NADP.
The finding that G-6-P has very little effect on 
the hydroxylation of biphenyl in vitro is similar to 
that found by Creaven et al.
_i—|.
Mg stimulates some, but not all, microsomal
mixed function'oxidases (Terriere and Chan, 1969) and
is, therefore, added routinely in many assays. It has
been shown here to increase the activity of biphenyl-
4-hydroxylase to a small extent. Creaven et al did not
++
investigate the effect of Mg
It is also shown here that the specific activity 
of rat liver preparations during the time course of 
the hydroxylation of biphenyl decreases when the old 
conditions of incubation are used, (see Pig. 3.3). Cram 
and Pouts (1966),using aminopyrine demethylation, have 
shown a similar decrease in rat liver preparations with 
time, although this does not occur in the liver of rabbits 
or mice. A similar species difference appears to exist 
with the stability of the enzymic hydroxylation of biphenyl. 
This is probably due- to the more rapid breakdown of NADP 
or NADPHg in rat liver.
The optimum substrate concentration for the
hydroxylation of biphenyl by rat liver preparations is 
-31.5 x 10 'll which is slightly less than for rabbit 
liver (2 x 10“"%).
The optimum pH for rat liver biphenyl-4-hydroxylase 
was found to be 8,1 compared v/ith 8.6 for rabbit liver.
As a final step in the comparison of the two methods 
the activity of rabbit liver preparations was compared 
using the old and the new incubation conditions, and 
also using different concentrations of HADP and the old 
conditions of incubation. Those of the former were as 
follows: old conditions, 5.45* new conditions 4*06yumoles 
4-hydroxybiphenyl produced/gm.liver/hour, these results 
being the mean of two animals. The results of the latter 
are shown in Table 3. 6.
Table 5. 6
The effect of HAD? concentration on the hydroxylation 
of biphenvl by rabbit liver preparations
NADP added' 
(yumoles)
Rate of formation of 4-hydroxy­
biphenyl yumoles/gm. liver/hr
Ho nicotinamide Plus nicotinamide 
1 mg/ml
o•o 1.01 3.63
0.25 2,91 5.45
0.5 4.08 5.88
1.0 5.88 5.88
2.0 6.09 5.45
4.0 5.88 5.03
o00 4.61 -
The original 3 ml. conditions were used.
These results show that In the rabbit the 
conditions described by Creaven et al (1965b) give a 
greater enzyme activity than the optimum method for the 
rat described here. They also show that the conditions 
devised by Creaven with respect to NADP and nicotinamide,
i.e. 0.25/imoles of NADP plus nicotinamide, give almost 
maximum results.
Hydroxylation of biphenyl in the 2-position.
Creaven et al (1965b) found no appreciable 
(<0.1 /imoles/gm.liver/hour) hydroxylation of biphenyl 
in the 2-position by liver preparations from adult rats, 
although there was activity in liver preparations from 
young rats (0.5 /imoles/gm.liver/hour). Using the 
revised conditions for 4-hydroxylation and the method 
described by Creaven et al (1965b) for the determination 
of 2- and 4-hydroxybiphenyls in the same mixture, the 
2-hydroxylation of biphenyl by rat liver preparations 
has been re-investigated. No appreciable (< 0.1 /imoles 
2-hydroxybiphenyl/gm.liver/hour) 2-hydroxylation was 
obtained in liver preparations from adult rats. In 
four determinations on liver preparations from young 
rats the extent of 2-hydroxylation ranged from 0.41 
to 0.88 /umoles 2-hydroxybiphenyl formed/gm.liver/hour. 
The results, therefore, agree qualitatively but not 
quantitatively with those obtained by Creaven et al 
(1965b).
Induction of hydroxylation with phenobarbitone
Since the concentration of NADP was found to be 
a critical factor in determining the hydroxylating 
enzyme activity, it was decided to investigate the 
effect of varying NADP concentrations on the biphenyl- 
4-hydroxylase activity of the livers of phenobarbitone- 
pretreat ed rats. Table 5*7 shows the results from 
male Black-hooded rats pretreated daily for three days 
with a dose of 40 mg./kg. i.p.. of phenobarbitone sodium.
The results show that at the level of 1.5 yumoles 
NADP per incubation both the control and pretreated 
liver preparations show-maximal activity. However, the 
percentage induction at different NADP levels is altered 
considerably. It is possible that at such high rates 
of activity some other factor, such as substrate con­
centration, becomes limiting. Alternatively pheno­
barbitone pretreatment might increase the concentration 
of NADP in the liver either directly or indirectly, for 
example by a more rapid regeneration of NADPH due to the 
enzymes involved in this reaction being induced as well, 
(Ernster and Orrenius 1965).
Table. 5. 7
The effect of NADP concentration on the 
biphenyl-^— hydroxylase activity of the 
livers of phenobarbitone pretreated male
rats
'.NADP .. - 
added ' 
^umoles)
Activity umoles/g.liver/ 
hr.
%
Induction
Controls Pretreat ed
0.25 0.95 3.62 281
0.75 3.23 7.24 124
1.50 . 4.78 7.83 64
3.00 4.37 7.32 68
These findings emphasize the importance of standard­
izing conditions when undertaking this kind of experiment, 
since one may obtain varying results with varying 
conditions, e.g. in this example if the NADP concentra­
tions were not exactly defined one may obtain as much 
as a four-fold difference in amount of induction.
Conclusion
The results obtained in this chapter show that 
the optimum conditions for the determination of the 
hydroxylation of biphenyl by rat liver microsomal 
preparations differ from the optimum conditions for 
rabbit liver microsomal preparations as previously 
determined by Creaven et al (1965b). As a result a 
revised system has been devised for determining the 
hydroxylation of biphenyl by rat liver microsomal 
preparations. The details of this sjsbem are given 
in Chapter two.
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CHAPTER IV
DEVELOPMENT AND INVESTIGATION OF 
4-MEPHYLUMBELLIEERONE GLUCURONYL TRANSFERASE 
DETERMINATION IN RAT AND RABBIT LIVER PREPARATIONS
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Introduction
Many substrates have been used for determining 
the activity of glucuronyl transferase in various 
tissues. The most common are q-aminophenol, p-nitro- 
phenol and phenolphthalein (Dutton 1966). All these 
procedures are based on colorimetric determinations 
either of the product or of the decrease in substrate 
concentration. The estimation of glucuronyl 
transferase using 4-methylumbelliferone (4— MU) as 
substrate is, however, based on fluorimetry, a far more 
sensitive procedure than colorimetry, and for this 
reason was used as the method, of choice. Since this 
method is . more suitable for tissue which is high 
in glucuronyl transferase activity per unit of protein, 
it is particularly suited to use on liver preparations.
This method has been used by several workers using 
different tissues, (Arias 1962, - human liver; Taketa 
1962, - mouse liver; Bollet et al, 1959 - rat stomach mucosa) 
but none appears to have investigated in detail the 
characteristics of the enzyme -using 4-MU as 
substrate in rat liver preparations.
The method is similar to that devised by Arias 
(1962) for human liver and is based on the fact that 
4—  I1U is highly fluorescent while its glucuronide is 
non-fluorescent. After initially incubating 4-MU
with uridine diphosphate glucuronic acid (UpPG-A) and liver 
homogenate the mixture is washed with chloroform to 
denature protein and to extract unconjugated 4-MU 
without removing the glucuronide. 4-MU is liberated 
from its conjugate by further incubation with 
p-glucuronidase (Mead et al 1955) and the subsequent 
increase in fluorescence is taken as a measure of 
original glucuronyl transferase activity. The method 
described by Arias (1962) was found unsatisfactory for 
rat liver, the chief reason being that a greater -amount of
UDPGA is required. It has been reported (Dutton 1966) 
that rat liver has a high requirement for UDPGA in 
in vitro determinations of glucuronyl transferase activity 
because of the rapid breakdown of the coenzyme by pyro­
phosphatase activity. However, since rats were to be 
used as the experimental animal in the study of other 
enzymes it was necessary to use rats for the measurement 
of glucuronyl transferase. Therefore the characteristics 
of 4-MU glucuronyl transferase in rats were determined, 
and the findings are described in this chapter.
Materials
4-Methylumbelliferone (Koch-Light)' was re-crystallised 
as described by Mead et al (1955). The substrate solution 
for the final standard procedure was prepared by 
dissolving 35#2 mg of the recrystallised substrate in 
100 ml. of 1.15$ W/v KC1 solution.
4-Methylumbelliferone glucuronide was prepared as 
described by Woollen and Walker (1965) from acetobromo- 
methylglucuronate and 4-methylumbelliferone• The 
acetobromomethyl glucuronate was prepared as described 
by Bollenback et al (1955).
Uridine diphosphate glucuronic acid (UDPGA), 
uridine diphosphate glucose (UDPG), NAD, NADP (all from 
Sigma) were used as supplied. Glucuronic acid, ATP, ADP,
AMP (all from B.D.II.) were used as supplied, p-glucuronidase 
(Sigma) prepared from bovine liver had a pH optimum of 5.
Tris buffer 0.1 M pH 7*6 )
a t  tj/ic \ prepared as described Acetate buffer 0.1 m pH 4.6 ) £y £awson et al (lg59)
Glycine buffer 0.5 M pH 10.4 )
Methods and Results
Adult female Wistar albino rats weighing 150-200 g. 
were used in all experiments unless otherwise stated.
Each animal was killed by cervical dislocation after an 
initial stunning. The liver was immediately removed
and placed in ice-cold 1.15% W/v KOI solution, then 
homogenised in a Potter-Elvehjem homogeniser with a 
Teflon pestle. The homogenate, diluted to give a 1 in 
4 dilution, was centrifuged in an USE High Speed 18 
centrifuge at 10,000 x g for 10 minutes. The 
supernatant from this was used as a source of the 
glucuronyl transferase.
Where rabbit liver’homogenates were used, New 
Zealand White does were killed by cervical dislocation 
and the liver homogenised and centrifuged in a similar 
manner to the rat livers.
Before evaluating the conditions of incubation 
it was necessary to plot a standard curve for the 
fluorescence of‘4-MU and also to check the recovery of 
products using authentic 4-MU glucuronide.
Fluorescence of 4-MU
A standard curve for the fluorescence of 4-MU was
produced by measuring the fluorescence of varying
amounts (0.001 - 0.01/imoles*) of 4-MU dissolved in 2.0
ml of the acetate buffer, diluted with 5*0 ml of the
2glycine buffer, in a 1 cm quartz cuvette in either an 
Aminco-Bowman or a Baird Atomic spectrophotofluorimeter. 
Concentration of 4-MU plotted against fluorescence 
intensity gave a straight line (Fig.4.1). The excita­
tion wavelengths were 368 and 355 nm 
and fluorescence was measured at 450 and 482 nm 
(instrumental readings) in the Baird and Aminco ,. •
fluorimeters respectively.
Recovery of 4-MU Glucuronide
The amount of ^-glucuronidase required to hydrolyze 
an amount of 4-MU glucuronide in excess of that produced 
in the first incubation was determined. A solution of 
0.5 nil containing 0.01 /imoles of 4-MU-glucuronide was 
incubated with 1.5 ml of the acetate buffer containing
varying amounts of J3-glucuronidase (50 - 500 units).
After 30 minutes incubation at 37°0, 5*0 ml of the 
glycine buffer was added and the fluorescence determined. 
Tubes containing 100, 200 and 500 units of ^-glucuronidase 
activity gave similar readings. Therefore 200 units of 
^-glucuronidase activity was chosen as the quantity 
to use in future experiments.
The experiment was then repeated keeping the amount 
of p-glucuronidase constant and varying the amount of 
4-MU,glucuronide' (0.001 - 0.01yumoles). The results 
indicated that the fluorescence of 4-MU liberated by 
the hydrolysis increased in direct proportion to the 
amount of 4-MU glucuronide added (Fig.4.2).
The overall recovery of 4-MU glucuronide was 
determined as follows. 4-MU (“0.01 and 0.05/imoles) 
was added to 3*0 ml of liver homogenate and co-factors 
which had been previously incubated at 37° C. for 30 
minutes (see later). This mixture was washed twice by 
shaking with 10 ml of chloroform and 0.5 ml of the 
remaining aqueous phase was incubated at 37° 0. for 
30 minutes with 1.5 ml of the acetate buffer containing 
200 units of ^-glucuronidase. The fluorescence of the 
4-MU liberated showed that at both concentrations the 
recovery of 4-MU glucuronide was 83%.
The possibility of 4-M.U glucuronide formed during 
the initial incubation being broken down by ^-glucuroni- 
dase present in the liver was investigated. 4-MU 
glucuronide was added before the initial incubation, 
and the extraction carried out as described above.
Recovery of 4-MU added prior to incubation was 82% 
showing that little or no ^-glucuronidase was present 
(or at least was not active under the prescribed 
conditions.)
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Fig* 4. 1. Standard curve for the fluorescence
of 4-methylumbelliferone
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Fig. 4* 2. Standard curve for the hydrolysis of 
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Determination of 4-methylumbelliferone glucuronide
As a result of the foregoing experiments the 
following standard procedure was adopted for determining 
the amount of 4-MU glucuronide formed in the primary 
incubation. The incubation was stopped by the addition 
of 2.0 ml of ice-cold distilled water and 10 ml of 
chloroform. The tubes were.shaken vigorously for 10 
minutes after which time they were centrifuged at 
2000 r.p.m. in an MSS Super Magnum for 15 minutes. The 
procedure was repeated with a second 10 ml portion of 
chloroform; the chloroform extracts w.ere discarded.
The aqueous layer .( 0.5 ml.aliquots ) was incubated with 
1*5 ml of the acetate buffer containing 200 units of 
p-glucuronidase for $0 minutes at 37°0 in a Mickle 
shaking incubator. Similar aliquots were carried through 
the same procedure but with the omission of the p- 
glucuronidase, and these served as blanks. 50 ml of 
the glycine buffer was added and the fluorescence 
determined in either an Amino-Bowman or Baird Atomic 
Spectrophotofluorimeter. The increase in fluorescence
following incubation with p-glucuronidase was taken to 
represent the amount of 4-MU conjugated with glucuronic 
acid in the initial incubation.
Primary Incubation Conditions
A. Rat The incubation conditions first used were 
similar to those described by Bollet et al (1959) and 
are given below:-
0.1 M Tris buffer pH 7*0 0.5, ml
4-MU 0.2 yumoles )
UDPGA 0.2 yumoles < in 1-15% 1.2 ml
Magnesium ) KOI
chloride. 50 /imoles \
Liver 10,000 x g supernatant diluted
1 in 10 0.5 ml
Total volume 2.2 ml
The incubation was carried out in 20 ml glass- 
stoppered test tubes (unstoppered during incubation) 
at 3 7 ° 0  for 3 0  minutes in a Mickle shaking incubator.
These incubation conditions did not give much 
glucuronyl transferase activity, and so it was decided 
to investigate them in more detail.
Effect of UDPGA
The effect obtained by varying UDPGA concentration 
was first studied using the conditions described above.
A linear response in activity was obtained even when 
the amount of UDPGA added to the incubation mixture was 
as high as 5 /imoles. The incubation conditions were 
therefore modified by decreasing the total volume from 
2.2 ml to 1.0 ml, thereby increasing the effective 
concentration of UDPGA; the new conditions were:-
0.1 M Tris buffer pH 7.6 0 . 3  ml
Magnesium chloride, none 
4-MU 0.6 yumole )
UDPGA different amounts j ln 1 *15% KC1 °*5 ml
Liver 10,000. x g supernatant diluted 1 in 10 0.2 ml
Total volume 1.0 ml
Using these conditions the optimum concentration 
of UDPGA was found to be 5 /imoles per incubation (Fig.4.3)« 
This concentration of UDPGA is very high, and since it is 
very expensive methods were sought to reduce the amount 
required (see later). These results were obtained at 
St. Mary’s Hospital Medical School using female Wistar 
albino rats obtained from Oxfordshire Laboratory Animal 
Colonies. However, on moving to the University of 
Surrey where the Wistar albino rats were bred, the 
concentration of UDPGA required for optimal 4-MU 'glucuronyl 
transferase activity was found to be 2.0 /imoles’ per=incubation. 
This concentration of UDPGA was considered to be
economically viable, in view of the fact that intro­
ducing other cofactors (see later) might introduce 
other variables, and was therefore adopted in the 
standard procedure for the assay.
Using female Black-hooded rats the optimum 
concentration of UDPGA, using the 1.0 ml incubation 
conditions described above, was found to be in the 
order of 0.5yumoles per incubation, which is considerably 
less than required for the Wistar albino rats.
Effect of substrate concentration
The conditions of the incubation for investigating 
this parameter, using Wistar rats at Surrey, were:-
0.1 M Tris buffer pH 7 0 . 5  Ml
UDPGA 1.0 yumole )
, _  n. ) in 1.15% KOI 1.2 ml
4-MU different amounts ^
Liver 10,000 x g supernatant diluted
1 in 10 0.5 Ml
Total volume 2.2 ml
The effect of varying the substrate concentration 
from 0.01 /imoles to 2.0 /imoles per incubation is shown 
in Fig. 4. 4.
At the time, the determination was carried out 
using sub-optimal levels of UDPGA. The determination 
was therefore repeated using two concentrations of 4-MU, 
namely 0.3 and 0.6/imoles per 1.0 ml incubation mixture 
as described above, to which varying amounts of UDPGA 
were added. The levels of enzymic activity were the 
same at the two substrate concentrations. A substrate 
concentration of 0.3 /imoles per incubation was therefore 
chosen for use in the standard procedure finally adopted. 
The apparent Michaelis-Menten constant for rat liver 
microsomal glucuronyl transferase with respect to 4-MU 
was calculated to be 5 x 10”^M.
Pig. 4. 3« Effect of UDPGA concentration on the activity
of 4-methylumbelliferone glucuronyl transferase in
rat liver preparations.
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Pig. 4. 4. Effect of substrate concentration on the 
activity of 4-methylumbelliferone glucuronyl 
transferase in rat liver preparations.
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Effect of Magnesium
The effect of Mg++ on 4-MU glucuronidation by rat liver 
was determined using the following incubation conditions:-
0.5 ml0.1 M Tris buffer pH 7*6
UDPGA 1.0 ^ imole
4— MU 1.0/imole
Magnesium chloride, different amounts
Liver 10,000 x g supernatant diluted 1 in 10 0.5 ml
Total volume 2.2 ml
Pig. 4.5 shows the effect of Mg++ to be inhibitory 
at higher concentrations (I00-250yumoles per incubation), 
and to have no effect at lower concentrations (10-50 
yumoles per incubation). No Mg++ was added, therefore, 
in the standard procedure.
Effect of protein concentration
Por this determination the modified conditions 
described under the effect of UDPGA were used, 
amounts of 10,000 x g supernatant (0.25 - 2.0 ml) were 
diluted to 10.0 ml with 1 .15% KC1 solution and 0.2 ml 
of the resulting dilution used in the determination as 
the source of enzyme. Pig« 4.6 shows the variation 
of activity,expressed as yumoles of 4-MU conjugated per 
tube per hour, with varying homogenate dilutions. The 
relationship is linear up to a concentration of 
homogenate equivalent to about 3 »0 mg of liver (wet 
weight) per incubation. Since rat liver 10,000 x g 
sup ernataiifc.. contains about 120 mg of protein per g. wet 
weight, activity is linear with respect to protein 
concentration up to 0.5 mg protein per ml. of incubation 
mixture.
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In the standard assay procedure finally adopted, 
therefore, an amount of homogenate equivalent to 2.5 mg 
of liver was used, i.e., 0.2 ml of the 10,000 x g 
supernatant diluted twentyfold with 1.15$ KC1 solution.
Effect of length of incubation
The rate of production of 4-MU glucuronide with 
length of incubation was determined using the incubation 
conditions described under protein concentration for 
primary incubation periods of 15, 30, 45 and 60 minutes. 
Pig. 4.7 shows the rate of production of 4-MU glucuronide 
with time. The relationship is seen to be linear up to 
about 45 minutes.
A period of 50 minutes was chosen for the primary 
incubation time in the standard procedure.
Effect of pH
The conditions of incubation were similar to those 
used in the last section, except that the pH of the Tris 
buffer was varied between 6.6 and 8.6. The results are 
shown in graphical form in Pig. 4. 8. The highest 
activity was obtained in the region of pH 7#4 - 7.6.
0.1 M Tris pH 7*6 was therefore used in the standard 
procedure.
Effect of other factors
As mentioned above, with regard to UDPGA. concentra­
tion, the amount required at St. Karyfs for rat liver 
(5*0 yumoles) was very high. In an attempt to reduce 
the amount of UDPGA required, in order to reduce the 
cost, various conditions were altered. Firstly the 
incubation volume was reduced, and then the effect of 
adding various compounds to have a sparing effect on 
UDPGA was investigated. The choice of these compounds 
was based on a consideration of the fact that the 
oxidation of UDPG to UDPGA requires NAD (Strominger 
et al 1957)• Thus the effect of adding UDPG, NAD
Fig. 4.7 Effect of length of incubation on the activity 
of 4-r-methylumb el lifer one glucuronyl transferase 
%  in rat liver preparations.
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and glucuronic acid to the incubation medium was 
investigated. The effect of several other nucleotides 
was also investigated.
UDPG
UDPG (1.0 yumole) added to the incubation in place 
of UDPGA resulted in negligible glucuronyl transferase 
activity. The effect of adding various concentrations 
of UDPG together with 1.0 yumole of UDPGA is shown in 
Pig. 4.9. The addition of 0.1yumole of UDPG per 
incubation together with 1.0 yumole of UDPGA almost 
doubled the activity; no further increase was obtained 
when greater amounts of UDPG were added, and in fact 
with very high concentrations, an inhibition was 
obtained. When 2.0 ^ imoles UDPGA were added with 0.1 
yumole of UDPG the activity increased from 29.6 to 44.6 
yumoles/g.'. liver/hr., an increase of 50%. With the 
optimal concentration of UDPGA, i.e. 5 yumoles per 
incubation, no increase could be produced by the 
addition of UDPG.
NAD
NAD (1.0 yumole) added to the incubation in place of 
UDPGAresulted in no glucuronyl transferase activity.
The effect of adding various concentrations of NAD 
together with 1.0 yimole UDPGA is shown as Pig.4.10.
The addition of Q.05 yumoles of NAD more than doubled 
the activity; with higher concentrations of NAD only a 
slightly greater activity was obtained; no inhibition 
was produced even when 5*0 yumoles of NAD were added.
When the amount of UDPGA added was increased to 2.0 
yimoles, 0.2 yumole of NAD increased the activity from 
29*6 to 49.4yumoles/g.liver/hr., an increase of 67%.
With 5*0 yimoles of UDPGA no increase could be produced 
in the activity'by. the addition of NAD. These observa­
tions were made with rats at St.Mary's; at Surrey no 
activation was produced by NAD in the presence of sub- 
optimal levels of UDPGA.
Fig.4.9 Effect of UDPG- on the activity of 4-methyl-
umbelliferone glucuronyl transferase in rat liver
preparations in the presence of UDPGA.
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Glucuronic Acid
As with the UDPG and NAD, glucuronic acid alone 
produced no glucuronyl transferase activity. By adding 
various concentrations together with 1,0 yumole of UDPGA, 
however, the activity could be increased above that in 
the presence of UDPGA alone; the results are shown>n 
Pig. 4.11. The addition of 3*0 and 7*5 yumoles of glucu­
ronic acid is shown to produce an increase in the order 
of 30% in the glucuronyl transferase activity, but 10 
^lmoles completely inhibited the glucuronyl transferase.
Combinations of UDPG, NAD and glucuronic acid
Various stimulatory concentrations of each of these 
substances were added in different combinations, both in 
the presence and absence of added UDPGA. The results 
are shown in Table 4.1.
Table. 4.1
Effect of combinations of UDPGA, UDPG, NAD and glucu­
ronic acid on the activity of 4-meth.ylumbelliferone 
glucuronyl transferase in rat liver preparations.
Compounds
*
added Level of activity ^
UDPGA UDPG NAD Glucu­
ronic
acid
yumojLes suDsuraue conju— 
gated/gm.liver/hour)
— _ — — 0.27
— + + 0.82
-f _ _ _ 14.2
+ + __ 21.8
+ __ + 32.2
+ _ + 22.3
+ + + _ 30.8
+ + _ + 19.2
+ + + 28.7
+ + + + 26.4
* Amounts added per incubation were UDPGA 1 umole,
UDPG 0.3 yumole, NAD 1 yumole and glucuronic acid 5 yumoles.
/ The results are the mean of two experiments, there 
being no significant difference between them.
Fig. 4.11. Effect of glucuronic acid on the activity
of 4-methylumbelliferone glucuronyl transferase
in rat liver preparations in the presence of UDPGA
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In the absence of UDPGA the only combination to 
increase the glucuronyl transferase activity was that 
of UDPG plus HAD. Combinations of UDPG, NAD and 
glucuronic acid in the presence of UDPGA did not 
produce additive effects, and in some cases less 
stimulation was produced by multiple combinations 
than singly.
Other compounds
Pogell and Leloir (1961) have shown that ATP and 
UDP-N-acetylglucosamine activate glucuronyl transferases 
particularly in the rat, possibly by inhibiting the 
pyrophosphatase activity which contributes to the 
breakdown of UDPGA. At Surrey several other nucleo­
tides were, therefore, investigated for their effect 
on the rat liver glucuronyl transferase activity; those 
used were NADP, AMP, ADP, and ATP. All were used at a 
concentration of 1.0 yumole per incubation together with 
1.0 yumole of UDPGA. None of them produced any 
stimulatory effect.
B. Rabbit •
The optimum conditions of incubation for the 
determination of 4-MU glucuronyl transferase in rabbit 
liver preparations were determined using methods similar 
to those described for the rat. The effect of varying 
the following parameters was determined: UDPGA, substrate 
Mg++ and protein concentrations, pH of the media and 
length of the initial incubation.
In respect of the substrate and protein concentra­
tions, pH of the medium and length of incubations the' 
optimum conditions were found to be similar to the rat. 
Optimum UDPGA and Mg++ concentrations, however, differed 
markedly from the rat. The effect of varying IvJg++ 
concentration is shown in Pig. 4.12. There is an initial 
stimulation followed by gradual fall off to almost 
complete inhibition. The effect of varying UDPGA
Fig, 4.12 Effect of Mg** on the activity of 4-
methylumbelliferone glucuronyl transferase in
rabbit liver preparations.
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concentration is shown in Fig.4.13. The optimal 
concentration is in the region of 0.25 yumoles per 
incubation.
Discussion
The 4-MU glucuronidation by rat; liver preparations 
was found to be low and inconsistent when determined 
using a method similar-to that described by Bollet 
et al (1959) for stomach mucosa. The activity could 
be improved by increasing the concentration of UDPGA, 
but even by increasing it to 1.5 mM the activity was 
still not maximal. This is in agreement with the 
observations of Dutton (1966) that rat liver possesses 
high pyrophosphatase activity which is responsible for 
breakdown of UDPGA to glucuronic acid-l-iphosphate. 
incubation volume was therefore decreased to 1.0 ml 
to increase effectively the concentration of UDPGA.
The optimum concentration of UDPGA was then found to 
be in the region of 5 mM. With change of laboratories 
and source of rats, however., the optimum concentration 
of UDPGA required changed to somewhat less than 
half of this concentration. By this time the modified 
method had been developed and further investigation 
into the cause of this difference was not undertaken.
So in view of the highcost of UDPGA, ihis was - "y 
considered fortunate. The most likely explanation is 
that the rate of breakdown of the UDPGA by pyrophospha­
tase is lower in the Surrey rats. In rabbit liver 
the pyrophosphatase activity is low (Pogell and Leloir 
1961) and this would account for the much smaller 
amount of UDPGA required for optimum 4-MU glucuronyl 
-transferase activity in the rabbit.
Various other characteristics of the system were 
investigated although the optimum concentration of 
UDPGA was not always employed. Thus, for the determi­
nations of pH optimum and effect of Mg++, below optimal
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levels were used, but for the effect of homogenate 
concentration and length of incubation the optimum 
level was used.
Mg++ did not stimulate the glucuronyl transferase 
activity in rat liver preparations, although Bollet 
et al (1959) and Taketa (1962) found that it did so in 
stomach mucosa and mouse liver respectively. I also 
found that Mg++ in low concentration had a stimulatory 
effect in rabbit liver. The rat liver is perhaps 
richer in endogenous Mg++ than these other tissues.
The glucuronyl transferase activity was only directly 
proportional to very small amounts of liver protein.
This is almost certainly due to the quenching effect 
of protein on the fluorescence of the 4-methylumbelli- 
ferone released in the second incubation, since 
insufficient shaking with the chloroform, and therefore 
insufficient protein precipitation, leads to very low 
and inconsistent fluorimeter readings. The method is 
therefore only suitable for small amounts of tissue 
relatively rich in glucuronyl transferase activity.
The activity was found to be proportional to- 
length of incubation up to three quarters of* an hour.
This seems rather a long time in view of the fact that 
the UDPGA is supposedly broken down by pyrophosphatase 
activity and that there is only a small amount of tissue 
present. The optimum UDPGA concentration, however, was 
determined on the basis of a thirty minute incubation 
so that if the UDPGA is being broken down it will not 
fall below the optimum level until after this period.
The results also show that the enzyme is quite stable 
under these conditions.
Attempts were made to reduce the amount of UDPGA 
required in ord,er to reduce the cost. Strominger et al 
(1957) showed that guinea-pig liver soluble fractions 
dehydrogenated UDPG to UDPGA via an NAD-1inked enzyme.
In the experiments described here neither UDPG nor E D  
added alone stimulated glucuronyl transferase activity; 
added in combination though they did increase the 
activity slightly. When added separately with below 
optimum levels of UDPGA, however, they caused a large 
increase in activity. It is unlikely,therefore, that 
they are acting as precursors of UDPGA and thus 
stimulating activity. Pogell and Leloir (1961) have 
shown similar effects with addition of UDP-N-acetyl- 
glucosamine or ATP to rat liver microsomes on p-nitrophenol 
glucuronyl transferase but were unable to show any effect 
with UDPG. These authors found that part of the activation 
of glucuronyl transferase was caused by inhibition of the 
breakdown of UDPGA to glucuronic acid-l-phosphate, 
glucuronic acid and uridine by phosphatases, but that 
there was an additional increase which was unexplained.
This unexplained increase manifested itself as an 
activation of the rat liver glucuronyl transf eraser in 
the presence of the optimum concentration of UDPGA.
Moreover, only certain nucleotides showed this phenomenon.
In the experiments described in this chapter no activation 
of glucuronyl transferase was produced by UDPG or NAD in 
the presence of optimum UDPGA concentration. Now it is 
unlikely that the NAD and UDPG produce their effects by 
competing with UD.PGA for the pyrophosphatase since they 
produce their effects at very low concentrations and do 
not produce greater stimulation with increasing 
concentration. _It is also unlikely that the activation 
is similar to that observed by Pogell and Leloir (1961), 
since the effects are not additive and no stimulation 
is observed in the presence of excess UDPGA. It is 
interesting to note that the effect of NAD in stimulating the 
glucuronidation'was not observed with the rats at Surrey, 
and the optimum level of UDPGA required was less. The 
effect of various other nucleotides (NADP, ATP, ADP, AMP)
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were also studied at Surrey, and did not stimulate the 
glucuronidation either. It was thus not possible to 
follow up the investigation of this stimulation.
The stimulation produced by addition of glucuronic 
acid can probably be explained on the basis of inhibition 
of phosphatase activity by product inhibition. Thus, 
with gradual increase in concentration of glucuronic 
acid the stimulation produced increases as the breakdown 
of UDPGA by pyrophosphatase decreases. The abrupt fall 
in activity to zero is probably attributable to the 
alteration in pH produced by the high concentration of 
the acid.
Pogell and Leloir (1961) have also shown that 
addition of EDTA to rat liver microsomes stimulated the 
activity of p-nitrophenol glucuronyl transferase. The 
EDTA inhibits the pyrophosphatase responsible for the 
breakdown of UDPGA.- Addition of EDTA, therefore, 
seemed a possible method of increasing the effective 
concentration of UDPGA. However, Miettinen and 
Leskinen (1963) have shown that EDTA also inhibits 
p-glucuronidase, so its use in the presfent method was 
not possible as this involved a second incubation with 
jB-glucuronidase. By virtue of the same fact it was 
impractical to add any other p-glucuronidase inhibitors, 
such as saccharic acid to the .primary incubation, although 
the results show that there was little p-glucuronidase 
activity present in the-hepatic tissue, so; that addition 
Oft. inhibition . , - would have produced little apparent 
increase in jthe activity of .rg.lucur.onyl transferase.
The final method adopted for determining the 
activity of 4-methylumbelliferone glucuronyl transferase 
in rat liver preparations is described 'in-Chapter two.
CHAPTER V.
EFFECTS OP PREGNANCY ON HEPATIC DRUG- 
METABOLIZING ENZYMES IN RATS AND RABBITS
Introduction
Previous studies carried out .on the effect o f .pregnancy 
on drug-metabolizing enzymes have been described in 
detail in Chapter one. A brief resume is given here.
Cessi (1952) found that the glucuronyl transferase 
activity of guinea-pig liver preparations from pregnant 
animals was 50$ that of. non-pregnant. . There is then a 
large gap in the literature until 1965 when Creaven and 
Parke (1965) found that in liver preparations from 
pregnant rabbits the T^-hydroxylation of coumarin, the 
4-hydroxylation of biphenyl and the conjugation of 
o-aminophenol with glucuronic acid were inhibited to 
the following respective extents; 50$, 83$ and 35$» 
while in pregnant rat liver preparations the hydroxy- 
lation of biphenyl was decreased by 60$. Pulkinnen 
(1966) has since shown that sulphate conjugation of 
p-nitrophenol by rat liver is decreased in pregnant 
animals.
•Since this work was commenced Halac and Sicignano 
(1969) have shown an inhibitory effect of pregnancy on 
glucuronide conjugation of bilirubin and p-nitrophenol 
by rat liver preparations. They find that during the 
course of pregnancy the conjugating capacity of the 
maternal liver towards both substrates gradually 
declines until delivery, after which it returns to 
normal within two days.
Peuer and Liscio (1969) have also shown that the 
effect of pregnancy on rat liver drug-metabolizing 
enzymes is an inhibitory one. The reactions they studied 
were the 3-hydroxylation of 4-methylcoumarin, and the 
conjugation of o-aminophenol with glucuronic acid.
Thus it appears from the literature that the effect 
of pregnancy oh drug-metabolizing enzymes is an 
inhibitory one.
The work described in this chapter is concerned 
with evaluating the effect of pregnancy in both rats 
and rabbits on the activity of hepatic drug-metabolizing 
enzymes responsible for the following reactions:
2- and 4-hydroxylation of biphenyl,
7-hydroxylation of coumarin,
reduction ofp-nitrobenzoic acid to p-aminobenzoic acid 
' ' and the conjugation of 4-methylumbelliferone 
 with-.glucuronic acid.
As cytochrome P450 has been shown to play an 
important role in drug metabolism the levels in 
livers from pregnant and non-pregnant rats and rabbits 
have been determined.
In order to obtain some insight, into the 
mechanism of decrease in the activities of drug- 
metabolizing enzymes in pregnant animals, the effects 
of phenobarhitone and methylcholanthrene treatment on 
these enzyme.:activities were investigated.
Since certain drug metabolites are found in the 
foetal circulation it is possible that the placenta 
and/or the foetal liver are sites of drug metabolism 
(Van Petten et al 1968). If this is so, then the 
overall capacity of the pregnant mother could be 
influenced. Therefore, placental and foetal liver 
preparations were investigated for drug-metabolizing 
activity using similar substrates and methods as for 
adult liver preparations.
Materials and Methods
The rats used were similar to those described 
in Chapter two, and weighed between 200 g. and 300 g.
Several methods were used for mating the rats 
and determining the length of pregnancy. The 
appearance of copulation plugs was tried but gave
unsatisfactory results as these sometimes fell out 
or were undetectable. Vaginal smears were also 
taken in another series every morning, and v/here 
sperm were present this indicated day one of pregnancy 
in that animal. However, this proved a rather 
laborious, time-consuming task and was abandoned. The 
method finally adopted was as follows: two male rats 
were placed in a large cage with four mature female 
rats during the late afternoon (several boxes were set 
up at a time); the animals were left together for 36 
hours, i.e. until early morning two days later, when 
the males were removed. This was taken as day one of 
pregnancy of those animals that were later found to be 
pregnant. After ten days the females were palpated on 
the abdomen, and in. those that were pregnant the 
foetuses could be detected. All the animals were 
placed,at this stage, in boxes on their own. Those 
that were not pregnant were used as controls (it was 
sometimes necessary to supplement the number of controls 
with similar animals that had not been mated)* Using 
this method it was possible to obtain about 60$ of the 
rats pregnant and be able to tell within a day the 
actual time of mating.
Rabbits were mated using two different techniques. 
The first, used .at St. Maryfs, consisted of placing a 
female rabbit in a buck’s cage and watching until 
mating was achieved. This occasionally took a long 
time but nevertheless gave a rate of about 80$ pregnant; 
the exact time of mating was thereby known. At Surrey 
the pregnant rabbits were obtained from Westwood Hybrid 
Table Rabbits Ltd., Plymouth, and were despatched one 
week before the expected delivery date. 100$ success 
was obtained by this method, but I had to rely on the 
word of the breeders as to when mating had occurred,
and also one had to realise that the animals may have 
been stressed by the travelling while pregnant.
Animals were killed and tissue homogenates 
prepared as described under methods in Chapter two.
The methods used for determining the hydroxylation 
of biphenyl and coumarin, the reduction of p-nitrobenzoic 
acid, the conjugation of 4-methylumbelliferone, and 
cytochrome P450 and protein concentrations in liver 
preparations are also described in Chapter two.
For studying these parameters in placentae and 
foetal livers of rats similar methods were used.
Placentae or foetal livers from one litter w e r e  pooled. 
Only . . - tissues from almost full-term rats were used, 
as in early - pregnancy these tissues are very small.
For preparing microsomal suspensions from the placentae 
and foetal livers, resuspension of the microsomal pellets 
was made in less than the original volume in order 
to give a more concentrated suspension.
Results
1) Rats
a) Effect on body and liver weights
The first feature to be noted in pregnant rats 
was the large increase in liver weight that took place, 
(Table 5*1)• This has been noted in the past (e.g. 
Campbell and Kosterlitz 1949) but does not seem to have 
been considered in relation to drug-metabolizing enzymes. 
Enzyme activity results are usually expressed in terms 
of yumoles product/gm.liver/hour, which does not take 
into account any alteration in liver weight. This 
method of expressing results is satisfactory if no
alteration in size of the liver occurs. However, if _
an alteration does occur in liver size, then this must 
be taken into account and the total activity of the 
liver expressed as well.
Table 5. 1
Effect of .pregnancy on Tjyer and body weights in the gat
G-roup No.
of
rats
Weight Ratio of
Biver 1 Q Q  
Body x ±uuBody (g) Liver (g)
Non-pregnant 
(19-20 day 
controls)
10 237 * 6 7.9*0*6 3.3
Pregnant 
(19-20 days) 10 325 * 10 10.9*0.4- 3.4
Non-pregnant 
(15-16 day 
controls)
6 260 * 13 7.5*0.8 2.9
Pregnant. 
(15-16 days) 7 314 * 12 10.3*0.9 3.3
Table 5. 1 shows the effect of pregnancy in the
rat on the body and liver weights at two different
stages of pregnancy. Table 5. 1 also shows the increase 
that takes place in the maternal liver during pregnancy.
It appears that the liver reaches its maximum size
(or very nearly so) by the 15th day of pregnancy and 
possibly even earlier. The ratio of liver to body 
weight is greater in the 15-day pregnant animals than 
the controls for that group; this would indicate that 
thereafter the increase in body weight outpaces the 
increase in liver size.
In the following work, therefore, enzyme results 
are expressed in terms of yumoles product/gm.liver/hour,
i.e. as a function of unit liver weight, and this is 
referred to as "specific activity", as well as in terms
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_of yumoles product/liver/hour, i.e. as a function of 
total liver weight, and this is referred to as "total 
activity" since this reflects the animalfs total 
capacity for drug metabolism.
b) Effect on the hydroxylation of biphenyl.
Before the assay procedure for the determination of 
the hydroxylation of biphenyl was revised for rat liver 
preparations, several experiments were carried out 
using the original method described by Creaven et - al 
(1965b). The activity of biphenyl-4-hydroxylase from 
livers of pregnant and non-pregnant rats - is shown in 
Table 5. 2..
Table 5. 2
Effect of pregnancy on the 4-hydroxylation of biphenyl by 
rat liver microsomal preparations as determined using the 
method of Creaven et al (1965b)
Eon-pregnant Pregnant
Liver
weight
(g;
Activ:-ty Liver
weight
(g)
Activity
nmoles 
product/ 
g.liver/ 
hr.
yumoles
product/
liver/
hr.
yumoles 
product/ 
g.liver/ 
hr.
yumoles
product/
liver/
hr.
7.0 0.44 5.1 9.5 0.54 5.1
9.0 0.46 4.1 9.0 0.56 5.0
8.0 0.24 1.9 16.0 0.22 5.5
7.5 0.56 2.7 14.0 0.55 4.6
8.0 0.77 6.2 11.5 0.22 2.5
9.5 0.52 5.0 12.0 0.52 5.8
8.0 0.54 4.5 12.5 0.91 11.4*
8 .0*0.3 0.48*0.07 3.6^0.5 12.0*1.0 0.36*0.06 4. 1*0 . 5
* Omitted from mean values.
The table shows the individual results obtained 
from seven 20-day pregnant and seven non-pregnant 
control rats; quite a wide range of results is obtained 
with both groups and they overlap markedly. The average 
results for the non-pregnant animals agree very closely 
with those obtained by Creaven and Parke (0.4-7 yumoles/ 
gin. liver/hour) (1965 )• The results for the pregnant 
rats, however, are considerably different. Creaven and Parke 
obtained an average value of 0.16 yumoles/gm.liver/hour, 
which amounted to a 60^ inhibition; in the series of 
experiments described above the mean value for the 
pregnant animals was 0.56 - 0.06 yumoles/gm. liver/hr. , 
an inhibition of only 25$» which is not significant.
These experiments were carried out (as was discovered 
afterwards) at below. optimal levels of NADP, and 
therefore it was thought that varying levels of this 
cofactor in the liver may have accounted for the wide 
range of values obtained. If this was so, then 
perhaps the inhibitory effect of pregnancy on hydroxy­
lation was due to a decrease in cofactor levels.
The effect of varying the NADP concentration on the 
biphenyl-4-hydroxylase activity in pregnant rats was 
therefore determined using the revised conditions of 
assay. The effect is shown in Pig. 5* 1. The 
illustration, which is the average of three determina­
tions, shows that at all concentrations of NADP, the 
effect of pregnancy is an inhibitory one, the degree
of inhibition being slightly higher at higher concentra­
tions of NADP. The optimal concentration of NADP is 
similar for both pregnant and non-pregnant animals, so 
that it can be concluded that the NADP concentration 
is not a limiting factor of the hydroxylation in the 
pregnant rat.
The effect of pregnancy in the rat on the hydroxy­
lation of biphenyl is shown in more detail in Tables 5. 5
and 5. 4. Table 5* 5 shows the effect of 19-20 days
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Pig, 5. 1. The'.effect- of NADP concentration 
on the hydroxylation of biphenyl by 
liver preparations from pregnant rats.
4
3
2
1
1.00.5
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c— — q  Pregnant
j____________,___« * - *
.5 2.0 2.5 3.0
added (/umoles)
pregnancy, the results being expressed as "specific 
activity", "total activity" and also in terras of 
microsomal protein concentration.
Table 5. 3
Effect of 19-20 days pregnancy on the hydroxylation of 
biphenyl by rat liver microsomal preparations
Parameter Eon-
pregnant
Pregnant Percent­
age
Differ­
ence
Body weight (grams) 228 i 7 332 t 7 + 45 ^
Liver weight (grams) 6.9 - 0.7 10.4^0.4 + 51 ^
Biphenyl-4-hydroxylase 
(yumole s/gm. liver/hour) 3.34^0.30 2.29^0.30
HK\1
Biphenyl-4-hydroxylase 
(yumole s/liver/hour) 23.1-3.7 23.8±3.3 + 3
Biphenyl-4-hydroxylase 
(ynnoles/mg. protein/hour)
0.11+0.01 0.07-0.02 - 33x
Biphenyl-2-hydroxylase 
^/umole s/gm. liver/hour)
0.14 0.13 - 7
The results were obtained from 12 animals in each group.
Significant differences represented by se p = 0.01,
/ p = 0.001.
The results show that there is a significant 
decrease (31$) in the specific activity of the liver 
from 19-20 day pregnant rats towards the hydroxylation 
of biphenyl in the 4-position. There is only very little 
2-hydroxylation of biphenyl in both the pregnant and 
non-pregnant animals. The total capacity of the livers 
from pregnant animals towards 4-hydroxylation of biphenyl
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is shown to be increased slightly above that of the 
non-pregnant' , since the decrease in enzyme activity 
is accompanied by an increase in liver weight. When 
the activity is expressed in terms of microsomal 
protein concentration there is a slightly greater 
inhibition than of the specific activity since the 
microsomal protein content of the pregnant liver is 
slightly greater than that of the non-pregnant (see 
later).
Later work (described in Chapter seven) on the 
effect of pregnancy on the duration of action of 
hexobarbitone showed that the latter was increased 
considerably in full-term (or nearly full-term) rats, 
but at fifteen days the action was only prolonged by a 
slight amount. This suggested that the metabolism of 
hexobarbitone was not inhibited to such a great extent 
in 15-16 day pregnant rats as in 19-20 day pregnant 
rats. It was therefore of interest to evaluate the 
effect of 15-16 days pregnancy on the drug-metabolizing 
enzymes described above. By determining the activity 
of these enzymes at a different stage of pregnancy, 
it was also hoped to obtain a greater insight into the 
mechanism of the inhibition. The effect of 15-16 days 
pregnancy on liver microsomal biphenyl hydroxylation in 
the rat was determined and the results are shown in 
Table 5* 4*
When the results are expressed as a function of 
unit liver weight a decrease of 13$ in the liver 
hydroxylase activity of the 15-16 day pregnant rats is 
obtained, but this is not statistically significant.
When, however, the results are expressed as a function 
of total liver weight the liver hydroxylase activity 
of the pregnant rats is 17$ greater than the non-pregnants. 
This is expected since the slight decrease in specific 
activity is accompanied by a considerable increase in 
liver weight. As there is no alteration in microsomal
Table 5« 4
Effect of 15-16 days pregnancy on the hydroxylation of
biphenyl by rat liver microsomal preparations.
Parameter Non-Pregnant Pregnant Per­
centage 
differ­
ence .
Body weight (g) 260 t  13 312 -  14 + 20s
Liver weight (g) 7.5 - 0.8 10.oil.0 + 33 ^
Biphenyl-4-hydroxy­
lase (yum oles/gm. liver/ 
hour).
4.12±0.36 3.6oio.34 - 13
Biphenyl-4-hydroxy­
lase (yumole s/liver/ 
hour). 30.9-5.6 36.0i6.7 + 17
Biphenyl-4-hydroxy­
lase (yumoles/ 
m B» /protein/hour) 0.142io.017 0.018i0.014 - 17
Biphenyl-2-hydroxy- 
lase (yumoles/gm./live^ 
hour). 0.14 0.12 - 14
The results were obtained from six animals in each
group. Significant differences represented by
x p = 0.02, / p = 0. 05
protein content ..at. 15-16 days pregnancy, the ..activity 
expressed'in..terms of protein concentration-or specific 
activity show- a similar decrease. As with the full-term pregnan 
animals there is very little 2-hydroxylase activity 
present.
c) Effect on the protein content of the liver.
The protein content of the 10,000 x g supernatant 
and of the microsomal suspensions of livers from pregnant 
and non-pregnant rats were measured. The results are
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shown in Table 5. 5* The results show there is no 
difference in the concentration of 10,000■’ x -g supernatant 
protein, but there is a-substantial increase of 57$ in total 
liver content cflO,000 x g supernatant protein in the 
19-20 day pregnant rats. There is a slight, but 
statistically insignificant, increase in the concentration of 
microsomal protein ,> The total microsomal
liver protein content is increased by 55$ in 15-16 day 
pregnant animals and by 68$ in 19-20 day pregnant 
animals. The results therefore show that the composi­
tion of the 'pregnant* liver with regard to protein is 
proportionally similar to the non-pregnant.
Table 5. 5
Effect of '■pregnancy on 10,000 x g supernatant and 
m icrosomal liver protein content in the rat
Protein
1
Hon-pregnant 15-16 hay 
Pregnant
19-20 day 
Pregnant
10,000 x g 
Supernatant 
(mg/gm.liver)
110.5 - 1 . 7  (6) — 110.4-1.5(6)
10,000 x g
Supernatant
(mg/liver)
696-9* 5 (6) 1093* il5.l(6)
Microsomal 
(mg/gm.liver) 28.9- 1.1(14) 30.5-1.3(7) 31.8^1.2(12)
Microsomal
(mg/liver) 202.3-13.1(14)
 ^+ 
314.2-22.0
(7)
340.3^ +18>6 
(12)
figures in parentheses represent the number of 
observations. Statistical difference from 
controls is indicated by s p = 0.001, / p = 0.01.
d) Effect on reduction-of p-nitrobenzoic acid 
The pattern of reduction of p-nitrobenzoic acid in 
pregnant and non-pregnant rat livers is shown in Tables 
5.6 and 5.7* In the almost full-term rats the specific 
activity of the liver, although slightly increased on 
average, is not significantly different in the pregnant 
animals from the non-pregnant. When the increase in 
liver weight during pregnancy is taken into consideration 
and the total liver capacity expressed, a 60fo increase of 
the pregnant. above the non-pregnant is obtained. The 
activity expressed in terms of protein concentration shows 
a slight but insignificant increase in activity in the 
pregnant animals.
The activity in the liver preparations from 15-16 
day pregnant rats follows a similar pattern to the 19-20 day 
pregnant animals. . • _- . • "
Table 5. 6
Effect of 19-20 days pregnancy on the reduction 
of p-nitrobenzoic acid by rat liver microsomal
preparations
Parameter Eon-pregnant Pregnant
|--------
Percen­
tage
differ­
ence
Body weight (grams) 240 t 5 345 - 15 + 44*
Liver weight(grams) 8.6 - 0.5 11.7 - 0.6 + 56s
Specific activity
2.32 -  0.24(8)(yumole s/gm. liver/hr) 1.97 - 0.08(8) + 18
Specific activity
Qumoles/mg. protein/ 
hr.) 0.072 - 0.004 0.084^0.013 + 17
Total activity
16.9 - 1.0 + 60^(yumoles/liver/hr.) 27.1 - 3 . 9
The number of animals used in each group was six. 
Significantly different x p = 0.001; / p = 0.05.
Table 5» 7
Effect of 15-16 days pregnancy on the reduction
of p-nitrobenzoic acid by rat liver microsomal
preparations
Parameter Eon-pregnant Pregnant Percen­
tage
differ­
ence
Body weight (grams) 260 ± 13 314 - 12 + 21*
Liver weight(grams) 7.5 - 0.8 10.3 - 0.9 + 37s
Specific activity
1.68 t 0.28Qumole s/gm.liver/hr) _2',32 ± 0.24 + 38
Specific activity
(nmoles/mg/protein/ 
hr.) 0.058^0.009 0.075-0.006 + 31
Total activity
(yumole s/liver/hr) 12.9 - 2.5 23.7 - 2.8 + 84s
The number of animals used in each group was six. 
x Significantly different p = 0.05
e) Effect on Cytochrome P450
The cytochrome P450 content of rat liver microsomes,
expressed in terms of mmoles, calculated using a molar
—1 —1extinction coefficient of 91 mli cm (Omura and 
Sato, 1964a),in non-pregnant and 19-20 day pregnant rat 
livers, is shown in Table 5* 8..
Table 5. 8
Effect of 19-20 days pregnancy on the cytochrome P450 
content of rat liver microsomes
Parameter Eon-pregnant Pregnant Percentage
Difference
Body weight (grams) 229 - 6.0 326 -  1 6 + 42 ^
Liver weight(grams) 7.6 i 0.4 10.7 -  0.5 + 40 ^
P 450 content 
(m^moles/gm.liver) 21.2±1.3 15.7- 1.0
V
OCM1
P 450 content 
(mpnoles/mg.protein) 0.73-0.03 0.52±0.02
/
- 29
P 450 content 
(iflyumole s/liver) 161.1±8.8 168.0^6.9 + 4
The number of animals used in each group was ten. 
Significantly different k p = 0.05? / P = 0.001
•The results show that the cytochrome P450 content 
seems to follow the pattern of the hydroxylation of 
biphenyl. The specific activity is reduced by 26$ and 
this is significant. There is no significant difference 
in the total content of cytochrome P450. The cytochrome 
P450 and microsomal protein are measured on the same 
fraction so that any slight variation in specific 
cytochrome P450 content due to the resuspension process 
is eliminated. The cytochrome P450 content when 
expressed in terms of protein concentration is decreased 
by 29$ in the liver microsomes of 19-20 day pregnant 
rats and the difference is highly significant.
The cytochrome P450 content of the liver microsomes 
of 15-16 day pregnant rats is shown in Table 5. 9«
- 127 ~
Table 5. 9
Effect of 1^-16 days pregnancy on the cytochrome P450 
content of rat liver microsomes
Parameter Eon-pregnant Pregnant Percen­
tage
Differ­
ence
Body weight (grams) 260 i 13 314 - 12 + 21s
Liver weight(grams) 7.5 - 0.8 10.3 - 0.9 + 37s
P450 content
(mp.moles/gm liver) 20.5 - 2.6 16.9 - 1.2 - 17
P450•content
(m^umole s/mg. protein) 0.70 i 0.06 0.55 i 0.02 - 21
P450 content
(nyumole s/liver) 146.1 ± 16.1 168.6^9.3 * 15
The number of animals used in each group was six. 
x Significantly different p = 0*05
The results show that in the liver microsomes from 
15-16 day pregnant rats the pattern of cytochrome P450 
again follows that of the hydroxylation of biphenyl, 
the specific content and that expressed in terms of 
protein concentration being reduced by some 30$, but 
these decreases are not statistically significant, while 
the total liver content of microsomal cytochrome P450 
is increased by 15$, though this is not significantly 
different either.
Thus, the cytochrome P450 content of the liver of 
15-16 day pregnant animals, expressed per g. of liver, 
is slightly, although not significantly, lower than 
non-pregnants, but greater than that of 19-20 day 
pregnant animals.
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f) Effect on conjugation of 4-methylumbelliferone 
with glucuronic acid.
Table 5.10 shows the effect of 19-20 days pregnancy 
in rats on the hepatic 4-methylumbelliferone glucuronyl 
transferase activity.
Table 5. 10
Effect of 19-20 days pregnancy on the conjugation of 
4-methylumbelliferone with glucuronic acid in rat liver
microsomal preparations
Parameter Non-pregnant Pregnant Percent­
age
differ­
ence
Body weight (grams)
Liver weight(grams)
Specific activity 
(pmoles/gm/liver/hr)
Specific activity
(jumoles/mg. protein/ 
hr.)
Total activity
(jumole s/liver/hr)
240 i 5 
8.6 i 0.5
105.9-5.8
3.90 ± 0.45
907 - 68
345 - 15 
11.7 -  0.6
77.6 - 8.3
2.88 - 0.46
906 t 109
+ 44 
+ 36 K
- 27^
- 26^
0
The number of animals used in each group was six. 
Significantly different x p = 0.001, / p = 0.05*
The conjugation of 4-MU with glucuronic acid also 
shows a similar pattern in 19-20 day pregnant rats to 
the biphenyl .hydroxylation, namely the specific activity 
is reduced, the total liver activity is unaltered, while 
expressed in terms of protein concentration the activity 
is decreased.
g) Effect of phenobarbitone pretreatment during
pregnancy
Three factors concerned with drug metabolism 
have been shown to be reduced in the livers of pregnant 
rats, namely the 4— hydroxylation of biphenyl, the 
conjugation of 4-MU with glucuronic acid and cytochrome 
P450. These factors, together with the other two 
measured - the reduction of p-nitrobenzoic acid and 
microsomal protein, which are not decreased, are all 
induceable in normal control rats by pretreatment with 
phenobarbitone. It was therefore of interest to see 
whether these factors could be induced in pregnant rats.
The evaluation of this effect was aggravated by 
the fact that conflicting results were obtained in two 
sets of experiments carried out. Both sets of results 
are shown in Table 5.11 (a and b). In Table a. the 
results are the mean of three rats in each group and 
the phenobarbitone pretreated were given a single daily 
injection of 50 mg./kg. of phenobarbitone sodium in 
normal saline i.p. three days before killing. Animals 
were killed 24 hours after the last dose. Table b. 
shows the results obtained from two animals in each 
group but the phenobarbitone pretreated rats were given 
phenobarbitone sodium as an 0*1$ solution in the 
drinking water (Marshall & McLean 1969) for the last 
five'days prior to killing. The discrepancy does 
not arise in the effect of phenobarbitone, but rather 
in the effect of pregnancy alone. Table 5. lib, 
shows that 19-20 days pregnancy in th se rats did 
not produce a decrease in the 4-hydroxylation of 
biphenyl or cytochrome P450 as it had done previously.
The effect had always been one of inhibition 
although the degre'e of inhibition varied flom 0*- 50’$'. •
Table 5» 11a
Effect of phenobarbitone pretreatment of pregnant and
non-pregnant rats on hepatic drug-metabolizing enzymes,
cytochrome P45Q and microsomal protein.
Group A N on- 
pregnant
N.P.
Pre­
treated
--------
Pregnant Pregnant
Pre­
treated
Body weight 227 i 6 243 -  8 321 i 7 336 ± 8
(grams)
Liver weight 6.0 i 0.4 8.9 - 0.7 9.2 i 0.5 11.2 -  0.8
(grams)
Biphenyl-4- 3.23 i 0.24 4.81 io.5L 2.55 ± 0.3]5.30i 0.6
hydroxylase
Qumoles/gm.
liver/hour) •
Bipheny1-2- 0.15 0.21 0.16 0.23
hydroxylase •
(jumoles/gm.
liver/hour)
P450-. 24.5 ^1.4 33.0 i 2.5 18.6 i 1.2 22.0^1.3
(lijumoles/ 
gm.liver)
Microsomal 30.8 ± 1.2 38.5 - 1 . 6 32.4 ii.i 39.5^1.5
Protein
(mg/gm*liver)
Table 5, lib
Effect of phenobarbitone pre/treatment of pregnant and 
non-pregnant rats on hepatic drug-metabolizing enzymes, 
cytochrome P450 an^ microsomal protein
Group B Non­
pregnant
N.P.
pre-
treated
Pregnant Pregnant
pre­
treated
Body weight 208,220 191,196 280,292 263,296
(grams) (2X4) (194) (286) (280)
Liver weight 6. 6,6.7 7.1,6 7 10.0,12.4 10.9, 10.8
(grams) (6.7) (6.9) (11.2) (10.9)
Biphenyl-4- 3.67,3.85 7.80,7.05 3.95,4.23 ' 7.71,6.86
hydroxylase
Oumoles/gm. • 
liver/hour)
(3.76) (7.43) (4.09) (7.29)
Reductase 1.34,1.12 1.89,1.48 1.42,1.62 2.32,2.11
(yumoles/gm. 
liver/hour)
(1.23) (1.69) (1.52) (2.22
F. 450 13.0,13.4 40.1,44.3 12.9,13.5 23.2,25.6
((kumoles/ 
gm.liver
(13.2) . (42.2) (13.2) (24.4)
Figures in brackets represent the mean of the two 
determinations.
No immediate cause was apparent although it was noted 
that the animals used in this set of experiments were 
younger than any used previously. Nevertheless, both sets 
of experiments show similar effects of phenobarbitone.
The 4-hydroxylation of biphenyl is elevated to the same 
level by phenobarbitone pretreatment in pregnants and non­
pregnants; the percentage increase, at least in the first 
set, is therefore greater in the pregnant than the non­
pregnant - 108$ and 49$ respectively. The 2-hydroxylation 
of biphenyl is also induced slightly in both non-pregnant 
and pregnant animals. The microsomal protein content which 
normally is increased by phenobarbitone pretreatment,
(Conney, 1967), is increased in both the
1pregnant and non-pregnant animals;- . Cytochrome
P450 is raised in both the pregnant and non-pregnant 
animals by phenobarbitone pretreatment, but the level 
in the non-pregnant:: is not attained by the pregnant 
in either group. The reduction of p-nitrobenzoic 
acid is increased by phenobarbitone pretreatment in 
both non-pregnant and pregnant rats.
h )  Effect of methylcholanthrene pretreatment 
during pregnancy
Two pregnant and two non-pregnant animals were 
pretreated with 20 mg/kg of methylcholanthrene daily 
for three days prior to killing. The effects on liver 
biphenyl hydroxylation, cytochrome P450 and microsomal 
protein are shown in Table 5. 12.
Table 5. 12
Effect of methylcholanthrene pretreatment of pregnant 
and non-pregnant rats on hepatic hydroxylation of 
biphenyl, cytochrome B450 and microsomal protein.
Parameter Eon-
pregnant
controls
Eon-
pregnant
Pretreated
Pregnant
Pretreated
Biphenyl-4-hydroxylase 3.20,3.60 6.36,5.96 6,69,5.15
(jumoles product/ 
gnu liver/hr)
(3.40) (6.16) (5.92)
Biphenyl-2-hydroxylase 0.14,0.18 2.13,2.55 2-. 80,2.28
(umoles product/ 
gm.liver/hr)
(0.16) (2.34) (2.54)
Cjyfcochrome P450 18.4,18.6 24.2,24.7 23.8,23.6
(m^umole s/gm. liver) (18.5) (24.5) (23.7)
Microsomal Protein 29.9,30.4 29.1 ,30.5 32.1,29.9
(mg/gm.liver) (30.2) (29.8) (31.0)
The number of animals used in each group was two.
Although the determinations were carried out in 
only two animals the results show definite character­
istics. Both 2- and 4-' hydroxylation of biphenyl and 
cytochrome P450 are induced in pregnant and non-pregnant 
rats; microsomal protein remains unchanged by pretreat­
ment .
i) Effect of second pregnancy
To see v/hether similar effects of pregnancy on 
drug-metabolizing enzymes were produced in a subsequent 
pregnancy a group of six rats was allowed to litter 
and the young were weaned after 4 weeks. Three of 
the six were again mated and the other three served as 
controls. 20 days after mating the six animals were 
killed and the various parameters measured. The 
results, expressed in terms of unit liver weight, are 
shown in Table 5* 15*
Table 5. 1 3
Effect of second pregnancy on liver microsomal enzymes, 
cytochrome P450 and microsomal protein in the rat
. Parameter Non­
pregnant
Pregnant Percent­
age
.differ- 
• ence
Body weight (grams) 290 ± 9 377 - 12 + 30
Liver weight(grams) 10.6 ± 0 . 3 12.6 ± 0.5 + 19
Biphenyl-4-hydroxylase 4.20 ± 0.28 3*51 ±  o.31 - 16
(/moles product/ 
gm.liver/hr)
Biphenyl-2-hydroxylase 0.22 0.17 - 23
(/moles product/ 
gm.liver/hr)
3.22 ±0.25 3.07-0.12p-Nitrobenzoic acid - 5
reductase (/moles
product/gm. liver/hr)
16.7 ± 1.2 14.2 ± 1.1Cytochrome P450 - 15
(npmoles/gm. liver)
27.3 ± 1.0Microsomal Protein 29.7 ± 0.9 + 9
(mg/gm.liver -
The rats were, as a result of the first pregnancy, 
larger and so were the livers. The livers of the 
pregnant animals did not increase in size to such a 
great extent as with the first pregnancy. The enzyme 
activities of the liver followed a similar pattern to 
those during the first pregnancies, although the 
effects were not so marked. Thus the hydroxylation 
of biphenyl and cytochrome P450 were decreased while 
the nitroreductase and microsomal protein remained 
virtually unaltered.
2) Rabbits
The drug-metabolizing activity of the livers of 
pregnant rabbits has not been so extensively investi­
gated. The results that have been obtained in full- 
term pregnant rabbits are shown in Table 5. 14.
The only significant difference between the 
non-pregnant and pregnant animals is in the hydroxy­
lation of coumarin; in the pregnant rabbit liver 
this is decreased by 68$. The hydroxylation of 
biphenyl, p-nitrobenzoic’ acid reductase, 4-MU' glucuronidation 
microsomal protein and cytochrome P450 show no. signifi­
cant difference betv/een pregnant and non-pregnant 
rabbit livers when expressed as a function of liver 
weight. As there is no increase in liver weight in 
the pregnant rabbit, there is obviously no difference 
in total liver content of the.se parameters, except of 
coumarin-hydroxylating capacity, which is decreased.
Inhibition of the hydroxylation of coumarin was 
also found in liver preparations from two 1 4 -day and two 
21-day pregnant rabbits to the extent of 46$ and 55$ 
respectively. The hydroxylation of biphenyl was not 
inhibited at either of these stages of pregnancy.
Table 5» 14
Effect of pregnancy on hepatic drug-metabolizing enzymes,
cytochrome P450 and microsomal protein in the rabbit.
Parameter Eon-pregnant Pregnant Percent­
age
differ­
ence
Body weight (kg) 4.0 - 0.2(8) 4.5 i 0.2(5) + 13
Liver weight (g) 115 - 11(10) i n  i 10 (5) - 3
Microsomal protein 2 2 . l t 0.9(4) 21.4^ 1.5(4) - 3
(mg/grn. liver)
Cytochrome P450
•4*
37.3- 36.2i(mjxmol e s/gm. 1 i ve r ) 5.5(4) 1.6(4) - 3
Biphenyl-4-hydroxylase
4-
4.03- 0.30(10) 4.59- 0.2](5) + 14
Qumoles/gm.liver/hr)
1.12i 0.36- i 00 $Coumarin-?-hydroxylase 0.15(8) 0.03(4)
(yumole s/ gm. liver/hr)
p-Nitrobenzoic acid
reductase
(yumole s/ gm. liver/hr) l . o g i 0.24(4) 1.29- 0.21(3) + 18
4-MUl glucuronyl
transferase , . 
yumoles/gm.liver/hr)
161 ± 10 (3) 135 - 15 (3) - 16
Figures in parentheses show the number of animals used. 
sSignificantly different from controls, p = 0.001
The effect of phenobarbitone pretreatment of pregnant 
rabbits was investigated by dosing two female rabbits 
with 50 mg/kg of phenobarbitone sodium i.p. for the 
three days, prior to killing on the penultimate day of 
gestation. The results, shown in Table 5*15, show that 
all the enzymes measured were induced in the pregnant 
and non-pregnant rabbit livers, although not all to the 
same extent.
Table 5. 15
Effect of phenobarbitone pretreatment of pregnant and
non-pregnant rabbits on hepatic drug-metabolizing
enzymes, cytochrome P450 and microsomal protein
Parameter
Hon-pregnant Pregnant
pretreated
(mean of 3 (mean of 2
animals) animals)
Body v/eight (kg) 3.2 ± 0.2 4.3,4.5
(4.4)
Liver weight (g) 105 - 9 103,100
25.21 1.4
(102)
Microsomal protein 25,7.,26,0
(25.9)(mg/gm.liver)
Cytochrome P450 85.4± 1 58.1,77.0
(mp.mole s/gm. liver)
S.ss* 0.09
(67.6)
Biphenyl-4-hydroxylase 6.55,8.55
(yumoles/gm. liver/hour)
I.52I 0.2
(7.55)
Coumarin-7-hydroxylase 0.93,0.97,
(/mole s/ gm. liver/hour) (0.95)
p-Nitrobenzoic.acid
1 .92- 0.26reductase 2 .'60,2.28
(/umoles/gm. liver/hour)
260 -  21
(2.44)
4 MU; glucuronyl transferase 149,163
(yumoles/gm. liver/hour) (156)
3) Hole of the placenta
Using conditions similar to those used for investi­
gating drug-metabolizing enzyme systems in liver 
preparations, no detectable activity was found in 
placental homogenates (25$ W/v) from 20-d§ty pregnant 
rats in the following systems:- 2- and 4-hydroxy^ation 
of biphenyl (4 observations) and reduction of p-nitrobenzoic 
acid (3 observations), but conjugation of 4-MU with glucu­
ronic acid was detected at a low rate, 0.7 ^moles/gm. 
placenta/hour (4 observations) which in terms of total
placental activity is 0.4$ of the total activity of 
the maternal liver. The protein content of the 
placental microsomal fraction (4.5 mg/gm. wet weight 
placenta) was, however, much lower than that of the 
liver microsomal fraction (25-30 mg/gm wet weight 
liver). More concentrated placental hornogenates 
(up to 60$ w/v) were then used in the enzyme 
determinations, but again no hydroxylation or nitro- 
reduction Could be detected.
Ho cytochrome P450 (5 observations) could be 
detected in microsomes resuspended in the original 
volume of KOI solution (this gave a protein concentra­
tion of about 0.4 mg per ml. in the cytochrome P450 
determination). Placental microsomes were, therefore, 
resuspended in smaller volumes of KC1 solution to give 
increased concentration of protein. The highest 
protein concentration used was 6.5 mg per ml in the 
cytochrome P450 determination, but even then no 
cytochrome P450 could be detected.
Similar determinations were carried out on 
placentae from pregnant rats that had been pretreated 
'with phenobarbitone (2 animals) or methylcholanthrene 
(2 animals) as previously described. Again no 
hydroxylation of biphenyl or cytochrome P450 could be 
detected, and the conjugation of 4-MU with glucuronic 
acid was not induced above the control level.
4) Role of the foetal liver
Poetal liver preparations from control, pheno­
barbitone and methylcholanthrene pretreated 20-day 
pregnant rats were investigated for drug-metabolizing 
activity and cytochrome P450 content. The results 
are shown in Table 5. 16.
Table 5. 16
Drug-metabolizing enzyme activity and cytochrome P450 
content of foetal livers from normal, phenobarbitone 
and methylcholanthrene treated pregnant rats
Parameter Control Pheno­
barbitone
treated
Methylchol- 
. anthrene 
treated
Hydroxylation of biphenyl
Oumoles/gm.foetal liver/ 
hour)
0.1(2) - -
Reduction of p-nitro­
benzoic acid
(nmoles/gm.foetal liver/ 
hour)
0.1(3) - -
Conjugation of 4-MU with
glucuronic acid
(yumoles/gm.foetal liver/ 
hour)
9.1(3) 6.4(2) 8.4(1)
Cytochrome P450
(iijumo 1 e s/mg. mi c r o s o mal 
protein)
0.02 (.3) 0.08(2) 0.08(1)
The results show that there is no appreciable
hydroxylation of biphenyl, reduction'of p-nitrobenzoic 
acid or cytochrome P450 in the foetal livers of control 
rats. There is, however, a small amount of conjugation 
of 4-MU with glucuronic acid but expressed as a percentage 
of the total capacity of the mother this is only 1.0$.
Pretreatment of the mother rats with phenobarbitone 
or methylcholanthrene does not affect the conjugation 
of 4-MU with glucuronic acid in foetal liver, but it 
appears to induce the formation of cytochrome P450, 
to a slight extent.
However, the total amount of cytochrome P450 represents 
only 0.1 $ of the total amount in the maternal liver.
Discussion
The study of the effect of pregnancy in the rat 
on the hydroxylation of biphenyl showed a similar 
qualitative effect to that described by Creaven and 
Parke (1965), namely one of inhibition.' In quanti­
tative terms, though, the effect was different; I found 
only 25$ inhibition of hydroxylation using a similar 
method to Creaven, and even then the results for 
individual animals varied over a wide range. These 
widely varying results can probably be attributed to 
the fact that the concentration of the cofactor, IfADP, 
used was insufficient for optimum activity so that the 
amount present in the liver homogenate varied from rat 
to rat. Even so, using the revised conditions for 
determining biphenyl hydroxylation, which employ an 
optimum amount of NADP, a similar inhibition of '31$ 
was obtained in the pregnant rats. This effect is 
only manifested in 19-20 day pregnant rats; in 15-16 
day pregnant animals a slight decrease in activity was 
obtained but it was not significant. The results are 
similar to those found by Peuer and Liscio (1969) that 
in 14-20 day pregnant rats the 3-hydroxylation of 
4-methylcoumarin activity is inhibited by 50$.
A similar decrease in 4-methylumbelliferone 
glucuronyl transferase activity was observed in the 
19^20 day pregnant animals. This also agrees with the 
finding of Peuer - and Liscio (1969) that o-aminophenol 
glucuronyl transferase is inhibited during pregnancy- 
in the rat, and with the findings of Halac and 
Sicignano (1969) that the glucuronyl transferases 
responsible for conjugating bilirubin and p-nitrophenol 
in rat liver are inhibited during pregnancy. The amount 
of inhibition reported by both of these authors was in 
the order of 50$ which is greater than that found here.
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The decrease in the activity of these two enzymes 
in pregnancy was accompanied by a decrease in the 
concentration of cytochrome P450. Various workers 
have attempted to correlate hydroxylase and other 
enzyme activities thought to involve cytochrome P450 
with the actual content of the cytochrome (Orrenius 
et al, 1965; Orrenius and Ernster, 1964; Hemmer et al 
1968). Although this is sometimes possible, it 
frequently is not (Kratz and Staudinger, 1967;
Degkwitz et al,1968) and other factors have been impli­
cated. Por example the rate of reduction of cytochrome 
P450, and the activity of the enzyme PADPH-cytochrome 
c reductase have been suggested as limiting factors 
(Davies et al, 1969) rather than the content of P450.
I have not measured the activity of these enzymes in 
pregnant animals, but it seems possible that in this 
instance it is the concentration of cytochrome P450 
that could be the limiting factor. It would be of 
interest to measure the rate of cytochrome P450 
reduction and the activity of PADPH-cytochrome c reductase 
in pregnant rats in relation to the 3-hydroxylation of 
4-methylcoumarin since this is decreased twice as much 
as the P450 content (Peuer and Liscio, 1969).
It has been suggested that the reduction of 
p-nitrobenzoic acid to p-arninobenzoic acid is mediated 
by cytochrome P450 (Gillette et al 1968). Their 
evidence for this is based on two facts, a) carbon 
monoxide blocks nitroreduction; b) the rate of nitro- 
reduction is proportional to the amount of cytochrome 
P450 in liver microsomes from animals previously 
treated with either phenobarbitone or carbon tetra­
chloride. It has been shown here, however, that 
pregnancy in the rat causes a decrease in the concentra­
tion of cytochrome P450 in the liver but does not alter, 
or indeed slightly increases, nitroreduction. One 
possible explanation, of course, is that P450 is not,
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in fact, involved in nitroreduction. It had been 
suggested that nitroreduction could take place at an 
earlier stage in the electron transport system of 
liver microsomes (Gillette et al 1968): if the cytochrome 
P450 content was decreased, this could possibly channel 
the system 'towards increased activity in this respect.
An explanation that fits in with the ideas of Gillette 
is that during pregnancy some compound is present that 
can combine with cytochrome P450, and by so doing can 
caus.e an apparent decrease in the cytochrome P450 
content and block ' hydroxylation reactions, but not 
interfere., with nitroreduction. Sasame and Gillette 
(1969) have in fact shov/n that substances that cause 
type I spectral changes in liver microsomes either 
enhance or do not alter nitroreduction, although they 
combine with cytochrome P450. When type I substances 
are added to microsomal preparations in vitro they 
do not alter the CO-difference spectrum of reduced 
microsomes; however, when rats are pretreated with a 
type I compound for short periods there is an apparent 
decrease in cytochrome P450 content possibly due to the 
complex between P450 and substrate not having the same 
spectral properties (H. Rahman) i.e. the complex 
between substrate and P450 produces an apparent decrease 
in P450. The possibility exists therefore that during 
pregnancy in the rat a substance(s) combines with
cytochrome P450 to alter the CO-difference spectrum 
and inhibit hydroxylation, but not ni.tr o- -
reduction. This point will be considered later when 
the causes of these effects of pregnancy are considered.
All the above inhibitory effects are based on 
expressing the results as a function of unit liver 
weight, i.e. the specific activity or concentration. It has 
been shown previously (Paschkis and Cantarow 1958) and 
it has been shown here, that in the rat the liver
increases in size during the course of pregnancy.
Although it has been reported that the ratio of liver 
weight to body weight is increased in pregnant rats 
(Bokelmann and Schering,1932) I only found this to be so 
in the rats used here in the 15-16 day pregnant animals; 
in the almost full-term the ratio was the same. This 
might suggest that the liver weight has reached its 
maximum by the 15th day of pregnancy, or even before, and 
thereafter the body weight increases without a correspond­
ing increase in liver weight.
Now, when the results are expressed as a function 
of total liver weight there is no longer a decrease in 
hydroxylation of biphenyl, glucuronidation of 4-MU or 
content of cytochrome P450. Although there is no 
difference in these parameters, there Is an increase in 
nitroreduction and microsomal protein. Thus the total 
content of- these two parameters in 19-20 day pregnant 
animals is significantly different from that of non­
pregnant-. In the 15-16 day pregnant animals the slight 
inhibitions of biphenyl-4-hydroxylase and cytochrome P450 
content are converted to increases when expressed as total 
liver amounts, but these differences are not significant.
Thus the total liver content of biphenyl-4-hydroxylase 
4-MU glucuronyl transferase and cytochrome P450 in pregnant 
rats is no different from that of non-pregnant, and 
therefore the capacity of the pregnant rat to metabolize 
drugs and other and other foreign compounds should be as 
great as that of non- pregnant. Indeed, in some instances, 
e.g. when the major route of metabolism involves nitro­
reduction, the capacity of the pregnant rat is increased, 
since the total liver content of p-nitrobenzoic acid reduct 
ase and microsomal protein is greater than the non-pregnant 
In the livers of 15-16 day pregnant rats all 
five parameters are increased indicating that
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15-16 day pregnant rats should have a greater capacity 
to metabolize drugs than the non-pregnant.
Having shown that the total capacity of these 
pregnant rats to metabolize drugs is no less than non­
pregnant. , it must be pointed out that, in the 19-20 
day pregnant rats at least, the ratio of the liver 
weight to body weight is the•same as in non-pregnant: .
Thus the activity of these enzymes in respect to body 
weight will be decreased. This may be of importance 
when the foreign compounds in the diet are considered; 
obviously the mother is going to eat a greater amount 
of food and will therefore have larger amounts of 
"anutrients1* to metabolize. Thus, an effectively 
decreased ability to deal with this situation would 
seem to be a bad thing.
The results have also been expressed in terms of 
the microsomal protein content of the liver. The liver 
microsomal protein content itself v/as slightly increased 
in both 15-16 day and 19-20 day pregnant rats, but the 
increase v/as not significant. This slight increase, 
however, had the effect of enhancing the percentage 
inhibition of those parameters that were inhibited, 
when the results were expressed in terms of protein 
content. The fact that the 10,000 x g supernatant and 
microsomal, protein concentrations in the livers of 
pregnant rats did not differ significantly from non­
pregnant , would suggest that the composition of the 
"pregnant" liver as far as protein is concerned is 
similar to the non-pregnant. One would have expected, 
therefore, that the specific activity of the drug-metabdlizh 
enzymes ■ would not be changed in pregnancy, since it 
ife associated with the microsomal protein. Therefore, 
in spite of the fact that the total capacity of the 
pregnant rat to metabolize drugs is similar to the
non-pregnant, something happens to the liver during 
pregnancy so that the specific activities of certain 
enzymes, together with cytochrome P450 content, are 
decreased.
What then are the possible causes of these 
effects? In view of the fact that it is thought that 
the same microsomal enzymes are involved in the 
metabolism of steroids and drugs (Kuntzman 1969) a 
reasonable explanation might be that there is competi­
tion between the high levels of sex hormones circulating 
in the maternal blood during pregnancy and.the drugs 
and foreign compounds that act as substrates for the 
enzyme measured. Several groups of workers have in 
fact shown that steroid hormones, including progesterone 
and various oestrogens, are capable of inhibiting drug- 
metabolizing enzymes both competitively and non­
competitive ly in vitro (Juchau and Pouts, 1966; Tephly 
and Mannering 1968). If one can explain the decrease 
in activity of the enzymes by competition from these 
steroids, how can this explain the decrease in cyto­
chrome P450 concentration observed in the liver of the 
pregnant rat? A possible explanation is the formation 
of a steroid-cytochrome P450 complex, as mentioned 
previously, which decreases or does not possess a 
CO-difference spectrum.
The presence of high steroid levels in the maternal 
blood may produce profound effects on the functioning 
of the liver cell, by, for example, interfering with 
protein synthesis and control thereof. It is known that 
oestrogens can affect protein synthesis in the uterus 
(Greenman and Kenny,1964; &orski and Morgan, 1967) 
so it would be-possible that protein synthesis in the 
liver could be affected. Campbell and Kosterlitz 
(1949) have shown that during the latter stages of
pregnancy in the rat there is an increased content of 
RNA phosphate with no increase in DNA phosphate in the 
maternal liver, which is indicative of increased protein 
synthesis. Moreover, the increase still takes place if 
the foetuses are removed but the placentae left intact, 
which would indicate that the effect is brought about by 
the hormones produced by the placenta (Campbell and 
Kosterlitz, 1949). The- question then arises as to why 
an increase in protein synthesis should be accompanied 
by a decrease in cytochrome P450 content. This could be 
a question of priorities, there being more important 
proteins required during pregnancy than cytochrome P450, 
the result being that the new liver tissue that is formed 
during pregnancy, although as rich, or even moreso, in 
microsomal protein as non-pregnant, is not as rich in 
cytochrome P450.
This idea can be explained by the hypothesis 
suggested by Parke (1968a) (see Chapter one) that 
stimulation of drug-metabolizing enzymes brought about 
by inducers, such as phenobarbitone, is due to induction 
of one or more genetic systems by de-repression, of an 
operator (gene(s). Whatever is responsible for the 
effects of pregnancy on protein synthesis, whether it is 
a steroid or not, it would need to stimulate production 
of a repressor substance or act as a repressor itself 
if the site of control is nuclear. In this way synthesis 
of proteins involved in drug metabolism, i.e. mixed 
function oxidases, or other components of the microsomal 
hydroxylation system could be repressed enabling the 
hepatic cell to synthesise other more important proteins.
Phenobarbitone pretreatment of non-pregnant rats 
is known to increase cytochrome P450 as well as various 
drug-metabolizing enzyme activities. It has been shown 
here that phenobarbitone treatment of pregnant rats
increases cytochrome P450 and the enzymes that are 
inhibited by pregnancy. The enzymes are increased to 
the same level as in the non-pregnant, but the cytochrome 
P450 is not induced to such a great extent. The 
results are in agreement with those of Peuer and Liscio 
(1969) and Halac and Sicignano (1969) all of whom have 
shown that various drug-metabolizing enzymes can be 
induced during pregnancy in the rat by pretreatment 
with phenobarbitone. Peuer and Liscio (1969) say that 
their results suggest that various factors required for 
the synthesis of drug-metabolizing enzymes are present 
in the liver of pregnant rats but are inhibited.
Another possible explanation is that the phenobarbitone 
upsets the balance of protein synthesis in the maternal 
liver and thereby induces cytochrome P450 at the expense 
of other possibly more important proteins. Halac and 
Sicignano5(1969) demonstrated that the administration of 
phenobarbitone during pregnancy was not without 
consequences to the wellbeing of the litter. Resorption 
occurred and the viability of the foetuses v/as adversely 
affected. This could fit in with the interpretation 
suggested above, if.hus, phenobarbitone v/ould derepress 
the operator gene, thereby allowing the synthesis of 
cytochrome P450 and mixed-function oxidases to take 
place,, again in preference to proteins needed for foetal grov/th.
Are all these changes, though, brought about by 
the increased steroid levels during pregnancy? This 
question is discussed more fully in the next chapter 
where the effects of1 addition In* vitro' “•
of progestogens and oestrogens to enzyme incubation 
mixtures and the effect of pretreatment of female rats 
with these steroids on liver microsomal drug-metabolizing 
enzyme systems are investigated.
What other possible explanations are there?
The effects observed could be due to a deficiency 
of some component that is required for cytochrome P450 
synthesis. It is well known that during gestation 
the pregnant animal has a  greatly increased requirement 
for iron, which is an important part of haemoproteins 
and consequently of cytochrome P450. Thus, during 
pregnancy a deficiency of iron in the diet could lead 
to decreased production of cytochrome P450 and hence 
decreased drug-metabolizing enzyme activity. The fact 
that'phenobarbitone induces cytochrome P450 and drug- 
metabolizing enzyme activity during pregnancy does not 
rule out this possibility because, if the explanation 
suggested above is true,the pretreatment would channel 
the available iron to cytochrome P450 formation at the 
expense of other proteins. Thus in normal pregnancy 
an insufficiency of iron in the diet might; lead to 
synthesis of other proteins at the expense of cytochrome 
P450 and other iron proteins. Such an explanation 'might 
account-for the fact that -'a. certain individual rats 
failed to show a decrease in cytochrome P450 or biphenyl 
hydroxylation, although the overall picture showed that 
a significant decrease was obtained. Thus those rats 
that showed no inhibition may have had sufficient iron 
in the diet. However, all rats were fed on 
t-he same diet ad libitum. At present no other
explanation of these discrepancies is apparent. It 
could be possible that there is a seasonal variation 
in the effect of pregnancy on drug-metabolising enzymes.
It has been established that under many conditions 
characterized by rapid growth of liver cells, microsomal 
drug-metabolizing enzyme activities are lower than 
normal (Pouts, 1963b). Por example, microsomal prepar­
ations of foetal or newborn livers, show decreased drug- 
metabolizing activity (Pouts and Adamson, 1959»Jondorf 
et al 1958; Pouts and Iiart,1965) as do livers which are
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rapidly growing after partial hepatectomy (Pouts et al 
1961). Tumour bearing rats have also been shown to 
possess less drug-metabolizing activity in the liver 
(Adamson and Pouts 1961) and a reduced cytochrome P450 
content (Kato et al 1968a). The presence of growth 
promoting factors has been reported in all of these 
groups of rats and in pregnant rats, (Kato et al 1968a). 
It is possible then that a similar mechanism is 
functioning in all these conditions, a mechanism in 
which growth promoting factors (hormones?) are 
stimulating one form of growth at the expense of the 
other, the ’other’ being the cytochrome P450 and drug- 
metabolizing enzymes. Pretreatment with an inducer 
of drug-metabolism then channels the effect of the growth 
hormone to stimulating cytochrome P450 and drug- 
metabolizing enzymes rat the expense of the other growth.
In this respect it is interesting to note that it 
is over the last seven days of pregnancy in the rat 
that the greatest increase in body weight takes place 
(see Table 7.2* Chapter seven) due to the rapid growth 
of the foetuses, and it is over the same period that the 
RNA "content of the liver increases (Campbell and 
Kosterlitz 1949)> and that the inhibitory effect of ' 
pregnancy on drug-metabolizing enzymes occurs, since 
there is no significant decrease in cytochrome P450 
content or enzyme activity in 15-16 day pregnant rats.
It would seem that the effect of a second pregnancy 
on drug-metabolizing enzymes in the rat liver is similar 
to the first, but less marked. The fact that the liver 
does not increase in size to the same extent as in the 
first pregnancy may account for this, since the total 
capacity will -remain the same.
The results obtained with pregnant rabbits were 
different from those with the pregnant rats. The only
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parameters that differed in the non-pregnant and 
pregnant rabbits were the body weight and hepatic 
coumarin hydroxylation. The body weight v/as 
increased, while the coumarin hydroxylation v/as 
decreased quite considerably. Hydroxylation of 
biphenyl, glucuronidation of 4-MU'and cytochrome P450 
content, all of which were altered in the rat liver by 
pregnancy, v/ere not altered in the rabbit liver by 
pregnancy. Neither were the reduction of p-nitrobenzoic 
acid nor the microsomal protein content, two- parameters 
that were not altered in the rat either. Moreover, 
the liver weight was not increased as it was in the 
rat. The result for hydroxylation of biphenyl does 
not agree with the findings of Creaven and* Parke (1965) 
while that on coumarin hydroxylation is in excellent 
agreement. However, they used a different strain of 
rabbit - the Chinchilla. The fact that the coumarin 
hydroxylation is inhibited at earlier stages of 
pregnancy as well, might suggest that this enzyme is 
inhibited by direct competition from steroids in the 
blood. However, Mikhail et al (1961) reported that 
progesterone levels in the pregnant rabbit are maximal 
at mid-pregnancy in which case one might expect more 
inhibition at 15 days. Phenobarbitone pretreatment of 
pregnant rabbits during the last three days of pregnancy, 
as in the rat, induces the hepatic drug-metabolizing 
enzymes measured and cytochrome P450.
It would thus appear that there is a species 
difference betv/een the rat and the rabbit in the effect 
of pregnancy on drug-metabolizing enzymes and cytochrome 
P450. The differences could possibly be accounted for 
by different dietary requirement or content of iron, 
but are more probably due to fundamental differences 
that are responsible for other species differences in 
drug metabolism but which are as yet unsolved.
The results obtained with placental and foetal 
liver tissue show that neither of these tissues is 
able to hydroxylate biphenyl or reduce p-nitrobenzoic 
acid to any measurable extent. Cytochrome P450 is not 
detectable either in these tissues. However, both of 
these tissues are capable of conjugating 4-KU with 
glucuronic acid. These results, therefore, do not 
agree with those of Juchau (1969) who showed that rat 
placentae are able to reduce p-nitrobenzoic acid to 
p-aminobenzoic acid. Dixon and Willson (1968) showed 
that rabbit placentae and foetal livers were unable to 
metabolize hexobarbitone, but were able to metabolize 
zoxazolamine. Thus it would seem that in this respect 
hexobarbitone and biphenyl belong to the same class.
It seems, therefore, that the placenta and foetal 
livers are unlikely to influence much the overall 
metabolism of drugs administered to the pregnant mother.
Treatment of pregnant rats for the last three days 
of pregnancy with inducers of drug-metabolizing enzymes - 
phenobarbitone or methylcholanthrene - had no effect on 
the hydroxylation of biphenyl, reduction of p-nitrobenzoic 
acid, conjugation of 4-MU with glucuronic acid or 
cytochrome P450 by the placentae. The effect of pheno­
barbitone agrees with the observations of Dixon and 
Willson (1968) that phenobarbitone failed to stimulate 
hexobarbitone or zoxazolamine metabolism in the placenta. 
There are several possible explanations for the lack of 
induction by phenobarbitone; the phenobarbitone may not 
penetrate the placenta, but this is unlikely; or, there 
may be no potential drug-metabolizing tissue present, 
so it cannot be induced..
Similar pretreatment with enzyme inducers does not 
affect the conjugation of 4-MU with glucuronic acid by 
foetal liver preparations, but it does appear to induce 
the formation of cytochrome P450, although by only a 
very small amount.
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The results described in this chapter have shown 
some effects of pregnancy in rats and rabbits on 
drug-metabolizing enzymes and cytochrome P450 in 
maternal and foetal livers and placentae. Suggestions 
have been made as to the possible causes of some of 
these effects. Some experiments designed to investi­
gate the role of the hormones produced during 
pregnancy in this context are described in the 
following chapter. Other experiments that could be 
designed to investigate the causes of these effects 
in pregnancy could include studying the effect of 
growth hormone and iron (both deficiency and 
supplements during pregnancy) on drug-metabolizing 
enzymes in non-pregnant rats.
s
CHAPTER VI.
EFFECTS OP PROGESTOGENS. OESTROGENS 
M E  ORAL CONTRACEPTIVE STEROIDS
ON HEPATIC DRUG-METABOLIZING ENZYMES
Introduction
The question has been posed as to what is the 
cause of the inhibitory effect of pregnancy on certain 
drug-metabolizing enzymes in rat liver. Hsia et al (1963) 
have suggested that the high blood level of progestogens 
in the human during pregnancy might inhibit glucuronide 
formation, so it may be possible that the same explanation 
could account for the inhibitory effects of pregnancy on 
this and other metabolic transformations of drugs 
in the rat. If these inhibitory effects are caused by 
the hormones of pregnancy are they due to competition 
of the steroids with the drugs for the drug-metabolizing 
enzymes or to non-competitive inhibition,or to some other 
mechanism of action? What also are the effects of the 
semi-synthetic steroids which are used as oral contra­
ceptive agents?
Several workers have investigated the effects of 
various steroidal hormones on the activity of drug- 
metabolizing enzymes in vitro and found inhibitory 
effects. Thus several steroids, including progesterone 
and oestradiol, were found to be competitive inhibitors 
of the metabolism of ethylmorphine, hexobarbitone and 
zoxazolamine in vitro (Tephly and Mannering, 1964 and 
1968, Juchau and Pouts, 1966). Progesterone, but not 
oestradiol, was found to inhibit guinea-pig liver 
glucuronyl transferases responsible for conjugating 
o-aminophenol, p-nitrophenol and 4-methylumbelliferone. 
(Hsia et al 1963). Pretreatment of animals with 
steroids has also been investigated to some extent.
Juchau and Pouts (1966) reported that one hour after a 
large dose of either progesterone or'norethynodrel the 
in vitro metabolism of hexobarbitone and zoxazolamine 
in rat liver was inhibited. However, twenty-four hours 
afterwards, the metabolism of both compounds was increased 
by the pretreatment with norethynodrel but was unaltered
by the progesterone treatment. Thus norethynodrel was 
found to be an inducer of certain drug-metabolizing 
enzymes.
The work described in this chapter, therefore, is 
directed towards determining the effects of the natural 
steroids of pregnancy on drug-metabolizing enzymes to 
ascertain whether these hormones play any part in the 
overall inhibitory effects of pregnancy on these enzymes 
in the rat liver. The effects on these enzymes of 
synthetic steroids used as oral contraceptives have 
also been studied to see whether they have an effect 
similar to the endogenous hormones or whether they may 
act as inducers of drug metabolism as previously 
suggested (Juchau and Pouts, 1966).
Remmer a t ’ al:, (1966) have investigated the 
effect of in vitro addition of various compounds on the 
absorption spectrum of cytochrome P450. They have shown 
that the addition of any substrate that is hydroxylated 
will change the absorption spectrum of the oxidised P450, 
giving rise to one of two different types of spectra 
indicating that two different types of binding to 
cytochrome P450 occur. The effects of progesterone and 
oestradiol on the absolute absorption spectrum of 
cytochrome P450 have now been studied to see whether 
they give rise to type I, type II or neither type of 
spectrum. The effects of these compounds on the 00- 
difference spectrum of reduced microsomes have also 
been determined to see whether the steroids can combine 
with cytochrome P450 and thereby interfere with the 
normal estimation procedure of this enzyme.
Materials and Methods
The experiments described in this chapter concern 
the effect of the following steroids - progesterone, 
pregnanediol, oestradiol, norethynodrel, ethynodiol, 
norethisterone, chlormadinone and mestranol on the
activity of the following drug-metabolizing enzyme
systems of rat and rabbit liver preparations:-
4-hydroxylation of biphenyl,
7-hydroxylation of coumarin,
dealkylation of 4-methoxybiphenyl and of 4-ethoxybipheny
reduction of p-nitrobenzoic acid,
cytochrome P450,
conjugation of’4-MU with glucuronic acid.
The structures of the steroids used and the methods 
for the determination of the enzyme activities are given 
in Chapter
The experiments performed were of 'two types:-
a) those in which the steroids were added directly 
to the enzyme system in vitro. This type of experiment 
was designed to show any direct inhibitory effect of the . 
steroids.
b) those in which rats were pretreated for 
varying lengths of time with the steroids and then the 
activity of the hepatic microsomal enzymes determined 
in vitro. Pretreatment for short periods of time, e.g. 
one hour, is likely to reveal any inhibitory effect which 
may not- be shown by simple in vitro addition of the 
steroid, for example, effects brought about by a metabo­
lite of the steroid. Pretreatment for twenty-four 
hours or three days will reveal any inducing properties 
that the steroids may possess (Conney, 1967)* Finally, 
pretreatment for longer periods of time may show effects 
that are produced by chronic exposure to steroids such as 
are found during natural pregnancy and the pseudo­
pregnancy state produced by oral contraceptive agents.
In vitro additions of steroids
In studying the effect of direct addition of a 
steroid to enzyme preparations in vitro, the steroid was 
dissolved in a suitable volume of acetone such that the
_ c
effects of final concentrations of 10 , 10 and 10 M
could be observed. The volume of acetone added was
never greater than 0.1 ml., and was often considerably 
less, depending on the solubility of the steroid. A 
similar volume of acetone was added to control,standard 
and blank enzyme incubations. Acetone (0.1 ml) 
produced a slight decrease in activity of the hydroxy- 
lating enzymes, but this decrease was less than 10$
of the activity in the absence of acetone: smaller ---
volumes did not alter the activity of any of the enzymes. 
Pregnanediol is insoluble in acetone,and was therefore 
added in dimethyl sulphoxide,(DMSO). This solvent alone did 
not alter the enzyme activity.
The natu.re of the inhibitory effect of progesterone 
on the demethylation of 4-methoxybiphenyl was examined 
using the Lineweaver-Burk (1934) plot. To obtain the 
data for this, three inhibitor concentrations and six 
substrate concentrations were used. The substrate 
solutions were all prepared from the original (12 yumoles/ml) 
solution by diluting v/ith 2$ w/v Tween 80 in 1.15$ w/v 
potassium chloride solution such that the volume of 
substrate solution added to each incubation was 0.5 ml.
This was done to eliminate any possible extraneous effect 
of the Tween 80, such as its effect on the solubility of 
the steroids.
Effects of the in vitro addition of steroids on 
cytochrome P450 were measured in a similar manner to 
that described by Remmer et al (1968). Female Wistar 
albino rats weighing approximately 150 gm. were given 
phenobarbitone sodium orally (0.1$ solution in the 
drinking water) for seven days prior to killing.
Untreated rats were used as controls. The cytochrome 
b^ and cytochrome P450 were determined in both the 
phenobarbitone- pretreated and the control animals. The 
cytochrome b^ v/as determined in a similar manner to the 
cytochrome P450 as described in Chaptertwo , except that 
the difference spectrum between oxidised and reduced
microsomes (reduced with 0 .1' ml, of a 2°/o NADPH2 
solution to 3 ml. of microsomes) was determined and the 
difference between the absorbance at 424 and 409 nm. 
was used as a measure of the cytochrome b^ content.
The increase in cytochrome b^ caused by phenobarbitone 
induction is not as great as the increase in cytochrome 
P450. Thus by diluting the induced microsomal suspension 
to give the same concentration of cytochrome b^ as in 
the control, the resulting difference spectrum between 
control and diluted induced microsomes is the absolute 
spectrum of cytochrome P450. Various steroids were 
then added to the induced microsomal suspension, 
dissolved in 0.01 ml. acetone, and any change in the 
absorption pattern measured.
A simpler method was also used for studying the 
effect of steroids on the absorption spectrum of 
oxidised cytochrome P450, in which microsomes from 
phenobarbitone induced rats alone were used. A sample 
(3 ml) of microsomal suspension diluted 1:2 with 0 .2Ii 
phosphate buffer, 'was placed in each of the two cuvettes. 
To one cuvette (the sample) the steroid dissolved in 
acetone (0.1 ml.), was added to give a final concentra­
tion of 10“4 or 10”^M ; to the other cuvette (the 
reference) acetone (0.1 ml.) alone was added, and the 
difference spectrum between the sample and reference 
cuvettes was determined between 450 and 350 nm.
The effect of several steroids on the 00-difference 
spectrum of reduced cytochrome P450 was also investigated. 
Por this the steroid, dissolved in acetone (0.1 ml), was 
added to the sample cuvette before the dithionite.
Acetone alone was added to the reference cuvette. The 
difference spectrum was then obtained in the usual manner 
with CO and compared with that obtained without the 
steroid.
Pretreatment with steroids
All steroids were administered in ethyl oleate, 
except for pregnanediol which was given in dimethyl- 
sulphoxide. Control animals received solvent alone 
at a dose level of 2 ml/kg. In acute studies, i.e. 
where only one single dose was given, the rats 
received a single intraperitoneal injection either 
one or twenty-four hours prior to killing. In 
subacute studies, i.e. three days pretreatment, the 
rats were given a daily intraperitoneal injection at 
the same time each day, and were killed twenty-four 
hours after the final dose. The rats that ware, 
chronically treated with steroids received a daily 
dose by either intraperitoneal or intramuscular 
injection at approximately the same time each day and 
were finally killed twenty-four hours after the last 
injection.' The volume of vehicle injected for intra­
muscular injections was in the order of 0.1 - 0.2 ml.
For studying the effect of prolonged pretreatment 
of female rats with low doses of progestogen it was 
obviously impractical to give the compounds by 
injection so the oral route was used. The steroids 
were dissolved in arachis oil which was then evenly 
dispersed in a ration of powdered rat chow. For the 
control animals arachis oil alone was used. A 
suitable ration for one rat for one day was found to 
be 20 g. of diet so that 0.1 mg. of steroid was 
mixed with each 20 gm. of food. The animals were 
kept in groups of six and each group was given 120 gm. 
of food daily at approximately 10.00 a.m. Thus 
the daily dose per animal was about 0.1 mg. of 
steroid (0.5 mg/kg).
Results
1• Effect of steroids on drug-metabolizing enzymes in vitro.
a. In the rat
i) The hydroxylation of biphenyl.
The effects of the addition in vitro of several 
progestogens and oestrogens on the hydroxylation of 
biphenyl by rat liver preparations were determined using 
both the original method of Creaven et al (1965b) and the 
modified method described in Chapter three. The major 
difference was the lower concentration of NADP employed 
in the former. The effects of the addition of progesterone, 
norethynodrel, norethisterone, ethynodiol diacetate, 
pregnanediol, oestradiol, oestrone and testosterone to 
liver preparations (10,000 x g supernatant) of mature 
female rats on the hydroxylation of biphenyl are shown 
in Table 6. 1.
The results show that all types of steroids 
examined - progestogens, oestrogens and androgen, are 
capable of producing inhibition of the hydroxylation 
of biphenyl by rat liver homogenates in vitro, but only 
at relatively high concentrations. Both progesterone 
and oestradiol produced about the same degree of 
inhibition at a concentration of 10 M, as did test-, 
osterone, which indicates that this action is fairly 
generalised. The synthetic progestogens derived 
from 19-nortestosterone: norethynodrel, ethynodiol 
diacetate and norethisterone acetate,allproduced a 
slightly greater inhibitory effect. The concentrations 
used in these experiments are very close to the limit of 
solubility of these steroids, and although this is 
enhanced by the presence of Tween 80, it could be that 
many of the differences in inhibitory action of the 
different steroids may be attributed to differences in 
solubility.
Although the concentration of steroid required 
to give a significant inhibition of the hydroxylation 
reaction is high, it is very similar to the concentra­
tion of substrate(biphenyl) used* In the original method the 
biphenyl concentration was 2 x 10~ % ,  whilst in the 
modified method it was 1.5 x 10 M. This difference 
probably accounts for the slightly greater inhibition 
obtained using the modified method.
Table 6. 1
Effect of in vitro addition of progestogens and oestrogens' 
on the hydroxylation of biphenyl by rat liver -preparations
Steroid Concentration
(M)
Percentage inhibition 
using
Original
Method
!
Modified
Method
Progesterone 10“5 . 0 0
it io"4 0 ii i 5
u O
1
37 i 3 43 - 3
Pregnanediol 10~4 3 -
Norethynodrel . 10" 5 1 5
tt 10~4 5 2 3 - 5
u 10" 5 6 8 - 3 72 ± 2
Norethisterone 10"4 0 2 9 - 3
tt 10" 5 32 ±  2 68 ± 1
Ethynodiol 10~4 0 22 t 5
diacetate 4- 4-tt 10 p 2 7 - 3 58 ± 1
Chlormadinone 10“4 — 4
acetate ■2 4-
tt 10 3 - 20 i 5
Oestradiol 10"4 2 5
it o
I V>
3
35 - 2 38 i 4
Oestrone 10”5 20 i 4 ~  .
Mestranol 10~3 -  ' 25 - 2
Testosterone ■ 10“3 - 5 3 - 1
The results are the mean of at least three separate 
determinations.
ii) The dealkylation of 4-methoxybiphenyl and 
of 4~ethoxybiphenyl.
The effect of several steroids in vitro on 
dealkylation by rat liver preparations was also inves­
tigated. The systems studied were the demethylation of 
4-methoxybiphenyl and the de-ethylation of 4-ethoxy- 
biphenyl (Creaven et al 1966). The incubation conditions 
used were similar to those described by Creaven et al 
(1966) for studying dealkylation by rabbit liver 
preparations, and are summarised in Chapter two. It is 
not known whether these conditions are optimal, 
particularly with respect to 1TADP, for rat liver 
preparations as they have not been re-investigated. 
However, since the steroids produced similar levels of 
inhibition of biphenyl hydroxylation with both the 
original and modified incubation systems, it is likely 
that the NADP concentration employed in the dealkylation 
experiments would prove adequate for the determination 
of enzyme inhibition.
The effects of progesterone, norethynodrel, 
norethisterone acetate, ethynodiol diacetate, oestradiol 
and oestrone on the dealkylation of 4-methoxybiphenyl and 
4-ethoxybiphenyl by liver 10,000 x g supernatant 
preparations from mature female rats are shown in 
Table 6. 2.
All of the steroids used’showed some degree of
-4 -3inhibition at the concentrations used— 10 and 10 M. 
The inhibition of dealkylation was greater than the 
inhibition of aromatic hydroxylation for a similar 
concentration of steroid, but this could be accounted 
for by the fact that the substrate concentration used 
in the dealkylations is 0.33 x 10 M which is about 
one-sixth of the substrate concentration used in the 
aromatic hydroxylation. The effect produced by the 
synthetic progestogens norethynodrel, norethisterone
and ethynodiol was again somewhat greater than that 
produced by progesterone. The oestrogens produced a 
less marked effect.
Table 6. 2
Effect of in vitro addition of steroids on the 
dealkylation of 4-methoxybiphenyl and of 4-ethoxybiphenyl 
by rat liver preparations.
Steroid Concentration
(M)
Percentage
of
inhibition
4-Methoxy- 
biphenyl 
demethyla­
tion
4-Ethoxy- 
biphenyl 
de-ethyl 
at ion
Progesterone
H
10“4
10“3
35
66
29
59
Horethynodrel 10“ 4 26 28
H 10“ 3 74 75
Norethisterone
acetate 10“ 4 ' 23 18
it 10"3 56 70
Ethynodiol
diacetate 10“ 3 55 52
r *
Oestradiol H O
1 V>) 43 41
Oestrone H O
1
12 11
The results are the mean of three determinations: no 
appreciable difference between individual results was 
obtained.
As progesterone produced a slightly greater inhibi­
tion of deraethylation than of aromatic hydroxylation, it 
was decided to use the former system to investigate the 
nature of the inhibition of the hepatic mixed-functional 
oxygenases by progesterone. The rate of demethylation
of 4-methoxybiphenyl by rat liver 10,000 x g supernatant 
was measured at several substrate concentrations without 
inhibitor and in the presence of three concentrations 
of progesterone. The data obtained from this 
determination which are the mean of at least three 
determinations, are shown in Table 6.3: the values of 
Km and Vmax were obtained graphically from a Lineweaver 
Burk (1934) plot of ~  against ~, which is shown in
v S
Pig. 6.1 .
Table 6. 3
Bemethylation of 4-methoxybiphenyl at various substrate 
concentrations in the presence and absence of progesterone
Substrate
concen­
tration
fyimoles/
incuba­
tion)
Velocity (pinoles 4-hydroxybiphenyl produced/
gm.liver/hr.)
Proges­
terone hone 
concen­
tration
10 Vi 0.5x10%
I
H O
1
1.0 0.43- 0.25 0.22 0.13
0.5 0.40 0.24 0.22 0.11
0.25 0.30 0.17 0.13'. 0.05
0.17- 0.22 0.13 - 0.03
0.125 0.19 0.10 - 0.02
H
•
O
0.16 0.09 0.08 0.02
S3-
1 
• 
!l 59.5xlO~6 92.6x10"6 lllxlO-6 714xl0"6
%iax ” 0.44 0.33 0.32 0.40
The near consistency of V and the characteristic
IilciX
configuration of the plotted data indicate that the mode 
of inhibition of the demethylation of 4-methoxybiphenyl 
■by progesterone is competitive in nature.
Pig, 6, 1. Inhibition of the microsomal demethylation 
of 4-methoxybiphenyl by progesterone in 
mature female rats.
20
10
2812 16 20
i X 10-3ms
-12 -4
v = pnoles 4-hydroxybiphenyl produced per gram liver per hour 
s = substrate concentration
A— A 10~^M Progesterone; ^— a. 0.5 x 10~%I Progesterone, 
o— o  10“4-M Progesterone; o— © Ho Progesterone
iii) The reduetidni. of p-nitrobenzoic acid
~  ' — —     - - ■—  -■■■■, .y . » »      - ■ ■  .......  —  „ „ ■ ,« »
The effect of progesterone, oestradiol, ethynodiol 
diacetate and’ mestranol on the reduction of p-nitrobenzoic 
acid by liver preparations from mature female rats is 
shov/n in Table 6. 4.
Table 6. 4
Effect of in vitro addition of progestogens and oestrogens 
on the reduction of p-nitrobenzoic acid by rat liver
preparations
Steroid 0 one e nt rat ion (M ) Percentage
Inhibition
Progesterone 10~3 3 0
h h-
> O
1 -P* 1 3
Ethynodiol
diacetate
N~\IoH 10
ti io-4 0
Oestradiol io-3 19
Mestranol io-3 19
The results are the mean of three determinations: 
no appreciable difference between individual results 
obtained. . -
The results show that with this enzyme system also 
the effect of adding various steroids to the enzyme 
incubation is inhibitory, although the effects produced 
are less marked than those observed with aromatic 
hydroxylation and the dealkylations. The substrate 
concentration -used was 2 x 10 I^i, which is the same 
as the concentration of biphenyl used in the original 
incubation conditions for the determination of the 
4-hydroxylation of biphenyl. Thus the percentage
inhibitions of the aromatic hydroxylation and nitro- 
reduction reactions by progesterone at a concentration 
of 10“%  and for similar substrate concentrations 
were 37$ and 30$ respectively. A minor, but possibly 
important factor, which might play a role here, is 
the presence of Tween 80 in the hydroxylation incuba­
tions but not in the reduction incubations. The 
presence of Tween 80 may help to maintain the steroids 
in solution.
iv) Cytochrome P450
Neither progesterone, at final concentration of 
10“4 and 10”% ,  nor oestradiol, at a final concentration 
of 10-%, produced any effect on the CO-difference 
spectrum; nor did hexobarbitone (10”% ) .
In the mature female rats used in these experiments 
phenobarbitone pretreatment induced the cytochrome b^ 
to almost the same extent as the cytochrome P450, 120?° 
and 140$ respectively (three determinations). The 
absolute spectrum of cytochrome P450 obtained was, 
therefore, only a very small peak. Nevertheless, 
hexobarbitone and aniline added at final concentrations 
of 10“%  caused detectable shifts in the spectrum 
typical of type I and type II substances respectively. 
Neither progesterone (10^ or 10"“% )  nor oestradiol 
(10“% )  caused detectable shifts of the peak.
Using the other method whereby microsomes from 
induced animals alone were used and difference spectra 
measured, again very small peaks were obtained. 
Hexobarbitone (10“% )  produced a typical type I 
difference spectrum but neither, progesterone (10“ % )  
nor oestradiol (10“% )  produced any detectable difference 
spectrum.
It must be emphasised that with all these experi­
ments involving the absolute spectrum of cytochrome P450
only very small peaks were obtained, and so detecting 
differences was very difficult.
b. In the rabbit
The effect of adding progesterone, norethynodrel 
and norethisterone acetate at final concentration 
of 10“3j>i to incubations of rabbit liver 10,000 x g 
supernatant on the 7-hydroxylation of coumarin, 
4-hydroxylation of biphenyl, demethylation of 4- 
methoxybiphenyl and de-ethylation of 4-ethoxybiphenyl 
are shown in Table 6. 5.
Table 6. 5
Effect of steroids in vitro on drug-metabolizing 
enzymes of rabbit liver microsomal preparations
Steroid Percentage inhibition 
activities:
of the following
7-hydroxy­
lation of 
c oumar in
4-hydroxy- 
lation of 
biphenyl
Eemethy- 
lation 
of 4- 
methoxy- 
biphenyl
Pe-ethyl- 
ation of 
4-
ethoxy- 
biphenyl
Progesterone 47 13 49 51'
Norethynodrel 60 15 55 65
Norethisterone - 13 60 54
The results are the mean of three determinations.
The results show that,■as with the rat, the effect
of these progestogens is inhibitory, although again 
only in high concentrations. The inhibition produced 
is also less than that which is produced by similar 
concentration of the steroids on the rat enzymes. The 
difference in effect on the two aromatic oxygenases is 
probably accounted for by the difference in substrate
concentrations used. For biphenyl this is 2 x .10“ %1 
and for coumarin 0.33 x 10" 3m . This explanation is 
supported by the fact that the two dealkylation 
reactions, where the substrate concentration is also 
0.33 x 10"5m , show a similar degree of inhibition to 
the 7-hydroxylation of coumarin.
2. Pretreatment studies with steroidal hormones
i* Progesterone
The effect of intraperitoneal pretreatment of . 
mature female- rats with progesterone on the hydroxylation 
of biphenyl was investigated by determination of the 
enzyme activity in vitro at various time intervals after 
injection. The results are shown in Table 6. 6. The 
dose of progesterone, 25 mg/kg in solution in ethyl oleate, 
was given intraperitoneally 1 and 24 hours prior to 
sacrifice. Those animals pretreated for three days 
received three daily doses of 25 mg/kg, and were killed 
24 hours after the final injection.
Table 6. 6
Effect of pretreatment of matuhe female rats with proges- 
gesterone on the hydroxylation of biphenyl by liver 
microsomal preparations
Period of 
pretreatment
Enzyme activity 
(Mmoles product/gm.liver/hr
Percentage
change
Controls Pretreated
None 
1 hour 
24 hours 
3 days
3.68^0.22 (13)
3.59-0.24 (9)
3.59-0.24 (9) 
4.27- .21 (6)
3.66to.l5(8)
3.15-0.10(6)
4.12±0.22(6)
+ 2 
- 12 
- 4
Numbers in parenthes. s represent the number of 
animals used for that determination.
The results show that none of the pretreatments 
produced any-significant change in the hydroxylation of 
biphenyl by liver preparations.
These results are in contrast to those of Table
6.7, which shows the effect of three days progesterone 
pretreatment on biphenyl hydroxylation and cytochrome 
P450 content of liver preparations of immature male and 
female rats. It should be noted, however, that the 
experiment has only been carried out on two rats in 
each group, so the results can only be considered as an 
indication that induction occurs.
Table 6. 7
Effect of pretreatment of immature male and female rats 
with progesterone on the hydroxylation of biphenyl r.
and cytochrome P450 content of liver preparations
Parameter Sex Controls Pretreated Percent­
age
differ­
ence
Body weight gain M 16,15 (16) 20 ,21 (21) + 31
. (grams) P 14,17 (16) 16 , 15 (16) 0
4-Hydroxylation of M 4.82,5.09 5. 66,5 • 58.
biphenyl (yumoles (4.96) (5. 62) + 14
product/gm.liver/ 
hour) P 4.91,5115
(5.03)
5. 46,5
(5.
.52.
49) + 9
2-Hydroxylation of M 0.87,0194 1. 01,1 .09
biphenyl (/imoles (0.91) (1. 05) + 15
product/gm.liver/ 
hour) P 1.24,1.06
(1.15)
1. 47,1
(1.
.58
55) + 33
Cytochrome P450 M 0.93,0.94 1. 13,1 .13
concentration (0.94) (1. 13) + 20
(npmoles/mg.
protein)
P 0.92,0.90 1. 05,1 .08
(0.91) (1 .07) + 18
The figures in parentheses are the means of the 
two individual results.
The results show that pretreatment of immature 
rats of both sexes with progesterone causes an upward 
trend in hydroxylating enzymes and cytochrome P450.
The effects of one hour and three days pretreatment, 
of mature female rats with progesterone, on other liver 
parameters, are shown in Table 6.8. The doses used were 
similar to those used for Table 6.6. The results are 
the means of three animals in each case.
Table 6. 8
Effect of pretreatment of mature female rats with 
progesterone on various liver parameters
Parameter . 1 hour pretreated 3 days pretreated
Controls Pre­
treated
Controls Pre-
treated
Body weight 
(grams)
189 -  5 194 -  2 246 - 12 249 - 12
Liver weight 
(grams)
6.1-0.4 6 . 0 - 0 . 4 7.8-0.1 8.1±0.1
Cytochrome P450 
(njjumoles/
mg/protein)
0.66±0.02 0 . 6 3 - 0 £ ) 2 0.68i04)l 0.67-0.01
p-Hitrobenzoic 
acid reduction 
(nmoles/ 
gin. liver/hr)
1.79-0.15 1.8li0.16 1.36-0.08 1. 54^-0.03
Microsomal protein 
(mg/gm.liver)
27.5-0.4 26.7-0.7 26.9-1.7 25.6^0.7
4-MU. glucuronida- 
(nmoles/ tion 
gm.liver/hr)
87.0±13 83. 5 - 3 70.8±4.1 70.oil.5
Again it was found that pretreatment-with proges­
terone either for one hour or three days produced no 
significant effect on the parameters measured.
The effect of pretreating mature female rats 
with progesterone at a. dose of 1 mg. per animal daily 
for 18 days is shown in Table 6.9* The hormone was 
administered by intramuscular injection to prolong 
its effect.
Table 6. 9
Effect of chronic pretreatment of female rats with proges­
terone on various liver ■parameters
Parameter Controls Pretreated Percent­
age
change
Body weight(grams) 
(Before) 215 - 5 205 i 6 - 5
(After) 232 - 4 235 - 8 + 1
Liver weight(grams) 8.8 t 0.4 6.9 - 0.4 - 22
Biphenyl-4- 
hydroxylation 
(yumoles/product/ 
gm.liver/hour)
2.78 ± 0.19 3.06 - 0.09 + 10
p-nitrobenzoic acid 
^reduction (yamoles 
product/gm.liver/ 
hour)
2.75 - 0.27 2.72 - 0.18 - 1
4 MU. glucuronidation 
Oumoles conjugated/ 
gm.liver/hour)
85 J 4 1 1 - 2 - 9
Microsomal protein 
(mg/gm.liver)
23.2 i 0.8 26.5 - 0.7 + 14
Cytochrome P450 
(mjumoles/mg. protein)
0.58 t  0.03 0.59 - 0.01 + 2
The results are the mean of three animals.
The liver weight is decreased in the treated 
animals; none of the other parameters is significantly 
changed although the microsomal protein content and 
hydroxylation of biphenyl are slightly increased.
ii. Pregnanediol •
The compound used was 4 pregnane-3©^ -20^ -diol, 
at a dose of 4 mg/kg, and the effect on various liver 
parameters of giving this dose (dissolved in dimethyl 
sulphoxide) daily for three days intraperitoneally 
to mature female rats is shown in Table 6.10.
Table 6. 10
Effect of three days pretreatment of mature female rats 
with pregnanediol on various liver parameters
Parameter Controls Pretreated °/o Pi 
ence
ffer-
Hydroxylation of 
biphenyl "
(yumoles product/ 
gm.liver/hour)
3.88 ± 0.33 4.34 - 0.18 + 12
tMUglucuronidat Ion 
(nmoles conjuga- 
ted/gm.liver/ 
hour)
85 -  8 102 ± 7 + 20
Reduction of
p-Hitrobenzoic
acid
(yumoles product/ 
gm.liver/hour).
1.29 -  0.6 1.23 - 0.09 - 5
Microsomal 
protein 
(mg/gm.liver)
25.5 -  0.9 24.1 - 0.8 - 5
Cytochrome P450 
(npmoles/mg. 
protein.)
0.72 ± 0.02 0.73 - 0.02 + 1
The results are the means of determinations on 
six animals.
The slight increases in biphenyl' hydroxylation '
. and -4--TIU glucuronidation are not statistically signifi­
cant and it would, therefore, appear that pretreatment 
of mature female rats with pregnanediol for three days 
does not have any marked effect on the liver, its content 
of cytochrome P450 and microsomal protein and certain of 
its drug-metabolizing enzymes.
iii. Oestradiol 
Oestradiol, chosen as a representative female hormone 
was given ,dissolved-in ethyl-oleate,to female rats-by 
intrap'er it oh eal injection at a dose ..of 5 mg/’ g.
Animals were pre treated for one hour, and daily for 
three days,before being killed and the following liver 
parameters measured: 4-hydroxylation of biphenyl; 
reduction of p-nitrobenzoic acid; 4-MU glucuronidation; 
cyt-.o chrome P4-50 and microsomal protein. The results 
are shown in Table 6.11.
Table 6. 11
Effect of pretreatment of mature female rats with 
oestradiol on various liver parameters.
Parameter One Hour's55 
pretreatment
/
Three days' r  
pretreatment
Controls Pre­
treated
Controls Pre­
treated
Body weight (grams) 189 -  5 190 I 2 212 t 14 197- 11
Liver weight(grams) 6.1 ±0.3 6.5-0.4 7. l h .  4 7.5±0.2
Biphenyl-4- 
hydroxylation 
(/umoles product/ 
gm.liver/hour)
4.45— 
0.40
4.56t
0.22
4.08±
0.22
3.69±
0.17
p-nitrobenzoic 
acid reduction 
Qumoles product/ 
gm.liver/hour)
1.79±
0.15
1.881'
0.20
1.36'-
0.07
1.46±
0.11
4-MU glucuronidation 
Qumoles conjugated 
gm.liver/hour)
87 -  
13
93 1 
3
7oi»
7
59± * 
2
Cytochrome P450 
nyimoles/mg. protein)
Microsomal protein 
(mg./gm.liver)
0 • 66— 
0.02
26.8± 
0.7
o.6oi
0.04
26.21
0.4
0.63±
0.03
4*
31.21
1.1
0.61±
0.02
28.9-
1.0
The results are the mean of: 5£ three rats / five (except 
4 MU glucuronidation)..rats, in each group.
Pretreatment for one hour only with oestradiol 
does not have any effect on any of the parameters 
measured. Three days pretreatment does, however, 
produce some slight effects, namely that' ‘
the body weight , - the microsomal protein content, 
the hydroxylation of biphenyl and 4-MU glucuronidation are 
decreased by small amounts, but none of these is 
significant. The nitroreduction and cytochrome P450 
content are unaffected.
Several mature female rats were then pretreated 
for 18 days with a dose of 0.1 mg (intramuscularly) 
of oestradiol per animal daily and the same parameters 
measured. The results are shown in Table 6.12.
Table 6. 12
Effect of chronic pretreatment of female rats with 
oestradiol on various liver parameters
i
Parameter Controls Pretreated fo Differ­
ence
Body weight (grains) 
Before 219 - 5.; 201 i 5 - 7
After 232 - 4 224 - 6 - 3
Liver weight(grams) 8.8 - Cl.4 8.8 - 0.5 0
Biphenyl-4- 
hydroxylation 
Oumoles product/ 
gm.liver/hour)
2.78io.l9 3.16^0.07 +14
p-nitrobenzoic acid 
reduction 
(nmoles product/ 
gm.liver/hour)
2.73-0.27 2.56±0.49 - 7
4 MU"glucuronidation 
(/moles con jug­
ate d/gm.liver/hr)
-L
8 5 - 4 88 - 4 + 4
Microsomal protein 
(mg./gm.liver)
23.2^0.8 21.8to.8 - 6
Cytochrome P450 
(ripmoles/ 
mg.protein)
0.58±0.03 0.62i0.02 + 7
The results are the mean of three animals in each group.
Apart from a slight increase in the hydroxylation 
of biphenyl there are no differences between the liver 
paramaters of the treated and untreated rats.
iv. Progesterone plus oestradiol
A combination of progesterone (25 mg/kg) and 
oestradiol (5 mg/kg) was administered to mature 
female rats by intraperitoneal injection in ethyl 
oleate daily for three days. The usual liver parameters 
were measured and the results are shown in Table 6.13. 
The effects of chronic (18 days) pretreatment of 
mature female rats with a daily intramuscular injection 
of progesterone (1 mg) plus oestradiol (0.1 mg) on the 
same parameters, are also shown in Table 6.13.
The results show that there are no significant 
differences between the pretreated and control rats 
in either group.
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3. Pretreatment studies with contraceptive steroids
i. Acute treatment
The effect of various periods of norethynodrel pre­
treatment on the hydroxylation of biphenyl by rat liver 
has been studied. The effects were investigated using 
both the original assay procedure for biphenyl which 
employed a low concentration of DADP, and the revised 
conditions which use a much higher concentration of NADP.
In those investigations using the old assay procedure 
the rats were given a single dose of 4 mg. of norethynodrel 
dissolved in DMSO (0.1 ml) by intraperitoneal injection 
at various time intervals prior to killing; those animals 
that were pretreated for three days received a similar 
daily dose and were killed twenty-four hours after the 
final injection. Control animals received DMSO alone.
In the investigations using the modified assay procedure 
the use of DMSO was abandoned, and instead the norethy­
nodrel was administered in ethyl oleate using a similar 
dose- pattern; controls for these received ethyl oleate 
alone. Table 6.14 shows the results for both assay 
procedures.
Using the original conditions of incubation the 
effect .of pretreatment with norethynodrel was found to 
be as follows: after one hour the 4-hydroxylation of 
biphenyl was inhibited to a small extent, but this was 
not significant; after four and twelve hours the 
activity had returned to normal, but after tv/enty-four 
hours the activity was increased significantly by 66$. 
Twenty-four hours after the final dose of three daily 
doses,'however, the activity was not enhanced.
Using the modified incubation conditions, a 
different picture v/as obtained. Again,after one hour, 
the activity was inhibited, but it was also inhibited 
after twenty-four hours to an even greater extent.
After three days treatment the activity was not changed.
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Thus there is a marked difference in the effect 
observed after twenty-four hours pretreatment with 
norethynodrel'using the two methods; the only other 
difference, apart from the method that is, was the 
fact that one group received the norethynodrel in DMSO, 
the other in ethyl oleate.
ii. Subacute treatment■
Several semi-synthetic progestogens and oestrogens 
were examined for inducing ability (or any other effect 
that might arise) in mature female rats by giving the 
animals three consecutive daily doses of the steroid 
dissolved in ethyl oleate by intraperitoneal injection.
They were killed twenty-four hours after the final dose 
and the usual parameters measured. The steroids used, 
together with the dose, were as follows: norethynodrel 
(20 mg/kg), chlormadinone acetate (20 mg/kg), norgestrel 
(10 mg/kg)' and mestranol (2 mg/kg). A combination of 
norethynodrel (20 mg/kg) and mestranol (2 mg/kg) was 
also used. The known inducer, phenobarbitone sodium, 
was also used at a dose of 40 mg/kg. The results 
obtained are shown in Table 6.15. The results are 
expressed as a mean percentage of the controls, and 
the number of animals used in each group is given in 
parenthesis.
The results in Table 6.15 show that pretreatment - 
of female rats with high doses of progestogen alone does 
not have any significant effect on liver weight, micro­
somal protein, cytochrome P450, 4-hydroxylation of biphenyl
reduction of £-nitrobenzoic acid or 4-MU glucuronidation. 
All of these parameters, except microsomal protein, 
are increased by similar pretreatment with a low dose of 
phenobarbitone. The semi-synthetic oestrogen,mestranol, 
increases liver weight, but does not affect any of the 
other parameters, and since it increases the liver size 
the actual amount of the other parameters must be increased 
Horethynodrel and mestranol combined treatment does not 
produced any alteration in these liver parameters.
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iii. Chronic treatment
Mature female rats were treated intraperitoneally 
daily for eighteen days.-with’ethynodiol diacetate 
(5 mg/kg), mestranol (0,5 mg/kg) and a mixture of both. 
The steroids were given in ethyl oleate; controls were 
given ethyl oleate alone, Ethynodiol diacetate was 
used in this study instead of norethynodrel since the 
supply of the latter became exhausted. Twenty-four 
hours after the last injection the animals were killed 
and the usual liver parameters measured. The results 
are shown in Table 6.16. The values are the mean of 
six animals in each group. The results show that 
pretreatment of female rats for eighteen days with 
the progestogen, ethynodiol, alone does not significantly 
alter any of the parameters measured. Pretreatment 
with the oestrogen,mestranol does not allow such a 
rapid increase in body weight as the controls, but 
increases significantly the liver weight; none of the 
other factors is altered. Pretreatment with a mixture 
of the two steroids also prevents such a rapid increase 
in body weight, which is presumably due to the mestranol; 
the liver, however, is not increased in weight, but the 
hydroxylation of biphenyl is increased significantly, by 
32$£ and the 4-MUglucuronidation is' slightly, but not 
significantly, increased.
Table '6.17 shows the effect of 120 days treatment 
of rats with norethynodrel, chiormadinone acetate and 
ethynodiol diacetate on body weight, liver weight, 
microsomal protein, cytochrome P450, biphenyl hydroxy- 
lation, p-nitrobenzoic acid reduction and glucuronidation 
of 4-methylumbelliferone. Prolonged oral pretreatment 
with the two closely related progestogens, norethynodrel 
and ethynodiol diacetate, did not allow the rats to gain 
as much weight as the controls during the course of the 
experiment. Chlormadinone acetate treatment did not 
produce this effect. The liver weight is reduced by
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chlormadinone acetate pretreatment (but this is only 
slightly significant (p = O.l); the other compounds 
do not affect the liver-weight. The 4-hydroxylation n
of biphenyl is decreased in both the chlormadinone 
acetate and the ethynodiol diacetate pretreated 
animals, but this decrease is only slightly signifi­
cant (p = 0.1 in both cases). The reduction of 
4p-nitrobenzoic acid, 4-MU glucuronidation,cytochrome P450 and 
microsomal protein are all slightly, but insignificantly, 
higher in the chlormadinone treated animals, and are not 
affected by norethynodrel or ethynodiol diacetate 
treatment.
Discussion
In vitro studies
The results obtained in the first section of this 
chapter show that at high concentrations both progestogens 
and oestrogens are capable of inhibiting hepatic microsomal 
drug-metabolizing systems in vitro. In the case of 
hydroxylation of biphenyl the synthetic progestogen 
derived from progesterone, chlormadinone, produced only 
about half the inhibition that progesterone itself 
produced, whilst those synthetic progestogens derived 
from testosterone, norethynodrel, norethisterone and 
ethynodiol, produced a much greater inhibition than the 
progesterone. With the dealkylation reactions, however, 
progesterone and the synthetic progestogens derived from 
testosterone produced similar degrees of inhibition. In 
this respect these results agree with those of Juchau 
and Pouts (1966) who found that progesterone and 
norethynodrel produced similar degrees of inhibition 
of the side-chain oxidation of hexobarbitone, but that 
norethynodrel produced a greater inhibition of the ring 
hydroxylation of 'zoxazolamine than progesterone. Here 
the similarity ends, for Juchau and Pouts (1966) obtained
70 - 80$ and 30 - 40$ inhibition of oxidation reactions 
using concentrations of steroids of 10“%  and 10“%  
respectively,•although the concentration of substrates 
was in the order of 10 li. Similar inhibitory effects 
were observed by Tephly and Mannering (1968) when 
studying the effect of in vitro addition of several 
steroids, including progesterone and oestradiol on the 
oxidation of ethylmorphine and hexobarbitone by male 
rat liver microsomal preparations. Thus, the concen­
trations of steroids that were found to result in 
inhibition in the present experiments are much higher 
than were found by previous workers. It is interesting 
to note, however, that for the same concentration of 
steroid the inhibition of the dealkylat ions, where the 
substrate concentration is 3 x 10“% ,  is greater than 
the inhibition of the aromatic hydroxylation where the 
substrate concentration is 1.5 x 10 M.
The nature of the inhibition of the dernethylation 
of 5^-methoxybiphenyl by progesterone was found to be 
competitive. Juchau and Pouts (1966) and Tephly and 
Mannering (1968) also found the nature of the inhibitions 
mentioned above to be competitive.
Progestogens and oestrogens, both natural and
synthetic, also inhibit the reduction of p-nitrobenzoic
acid to p-aminobenzoic acid, but again only at high
concentrations of steroids. • The inhibition produced is
much less than that of the aromatic hydroxylation or
dealkylation, and Juchau and Pouts (1966) were unable to
demonstrate any inhibitory effect of either progesterone
— 4 — 5or norethynodrel at 10 >1 and IQ M on the reduction of
p-nitrobenzoic acid. Thus these steroids appear to 
inhibit oxidation reactions to a much greater extent 
than they do reduction reactions.
. Inhibition of aromatic hydroxylation and dealkylation 
by progestogens was also demonstrated with rabbit liver
preparations as well as with the rat enzymes. However, 
the results were quantitatively different, inhibition 
being-greater-with the rat enzymes, particularly in 
the case of biphenyl hydroxylation. There was also a 
striking difference with the rabbit preparations in 
the extent of inhibition of the two different aromatic 
hydroxylations, the inhibition of the hydroxylation of 
coumarin being some four times that of the hydroxylation 
of biphenyl.
The above results provide further evidence that 
the liver microsomal enzymes that catalyze certain 
oxidations of drugs and foreign compounds also catalyze 
oxidations of steroid hormones (Kuntzman et al 1964).
Now Remmer et al (1968) have stated that any substrate 
that can be hydroxylated will change the absorption 
spectrum of oxidised cytochrome P450, giving rise to 
one of two■types of spectrum, called type I and type’ll . 
One might expect, therefore, that progesterone and 
oestradiol would’combine with cytochrome P450 to give 
either type I or type II spectra. The results obtained 
here did not demonstrate either type of change, although 
typical type I and type II difference spectra were 
obtained with hexobarbitone and aniline respectively'. 
However, all the differences obtained were very small, 
and there was a lot of interference from light scattering 
so that firm conclusions could not be reached. It was, 
however, shown quite definitely that addition of .either 
progesterone . or oestradiol produced no decrease in the 
CO-difference spectrum of reduced microsomes. This 
observation can be interpreted in several ways. Firstly 
if it is assumed that a complex is formed between the 
steroid and the cytochrome P450, either in the oxidised 
or the reduced form, then this complex Joes not 
interfere with the formation of the CO-ligand 
complex. ' ■ A second possibility is that a
complex is not formed between the cytochrome P450 and 
steroid, or that formation of a complex requires the 
intact endoplasmic reticulum. Whichever explanation 
is correct, the fact remains that the mere presence of 
progesterone or oestradiol is not sufficient to cause 
an apparent decrease in the cytochrome P450 CO-difference 
spectrum.
It is pertinent t o ‘question if these results 
in vitro shed any light on the cause of the effect of 
pregnancy on drug-metabolizing enzymes. It would 
certainly seem that if the inhibitory effect of 
pregnancy is due to substrate competition from endogenous 
steroids then the amount present in the liver would 
have to be very high indeed. For example, in order to 
produce a steroid concentration of 10“%  in the 
determination of biphenyl hydroxylation, it would require 
the equivalent of 0.5 mg of progesterone to be present 
in each gram of liver. Furthermore, although inhibition 
of the reduction of p-nitrobenzoic acid was not observed 
with pregnant animals, the inhibition seen with addition^ 
of steroids in vitro is not unreasonable since it has 
been shown that the reduction of nitro groups may also 
be mediated through cytochrome P450 (Gillette et al 1968). 
However, Juchau and Fouts (1966) did not find any 
inhibition of nitroreduction in vitro by progesterone 
or norethynodrel at concentrations of 10 and 10 Ft.
Nevertheless it is of interest that in rabbit liver 
preparations progesterone produces much less inhibition 
of biphenyl hydroxylation than in rat liver preparations, 
whereas the inhibition of coumarin hydroxylation is quite 
large, a picture which is reminiscent of the effect of 
pregnancy on aromatic hydroxylations in the rabbit.
The fact that neither progesterone nor oestradiol 
affected the GO-difference spectrum of reduced cytochrome 
P450 does not rule out the possibility that they would
not affect it if present initially in the intact cell, 
but it adds weight to the idea that the simple presence 
of steroids does not decrease the effective concentration 
of cytochrome P450, as found in pregnancy in the rat.
Pretreatment studies: a. Naturally occurring steroids
The results obtained in the second part of this 
chapter show that pretreatment of mature female rats 
with progesterone and oestradiol, both alone and in 
combination, and with pregnanediol for various lengths 
of time are without significant effect on the hepatic 
microsomal content of cytochrome P450 and protein and 
on the hydroxylation of biphenyl, the reduction of 
p-nitrobenzoic acid, and the glucuronidation of 
4-methylumbelliferone by rat liver microsomes. These 
results in part agree with those obtained by Juchau 
and Pouts (1966) who found that progesterone pretreatment 
of immature male rats caused inhibition of the hydroxy- 
lations of hexobarbitone and zoxazolamine in liver 
microsomes both one and twenty-four hours after 
administration, although activity returned to normal in 
between; the pretreatment did not, however, affect the 
hydroxylation of 3,4-benzpyrene or aniline, or pathways 
involving N-demethylation, 0-dernethylation or sulphoxi- 
dation. It should be pointed out that these authors 
were using a large dose of progesterone (50 mg/kg.) and 
they were also using immature male rats. These 
differences may account for the differences between 
their results and those described here.
It was interesting to note that three days pretreat­
ment of young male and female rats with a high dose of 
progesterone caused an upward trend in hydroxylating 
activity, particularly of biphenyl in the ortho position, 
and in cytochrome P450 content, (cf. Juchau and Pouts 
1966). At this stage of development the drug-metabolizing 
activity of the young animal is undergoing rapid changes
and it is perhaps not surprising that a different ‘ 
effect is produced. Indeed, Kato and Takanaka (1968) 
have shown that the inducing effect of phenobarbitone 
is much more marked in young rats than in old.
Do these pretreatment studies shed any further 
light on the role of steroid hormones in pregnancy with 
respect to drug-metabolizing enzymes? If they do then 
the answer must be that the steroids, at least progesterone 
and oestradiol, and probably their metabolites, are not 
responsible for the effect. However, what relation do 
these pretreatments with.steroids bear to pregnancy?
During pregnancy the steroids are being produced 
continuously so that presumably the liver is having to 
metabolize them all the time. Thus there could 
conceivably be an inhibitory concentration of steroid 
.present all the time. Nov/, none, of the pretreatment 
studies carried out here produce this effect exactly. 
However, one would expect that after a brief pretreatment 
time with a high dose of steroid there would, be sufficient 
circulating in the blood to produce a reasonable level in 
the liver. Thus, one hour’s pretreatment might have 
been expected to produce this effect. Such a pretreat­
ment period with either progesterone or oestradiol did 
not alter any of the parameters measured.
It was shown in Chapter five, however, that it was 
only towards the end of pregnancy that inhibition of 
certain drug-metabolizing enzymes occurred, which might 
suggest that prolonged "exposure" to steroids was 
required to produce the effect, whether by direct 
competition or by some other means. Eighteen days’ 
intramuscular pretreatment of rats v/as therefore carried 
out, but this did not alter the level of drug-metabolizing 
enzymes or cytochrome P450. Neither did any of the 
treatments cause an increase in liver size, which is 
associated with pregnancy, although progesterone did 
lead to an increased body weight.
—  jl y u  —
It should, of course, he recognized that only one 
dose regimen has been used in these studies and that 
different effects may be produced by other doses. 
Nevertheless, one might have expected some indications 
of inhibition if, in fact, these steroids produce such 
an effect.
It would appear that neither progesterone nor 
^oestradiol pretreatment'affect hepatic microsomal drug 
metabolism in the same manner as was observed with, 
addition of these steroids in vitro. These findings 
are not contradictory since in the latter instance 
extremely high levels of steroid were required to 
produce inhibition and comparable levels were unlikely 
to be produced either in the pretreatment experiments 
or pregnancy.
The evidence provided here does not support the 
idea that either natural progestogens or oestrogens are 
responsible for the inhibitory effect of pregnancy on 
drug-metabolizing enzyme systems in the rat.
Pretreatment studies; b. Oral contraceptive steroids
The results obtained in the third section of this 
chapter indicate that synthetic steroids used as oral 
contraceptives do not produce any generalized inhibitory 
or inductive effects on hepatic microsomal drug- 
metabolizing enzymes in the mature female rat.
The effect of pretreatment of female rats with a 
large dose of norethynodrel produced contrasting effects 
in several experiments on the hydroxylation of biphenyl. 
When the hydroxylating activity was determined using 
the original assay conditions (Creaven et al 1965b) and 
the norethynodrel was administered in dimethyl sulphoxide 
an effect similar to that produced by certain other drug- 
metabolizing enzyme inhibitors (such as SKF 525-A) where 
there is an initial inhibition followed by an enhancement
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of the enzyme activity, was obtained. ‘This finding 
is similar to that obtained by Juchau and Pouts (1966). 
However, when-given in ethyl'oleate, and with the 
hydroxylating enzyme activity determined using the 
revised method, norethynodrel produced inhibition of 
the hydroxylation both one and twenty-four hours after 
administration. There seem to be two possible 
explanations for these results. One is that the solvent 
played a part in the effect, the dimethyl sulphoxide 
perhaps giving a more rapid absorption of the steroid 
so that it was metabolized and removed more quickly and 
in so doing produced induction, whereas the ethyl oleate 
gave rise to a slow release of the steroid so that it 
was still around in sufficient quantity twenty-four 
hours later to produce an inhibition. The second possible 
explanation is that norethynodrel increased the cofactor 
levels in the liver, so that once its initial inhibitory 
effect was over, it caused stimulation under the assay 
conditions in which* there was a limiting concentration 
of cofactor (MADP), but inhibition where the cofactor 
was optimum (high levels of HADP were found to inhibit 
the hydroxylation of biphenyl).
In spite of these results, three days’ pretreatment 
with norethynodrel did not affect the hydroxylation of 
biphenyl. Indeed, three days’ pretreatment of mature 
female rats’ with the various steroids produced no 
significant effects on the hydroxylation of biphenyl, 
or on any of the other drug-metabolizing enzymes or 
cytochrome P450, Phenobarbitone, which is one of the 
most potent inducers of drug-metabolizing enzymes, did 
produce a significant induction of these enzymes under 
the same conditions, but the induction was not very 
marked, probably because mature animals were used (Kato 
and Takanaka, 1968). It cannot be stated that these 
steroids are not inducers of drug metabolism because
this is usually tested for in immature animals, hut it 
can be said that in mature female rats they do not produce 
any induction of drug-metabolizing enzymes using the 
normal three-day test for induction. (It should be 
remembered that it is in mature females that these 
steroids are generally used.)
One significant point is that mestranol pretreatment 
tfor both three and eighteen days increased the liver 
weight. Consequently the total activity of the various 
enzymes was increased, although the specific activity 
remained the same. This effect was not produced in 
combination with ethynodiol .
Chronic administration of ethynodiol diacetate 
together with mestranol by intraperitoneal injection 
produced a significant increase in the hydroxylation of 
biphenyl, but did not affect any of the other enzymes or 
cytochrome P450 content. This effect could not be 
attributed to either of the components alone, and is 
similar to the observation that chronic administration 
of medroxyprogesterone acetate with ethinyloestradiol 
produces an increase in the hepatic microsomal enzymes 
responsible for the hydroxylation of aniline, the 
H-demethylation of aminopyrine and the O-demethylation 
of p-nitroanisole (Jori et al 1969), although this was 
shown to be due to the progestogen. However, this is in 
contrast with the observation that norethynodrel with 
mestranol treatment of rats decreases the hydroxylation 
of hexobarbitone (Juchau and Pouts, 1966) in liver 
microsomes.
Prolonged oral administration of ethynodiol diacetate 
alone at a much smaller dose decreased body v/eight gain 
and the 4-hydroxylation of biphenyl by liver preparations 
but did not affect any of the other parameters. Similar 
treatment with norethynodrel produced a similar effect 
on body weight' but did not affect any of the other
parameters. With prolonged oral administration of 
chlormadinone acetate, however, the liver weight and 
4-hydroxylation of biphenyl were decreased but none of 
the other parameters was affected. Thus the only reaction 
to be affected was the aromatic hydroxylation. It would 
seem unlikely that such a small dose of steroid could 
produce inhibition by competition with the enzyme 
substrate, especially as the dose is only given once 
daily. However, the steroids may be retained in the 
body on prolonged administration to different extents, 
and then released very slowly, or alternatively produced 
their effect in some other manner.
Contrasting results have been shown here; the 
administration of a mixture of progestogen and oestrogen 
have been shown to stimulate hydroxylation of biphenyl, 
while administration of a different progestogen alone 
has been shown to inhibit the hydroxylation. These 
results contrast with those of Juchau and Pouts (1966) 
who showed that the administration of a mixture of 
progestogen or oestrogen caused inhibition of the 
hydroxylation of hexobarbitone, but that the progestogen 
alone produced a stimulation of the hydroxylation.
The results obtained in this chapter, therefore, 
show that although both naturally occurring and synthetic 
progestogens and oestrogens produce inhibition of drug- 
metabolizing enzymes in vitro in large concentrations, 
pretreatment of mature female rats with them for 
prolonged periods does not produce any generalized 
effect.
-  “
CHAPTER VII
EFFECTS OF PREGNANCY AND CONTRACEPTIVE 
STEROIDS ON THE PHARMACOLOGICAL
ACTIVITY OF HEXOBARBITONE
Introduction
The previous two chapters have been concerned with 
the effect of pregnancy and oral contraceptives on drug . 
metabolism at the molecular level. It is obviously 
desirable to investigate these effects in the intact 
animal as well, and this has been done by studying the 
duration of action of hexobarbitone, and the in vivo 
metabolism of phenacetin (see Chapter eight).
The duration of narcosis following administration 
of hexobarbitone affords a convenient in vivo measure 
of hepatic microsomal enzyme function since the duration 
of action is primarily dependent on the rate of micro­
somal detoxication of the drug in the liver (Conney,1967). 
Thus the effect of pregnancy and pretreatment with 
naturally occurring and semi-synthetic steroids on the 
response to hexobarbitone in rats is described in this 
chapter.
There has been one previous report of the effect 
of pregnancy on the duration of pentobarbitone 
anaesthesia in rats (King et al, 1963) and one recent 
report (Feuer and Liscio, 1969). Both of these show 
that pregnancy increases the duration of action of 
pentobarbitone, indicating that the metabolism of pento­
barbitone has been inhibited. The reasons for the 
increase are not known, although it has been suggested 
that sex hormones play a role.
The duration of action of hexobarbitone is much 
longer in adult female rats than in adult males (Quinn 
et al, 1958), a difference that only becomes apparent 
at the age of five to six weeks, when there is an abrupt 
decrease in the action of the drug in male rats due to 
increased activity of the hexobarbitone metabolizing 
enzyme(s). It was therefore suggested that the male 
hormones were responsible for this change at puberty.
Oestrogen, but not progesterone, treatment of male rats 
decreases the activity of liver microsomal systems that 
metabolize hexobarbitone (Quinn et al, 1958; Juchau and 
Fouts, 1966). The lower levels of cytochrome P450 in 
liver preparations from pregnant rats (Chapter 'five')might 
suggest that the metabolism of hexobarbitone would be 
inhibited and, therefore, its duration of action longer 
in pregnant rats. However, the fact that the total 
hepatic content of cytochrome P450 is the same in 
pregnant and non-pregnant rats would suggest that there 
would be no difference in duration of action of hexo­
barbitone.
It was of interest therefore to investigate the 
effect of pregnancy on hexobarbitone sleeping time, and 
the effect of treatment of mature female rats with 
progestogens and oestrogens.
Materials and Methods
The rats used were all of the Wistar albino strain 
and were kept under similar conditions to those described 
in Chapter two. Pregnancy was established using methods 
described in Chapter five.
In the acute and subacute pretreatment studies the 
steroids were administered in ethyl oleate (0.5 ml) 
intraperitoneally at doses of 10 - 20 mg/kg for 
progestogens and 0.5 - 1 mg/kg for oestrogens; controls 
received ethyl oleate alone. In acute studies animals 
received a dose of hexobarbitone at various intervals 
after a single dose of steroid. Subacute pretreatment 
studies involved treating rats with a daily dose of 
steroid for three days and then administration of the 
hexobarbitone twenty-four hours after the final dose.
In the chronic studies the rats received a daily dose 
of the steroid (10 mg progesterone/kg,i.m., 2 mg 
oestradiol/kg,i.m., 5 mg ethynodiol diacetate/kg,d.p.
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or 0.5 mg mestranol/kg, i.p.) for eighteen days and 
were given the hexobarbitone twenty-four hours after 
the final injection of steroid.
Hexobarbitone was administered as a solution of 
the sodium salt in water. Initially hexobarbitone 
sodium as nCyclonal sodium" (May and Baker) was used, 
but later the solution of the sodium salt was prepared 
‘by dissolving hexobarbitone base (May and Baker) in an 
equivalent amount of sodium hydroxide solution. All 
solutions of hexobarbitone sodium were prepared freshly 
for each experiment.
The duration of action of hexobarbitone, otherwise 
known as hexobarbitone sleeping time, was determined as 
follows. Rats were weighed immediately before dosing 
and given a dose of 100 mg/kg (females) and 200 mg/kg 
(males) dissolved in water by intraperitoneal injection. 
The time of injection was taken as the start of the 
sleeping time although this was not strictly correct 
as the animal did not lose its righting reflex" until 
some two to three minutes later; however, it was 
impractical, when injecting large numbers of animals, 
to determine the point of loss of righting reflex 
accurately. Once the animal had lost consciousness it 
was laid on its back on the bench under an electric 
light to keep it warm. During the period of anaesthesia 
the tail of each animal was pinched every five minutes 
for the first thirty minutes, then every two minutes 
until the righting reflex was restored. If this 
stimulus was not given it was found that the rats tended 
to "sleep" longer and more irregularly. The righting 
reflex^ was considered to be restored when the animal 
could "right" itself three immediately consecutive times 
after being laid on- its back. The difference between 
the time of injection and this time was taken as the 
hexobarbitone sleeping time.
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Results
Effect of pregnancy
The duration of action of hexobarbitone given on 
a weight basis in non-pregnant rats and in pregnant 
rats at different stages of pregnancy was investigated 
and the results are shown in Table 7.1*
Table 7* 1
Duration of action of hexobarbitone in non-pregnant and 
pregnant rats at different stages of pregnancy
length of 
pregnancy 
(days)
No. of 
animals
Sleeping time 
(mins.)
Percentage 
difference from 
non-pregnants
Ron- 22 53 - 3
pregnant
3 7 46 i 4 - 13
10 2 54 -  2 + 2
13 . 6 6 4 - 2 + 21 /
15 6 68 -  3 + 28 £
17 6 8 7 - 4 + 64 s.
20 6 113 - 2 +113 *
1 day 3 56 ± 3 + 6
post partem
Significantly different from controls / p = 0.01; k  = 0.001
The results show that in three-day pregnant animals 
there is a slight decrease in the sleeping time but this 
is not significant. There is no difference in sleeping 
time between non-pregnant animals and two ten-day 
pregnant animals tested. However, there is a progressive
increase in sleeping time thereafter until the twentieth 
day of pregnancy when the increase is 113/&. One day 
post partem the sleeping time is hack to that of non­
pregnant animals.
During pregnancy the rat increases in weight quite 
considerably. The mean increase in body-weight in six 
rats is shown in Table 7*2.
Table 7« 2
Body weight increase during pregnancy in the rat
Days Pregnant Weight (g) Percentage 
increase above 
initial (g)
0 271 - 7 -
3 . 274 -  8 1
6 284 i 7 5
10 295 - 8 9
13 305 ± 9 13
15 316 i 8 17
17 330 i 10 22 .
20 361 ± 5 33
1 day post partem 304 ± 7 12
The table shows that it is over the last week that 
most of the weight gain occurs. This is probably due to 
the growth of the foetuses since it is at this stage that 
they begin increasing in size. The gain in v/eight before 
this is due to 'the mother increasing in size. Thus, 
after the mother has littered, the body weight returns 
to what it was at the ■ thirteenth day and not what it 
was initially.
The sleeping time and "body weight, therefore, both 
increase during pregnancy. Fig. 7.1 shows the relative 
percentage increases in body weight and sleeping time 
with increased duration of pregnancy. During the first 
half of pregnancy the sleeping time does not increase 
although the body weight does, indicating that the 
mother is able to metabolize the hexobarbitone at the 
same rate as the non-pregnant rat. During the second 
half of pregnancy, however, the sleeping time increases, 
and at a greater rate than the weight increases, 
indicating that the mother is unable to metabolize the 
increased amount of hexobarbitone at the same rate as 
the non-pregnant. Is the increase in sleeping time 
simply due, then, to the increased amount of hexobarbitone 
that the.animal receives due to its increased weight, or 
is it due to some other factor such as inhibition of the 
hepatic drug-metabolizing enzymes? To investigate this 
further the dose/response for hexobarbitone in normal 
animals was studied. Four groups of eight non-pregnant 
female rats were given doses (50, 100, 115 and 150 mg/kg) 
of hexobarbitone, and the sleeping times were determined 
as previously described. The doses were chosen to 
correspond to the amounts given to the pregnant animals; 
thus a s 'the full-term pregnant animal was given a 30$ 
increase in total dose, to to a 30$ increase in dose 
was used in these experiments v/ith non-pregnant animals. 
The results are shown in Table 7.3.
Table 7* 3
Dose-response for hexobarbitone in female rats
Dose of hexobarbitone
(mg/kg) .....
3£Sleeping time 
(mins.)
50
I—
1
+ 
1
l—
1 
I—
1
100 6 9 - 4
115 ■ 83 - 9
130 1X3 - 6
3£ The results are the mean - 
animals in each group.
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Pig. 7.1 Relative percentage increases in body weight 
and hexobarbitone sleeping time during pregnancy 
in the rat.
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The results' show that there is an almost linear 
relationship between-dose and sleeping time over the dose 
range used. However, for an increase of 30$ in the dose 
from 100-130 mg/kg, -the sleeping time increases by 63$.
The question then arises as to whether the pregnant 
rat is as capable as the non-pregnant in metabolizing 
the same total dose of hexobarbitone. An experiment 
was carried out, therefore, whereby pregnant rats were 
given a dose of hexobarbitone of lOOng/kg based on their 
weight before mating. Controls were weighed at the same 
time and given a dose on the same basis. The results 
are shown in Table 7*4.
Table 7« 4
Duration of action of hexobarbitone in non-pregnant 
and pregnant rats dosed on a basis of their original
non-pregnant weight
Days
pregnant
No. of 
animals
Sleeping
time
Percentage 
difference from 
non-pregnants
Non-pregnant 5 47 - 4 -
7 3 4 3 - 1 - 8
10 • 2 42 -  2 - 10
15 5 33 -■ 6 - 30
20 ’ 3 4 4 - 5 -  6
The results show that at all stages of pregnancy the 
pregnant rat is just as capable, and in some cases more 
capable, of metabolizing the same total dose of hexobar­
bitone. Thus, in the 15-day pregnant animal the sleeping 
time is reduced by 30$, but in the 20-day pregnant 
animal it is not reduced.
Effect of pretreatment with steroids
Table 7*5 shows the effect of acute pretreatment 
of both male and* female rats with progesterone on 
hexobarbitone sleeping times. The dose of progesterone 
used was 10 mg/kg; both male and female rats were given 
a.dose of 100 mg/kg of hexobarbitone.
Table 7. 5
Effect of acute progesterone pretreatment on hexobarbitone 
sleeping time in male and female rats
Pretreatment
period Sex Sleeping time (minutes)
Controls Pretreated
Eone M 23 - 1.2 (6) -
1 hour M 23 -  0.3 (3) 23 -  0.7 (3)
24 hours M 22 1 1.2 (3) 24 -  1.0 (3)
Eone F 81 ±-5 (6) -
1 hour F 86 i 3 (6) 116*i 10 (3)
24 hours F 81 ± 4 (4) 79 -  2 (4)
Figures in parentheses refer to the number of rats in 
each group.
x Statistically different from controls p = 0.02.
The results show that pretreatment of male rats with 
progesterone for one or twenty-four hours does not alter 
the hexobarbitone sleeping time. With female rats the 
results are different; one hours pretreatment resulted 
in an increased sleeping time, but twenty-four hours 
pretreatment produced no difference.
Similar acute pretreatment studies were carried out 
using the semi-synthetic progestogen norethynodrel.. A 
dose of 20 mg/kg was given in dimethyl sulphoxide, and 
the results are shown in Table 7.6.
Table 7. 6
Effect of acute norethynodrel pretreatment on hexobarbitone 
sleeping times in male and female rats
Pretreatment
period Sex Sleeping time (minutes)
Controls Pretreated
Eone M 2 3 - 1  (6) -
1 hour M 19 -  4 (3) 3 4 - 1  (3)
24 hours M 24 - 1  (3) 25 i 2 (3)
Eone E 81 ± 5 (6) rnmrn
/ ,
1 hour E 72 -  3 (4) 136 i 3 (4)
24 hours E 7 3 - 3  (4) 72 - 5 (4)
-* X
48 hours F 76 ± 9 (3) 4 5 - 3  (3)
figures in parentheses refer to the number of animals in 
each group.
Statistically different from controls s p = 0.05;/ p = 0.001
Pretreatment of male rats one hour previously with 
norethynodrel caused an increase in the sleeping time of 
80$, but 24 hours pretreatment produced no difference. 
Similar results were obtained with female rats although 
the increase in sleeping time after one hour's treatment 
was slightly greater than in the males (90$). The effect 
of a single dose of norethynodrel 48 hours before hexobar­
bitone caused a decrease in sleeping time of A0°/o in the 
female rats indicating that the metabolism had been 
increased.
The effect of pretreatment of female rats with a 
single dose of various.contraceptive hormones dissolved 
in ethyl oleate twenty-four hours before hexobarbitone 
is shown in Table 7*7* The hormones used were 
chlormadinone acetate (20 mg/kg)j norethynodrel (20 mg/kg), 
and mestranol (1.0 mg/kg).
Table 7. 7
Effect of twenty-four hours pretreatment of female rats 
with contraceptive steroids on the duration of action
of hexobarbitone
Steroid No. of 
animals
No. of
animals
losing
righting
reflex/
Sleeping 
time 
(mins.)
Percent­
age
differ­
ence
from
controls
Controls 12 12 85 - 4 -
Chlormadinone 6 5 80 -  4 - 6
Norethynodrel 6 5 58 - 5 - 32s
Mestranol 6 6 62 ± 5 - 26s
k  Statistically different from controls p = 0.01
/ The' sleeping time is the mean of those animals which 
lost their righting reflex.
The results show that twenty-four hours after a 
dose of norethynodrel or mestranol the hexobarbitone 
sleeping time is significantly decreased, but after a 
dose of chlormadinone, it is not significantly different 
from controls. The results for norethynodrel differ 
from those given in Table 7*6, where no difference in 
sleeping time after twenty-four hours was observed.
Those results were obtained at St. Mary’s, while these 
were obtained in Surrey. The other difference was that
the norethynodrel in the first instance was given in 
dimethyl sulphoxide, and in the second in ethyl oleate.
The effects of pretreatment of female rats with 
various hormones for three days on the duration of 
action of hexobarbitone•are shown in Table 7.8. The 
steroids used were progesterone (20 mg/kg), oestradiol 
(0.5 mg/kg), chlormadinone acetate (20 mg/kg),.. 
norethynodrel (20 mg/kg) and mestranol (l.O mg/kg).
Table 7. 8
Effect of three days pretreatment of female rats with 
progestogens and oestrogens on the duration of action
of hexobarbitone
Steroid No. of 
animals
No. of
animals
losing
righting
reflex/
Sleeping 
time 
(mins.)
Percent­
age
differ­
ence
from
controls
Controls 12 12 86 ± 4 -
Progesterone 6 6 8 5 - 5 -2
Oestradiol 6 6 87 i 5 +3
Chlormadinone
acetate
6 5 73 - 5 -15
Norethynodrel 6 3 5 9  -  3 -31s
Mestranol 6 6 5 4  - 2 -38s
& Significantly different from controls: p = 0.01
/ The sleeping time is the mean of those animals which 
• lost their righting reflex.
The results in Table 7.8 show that progesterone and 
chlormadinone acetate do not produce any significant 
difference in sleeping time from the controls, while 
norethynodrel and mestranol produce similar decreases in
sleeping time, which are significant, Oestradiol does 
not alter the sleeping time. It should he noted that 
with the norethynodrel the number of animals that 
did not lose their righting reflexes was quite high.
This might indicate that induction was greater in these 
animals, or that norethynodrel alters the sensitivity 
of the nervous system to hexobarbitone.
The effect of three days pretreatment of male rats 
with these hormones is shown in Table 7*9* The hormones 
used were progesterone (10 mg/kg), chlormadinone acetate 
(10 mg/kg), norethynodrel (10 mg/kg) and mestranol 
(l mg/kg). The dose of hexobarbitone used was 200 mg/kg.
Table 7. 9
Effect of three days pretreatment of male rats with 
progestogens and oestrogens on the duration of 
action of hexobarbitone
Steroid No. of 
animals
No. of 
animals 
losing 
righting 
reflex, x
Sleeping 
time 
(mins.)
Percent­
age
differ­
ence
from
controls
Controls 12 10 42 ± 6 -
Progesterone 6 6 46 1 2 +9
Chlormadinone
acetate
6 5 43 - 2 +2
Norethynodrel 6 5 5 2 - 3 +24
Mestranol 6 6 8 5 - 8 +102^
3E The sleeping time is the mean of those animals 
which lost their righting reflex.
£  Significant difference from controls p = 0.001.
The results show that neither progesterone nor 
chlormadinone acetate have any effect on the duration of
action of hexobarbitone in male rats at the dose used 
here. Norethynodrel, however, causes a small but insig­
nificant increase in sleeping time, while mestranol causes 
a very large significant increase.
The final results in this chapter are concerned with 
the prolonged treatment (18 days) of female rats with 
progestogens and oestrogens both separately and combined.
The natural hormones used were progesterone (2.5 mg. per 
animal daily and oestradiol (0.5 mg per animal daily) and 
combined at the same doses. The semi-synthetic hormones 
used were ethynodiol diacetate (1.0 mg per animal daily) 
and mestranol (0.1 mg per animal daily) and combined at 
the same doses. The effects of such treatments on the 
duration of action of hexobarbitone are shown in Table 7.10.
Table 7. 10
Effect of eighteen days pretreatment of female rats with 
progestogens and oestrogens on the duration of action of
hexobarbitone
Steroid No. of 
animals
Sleeping
time
Percentage
difference
from
controls
Controls A 5 72 i 7
H B 6,
CM
 
+ 
1
H00 -
Progesterone 5 6 6 - 3 -8
Oestradiol 6 68 i 4 -6
Progesterone
+ Oestradiol 4 6 9 - 3 -4
Ethynodiol diacetate 6 58 i 2 -28 x
Mestranol 6 6 9 - 6 -15
Ethynodiol diacetate -4-
+ Mestranol ' 6
-It-LT\ i V-S
!
O ft
x Significantly different from controls: p = 0.001
A = controls for progesterone and oestradiol animals
B = 11 " ethynodiol diacetate and mestranol animals.
The results show that the sleeping times are not 
altered by prolonged treatment with progesterone or 
oestradiol either alone or combined. Treatment with 
mestranol does not significantly alter the sleeping time 
although it is slightly reduced, while treatment'with 
ethynodiol diacetate, either alone or in combination 
with mestranol significantly decreases the sleeping 
time.
Discussion
It has been shown that in the 20-day pregnant rat 
the duration of action of hexobarbitone is more than 
doubled when compared with non-pregnant rats, when the 
animals are dosed on a weight basis. This finding agrees 
with those of King et al (1963) and Peuer and Liscio (1969)* 
that pentobarbitone anaesthesia is prolonged in pregnant 
rats. It has also been shown that the pregnant rat 
increases in weight during pregnancy, and it therefore 
receives a greater amount of hexobarbitone than the non­
pregnant when dosed on a weight basis. Is the increased 
sleeping time, therefore, simply due to the fact that 
the pregnant animal receives a greater total of hexo­
barbitone, or is it due to some other factor such as 
inhibition of its metabolism? Taking the 20-day pregnant 
rat as a whole, its increase in weight, and therefore the 
increase in the dose of hexobarbitone it receives, is 
approximately 30fo, and this increases the sleeping time by 
over 100$. ■ When a non-pregnant rat is given a similar 
increase in dose, the sleeping time is only increased 
by 63/S i.e. about half this amount. This would indicate 
that the greater amount of hexobarbitone that the pregnant 
rat receives could be responsible for some, but not all, 
of the increase in sleeping time. However, it was shown in 
Chapter five that in the 20-day pregnant rat the liver 
weight increases in proportion to the body weight. If, 
therefore,the specific activity (the activity of lgn. of
liver) for hexobarbitone metabolism of the liver from 
the pregnant rat was the same as that of the non-pregnant, 
then the hexobarbitone should be metabolized at a similar 
rate and the sleeping time should be the same when animals 
are dosed on the basis of body weight. The fact that it 
is not, suggests that the specific activity of the liver 
with regard to hexobarbitone metabolism is decreased in 
pregnant rats. This agrees with the findings in Chapter 
five that the hydroxylation of biphenyl and cytochrome P450 
content are decreased in the livers of 20-day pregnant ;- 
rats when the results are expressed as a function of unit 
liver weight. These findings suggest that the increased 
sleeping time in pregnancy could be due to the impaired 
ability of the liver to metabolize hexobarbitone, and not 
simply to the increased amount of hexobarbitone that the 
pregnant rat receives.
Could the impaired liver function be responsible for 
an increase of over 100$ in the sleeping time? On the 
face of it this would require the metabolism to be 
inhibited by over 50$. It should be remembered, however, 
that there is a threshold dose (the dose response data 
obtained did not use a dose as low as this threshold) 
of hexobarbitone, and it is only the dose above this 
threshold that is effective in causing anaesthesia. Thus, 
merely doubling the dose of hexobarbitone from 50 mg/kg 
to 100 mg/kg increases the sleeping time sixfold.
Therefore, in doing the reverse, i.e. inhibiting the 
metabolism, it would not be necessary to inhibit the 
metabolism by 50$ to double the effective dose above the 
threshold. Therefore the decrease of 26$ observed in 
cytochrome P450 in chapter five may be sufficient to produce 
the 113$ increase in sleeping time. Nevertheless other 
possible causes should be borne in mind.
The sleeping time was only increased during the 
second half of .pregnancy, the greatest increase being 
over the last seven days. The body weight, though,
increases all the time during pregnancy, although there 
is a more rapid growth during the last seven days. This 
would indicate that over the first half of pregnancy, 
when the increase in weight is due mainly to the 'growth of
maternal and placental'tissues ,the Uver maintains jts metabolizing 
ability, but during the second half, and more particu­
larly the last seven days, when the increase in weight 
is due to the growth of the foetuses,the liver is unable 
to maintain its metabolizing ability. Now the foetuses 
are separated from the mother by the placental barriers, 
and although the hexobarbitone will diffuse across the 
placental barrier it will probably not do so as rapidly 
as it can diffuse around the mother's body. Therefore 
the effective dose in the mother's body will be slightly 
increased, so contributing to the increased duration of 
action, though this is unlikely to account for all 
the increase. However, it does raise one other important 
point, and that is the distribution of the hexobarbitone 
in the pregnant rat. If the distribution of the hexo­
barbitone is similar in the pregnant and non-pregnant 
animal, then the increased duration of action is probably 
due to inhibition of its metabolism. If the distribu­
tion is not similar, then this may contribute to the 
increased duration of action.
Although it has been shown that the duration of 
action of hexobarbitone is increased in pregnant rats 
when the hexobarbitone is given on a weight basis, when 
the same total dose is given to 20-day and non-pregnant 
rats there is no difference in sleeping time, indicating 
that the total capacity of the liver for hexobarbitone 
metabolism is unaltered by pregnancy. With 15-day 
pregnant rats dosed similarly, the sleeping time is less 
than the non-pregnants. These results also agree with
the findings in Chapter five that the total capacity of the 
liver for hydroxylation of biphenyl and for cytochrome P450
content is similar in the 20-day pregnant and non­
pregnant rat, hut slightly greater in the 15-day. pregnant 
rat.
It has been established for some time now that 
certain steroids employed in high doses have an anaesthetic 
action (Selye 1941; Pan and Laubach 1964), and progesterone 
has this action. It seemed possible, therefore9 that the 
‘increase in duration of action of hexobarbitone could be 
due to an additive effect of the progesterone and hexo­
barbitone, or similarly progesterone lowering the threshold 
level of hexobarbitone. Progesterone levels are, in 
fact, very high during pregnancy, but in the pregnant rat 
progesterone levels are maximal at the fourteenth to 
fifteenth day of gestation (Eto et al, 1962; Hashimoto 
et al, 1968) and thereafter decline steadily until 
parturition. It seems unlikely, then, that the increased 
duration of action of hexobarbitone is due to the 
anaesthetic action of progesterone, as there is an 
inverse relationship between the levels of the proges­
terone and the sleeping time.
Juchau and Pouts (1966) found that progesterone 
inhibited hexobarbitone metabolism when added in vitro 
at concentrations of 10“ to incubations of rat liver 
homogenate. They also found that pretreatment of young 
male rats with progesterone (50 mg/kg) for one hour or 
twenty-four hours caused inhibition of the in vitro 
hydroxylation of hexobarbitone. These observations 
might suggest that progesterone increases the duration 
of action of hexobarbitone by inhibiting its metabolism, 
and one could therefore implicate it as having this role 
in pregnancy. However, the same argument to that applied 
in the preceding paragraph can be forwarded. If proges­
terone were the cause, one would expect maximal inhibition, 
and therefore longest duration of action of hexobarbitone, 
about the fifteenth day of pregnancy.
The effect of pretreatment of male and female rats 
with progesterone was carried out to see whether it did 
have any effect on the duration of action of hexobarbitone. 
Pretreatment of male rats did not alter the sleeping time. 
These results do not agree with those of Juchau and Pouts 
(1966), but they were using younger rats and a larger dose 
(50 mg/kg) of progesterone. Pretreatment of female rats 
was studied for one hour, twenty-four hours, three days 
and eighteen days; only the one hour's pretreatment caused 
any significant alteration in hexobarbitone sleeping time. 
This would indicate that the presence of progesterone in 
the body does increase the hexobarbitone sleeping time by 
one of the methods mentioned above, but that for this 
effect to become apparent the level needs to be very high 
indeed. Why does progesterone pretreatment for one hour 
cause inhibition in the females but not in the males? Now 
male rats metabolize hexobarbitone more rapidly than 
females, consequently the sleeping time of the former 
induced by the same dose of hexobarbitone is less. The 
rate of metabolism in the male, as it is so rapid, may 
not be the limiting factor which determines the duration 
of anaesthesia,- so that any inhibition produced by 
progesterone is not manifested. Alternatively, the 
progesterone may also be metabolized more rapidly so that 
any effect would disappear after one hour.
It is not possible to state categorically that the 
inhibition of hexobarbitone metabolism during pregnancy is 
not due to progesterone, because although eighteen days 
chronic treatment does not increase the sleeping time, 
only one dose level has been used, and that was given once 
daily, albeit by intramuscular injection. The inhibition 
of metabolism in pregnancy could, of course, be due to 
oestrogen, or may require a combination of oestrogen 
and progesterone. However, neither oestradiol 
nor progesterone plus oestradiol affected hexobafbitone 
sleeping time in female rats dosed for eighteen days.
It should be pointed out here that during pregnancy 
these hormones are being produced continuously. It is 
not possible to do this in pretreatment studies, although 
intramuscular injections do give a prolonged release, but 
necessarily at low levels. Therefore, the effect of the cont 
inuous presence of st.eioids injregnancy may be similar to that 
produced by onehourh pretreatment with progesteroneV Neverthe­
less the results do suggest that it is not these steroids 
that are responsible for the increased sleeping time 
during pregnancy.
The explanation suggested in Chapter five fits in 
with the results found here. There if was suggested that 
during the later stages of pregnancy when the maternal 
organism has to provide the material for a very rapid 
protein synthesis, this, i-s channelled away from 
producing, drug-metabolizing enzymes and cytochrome P450.
This is possibly brought about by increased genosnal 
repression produced by growth hormones. Now the most 
rapid growth, and therefore presumably most rapid 
production of growth hormone occurs over the last seven 
days of pregnancy, and this corresponds to the period 
over which duration of action of hexobarbitone increases.
It is possible, therefore, that the growth hormone 
produced during pregnancy is responsible for the decreased 
metabolism of hexobarbitone.
Whether the natural steroids of pregnancy are 
responsible for the effect on the duration of action of 
hexobarbitone or not, what are the';,effects of steroids 
used as oral contraceptive agents?
Norethynodrel pretreatment of both male and female 
rats for one hour resulted in the duration of action of 
hexobarbitone being almost doubled. This finding is in 
agreement with that of Juchau and Pouts (1966) who found 
that the hexobarbitone hydroxylase activity of the liver 
of young male rats was decreased one hour after a dose of
norethynodrel. ' Jori et al (1969) have also reported 
that the pentobarbitone anaesthesia of female rats dosed 
two hours previously with norethynodrel is increased.
The effect has been suggested to be due to inhibition 
of hepatic metabolism by norethynodrel, since it has 
been shown competitively to inhibit hexobarbitone 
metabolism in vitro (Juchau and Pouts, 1966).
Twenty-four hours.pretreatment of male or female 
rats with norethynodrel dissolved in dimethyl sulphoxide 
did not affect hexobarbitone sleeping time; a single 
dose forty-eight hours before the hexobarbitone did, 
however, decrease the sleeping time in female rats. 
Pretreatment of female rats with norethynodrel dissolved 
in ethyl oleate, however, decreased the sleeping time 
after twenty-four hours. It would seem that the rate 
of absorption was different from the two solvents.
These results also agree with those of Juchau and Pouts 
(1966) since they found that twenty-four hours pretreat­
ment with norethynodrel increased the hexobarbitone 
hydroxylase activity of the liver. Jori et al (1969) 
did not find any decrease in the pentobarbitone 
anaesthesia twenty-four hours after norethynodrel.
Based on their results on hexobarbitone and 
zoxazolamine hydroxylation, Juchau and Pouts (1966) 
came to the conclusion that norethynodrel stimulated 
drug metabolism, but only after an initial inhibition.
The results obtained in this chapter using an jjl vivo 
technique would agree with this. Thus norethynodrel may 
act like certain other drug-metabolizing enzyme inhibitors 
such as SKP 52 5-A, which also enhance hepatic microsomal 
enzyme activity after an initial inhibition (Anders and 
Mannering, 1966; Kato et al, 1964). The results obtained 
in Chapter six. however, should be borne in mind since 
there, using other enzyme systems, no stimulatory phase 
was observed with norethynodrel treatment*
Pretreatment of female rats with chlormadinone for 
twenty-four hours did not alter the sleeping time. 
Chlormadinone is a progestogen but, unlike norethynodrel 
which is more closely related to testosterone structurally, 
it is more closely related to progesterone. It has been 
shown here that progesterone treatment of female rats 
for twenty-four hours does not affect duration of action 
Qf hexobarbitone, and it'is known that the treatment of 
female rats with testosterone increases the metabolism 
of hexobarbitone (Quinn et al, 1958), so these results 
are not altogether unexpected. However, treatment for 
twenty-four hours of female rats with the oestrogen, 
mestranol significantly decreases the sleeping time, and 
this is perhaps a little unexpected, especially as", 
hexobarbitone metabolism is decreased in male rats 
treated with oestrogen (Quinn et al, 1958).
Treatment of female rats for three days with 
chlormadinone, norethynodrel or mestranol produced similar 
effects to the twenty-four hour treatment. The average 
chlormadinone-treated sleeping time was slightly less than 
the controls, but was not significant. Pretreatment of 
male rats for three days with the steroids produced 
somewhat different results. Mestranol increased the 
duration of action of hexobarbitone by 100$, a result 
that agrees with previous findings that oestrogen treat­
ment of male rats decreases hexobarbitone metabolism 
(Quinn et al, 1958). Norethynodrel also increases the 
sleeping time, but this effect is not as marked as that 
of mestranol. It is possible that the small amount of 
mestranol that is present in the commercially available 
norethynodrel is sufficient to produce this effect.
Neither progesterone nore chlormadinone affected the 
sleeping time in male. rats. The norethynodrel results 
do not agree with the in vitro results of Juchau and 
Pouts (1966) who found that in male rats three days 
pretreatment stimulated the metabolism of hexobarbitone.
Chronic treatment of female rats with norethynodrel 
was not possible as the supply became exhausted. Instead 
a very closely related synthetic steroid, ethynodiol, 
as its diacetate was.used, which like norethynodrel 
is a derivative of testosterone. Chronic pretreatment 
of rats with a dose of ethynodiol lower thhn that used for 
norethynodrel in acute studies, produced a significant 
decrease in sleeping time. The same effect was obtained when 
ethynodiol was given in combination with mestranol.
Mestranol itself did not have any significant effect on 
the sleeping time, but the average time was slightly 
decreased. These results suggest that ethynodiol 
diacetate induced the hepatic drug-metabolizing enzymes 
responsible for metabolizing hexobarbitone. These 
results are therefore in agreement with the findings in 
Chapter six that chronic pretreatment of rats with 
ethynodiol induces hydroxylation of biphenyl. Jori 
et al (1969) have made similar findings with-the 
synthetic progestogen, medroxyprogesterone acetate, but 
which is more closely related to progesterone than 
testosterone. They found that thirty days treatment 
with this steroid either alone or in combination with 
ethinyloestradiol, decreased the pentobarbitone 
anaesthesia time, indicating that the metabolism was 
increased. However, they also measured concentra­
tions of pentobarbitone in the brain and found that after 
medroxyprogesterone acetate treatment the sleeping time 
and brain concentrations ninety minutes after pento­
barbital administration were not statistically correlated 
as in the control animals. This suggests that progest­
ational compounds affect pentobarbitone activity by 
several mechanisms in addition to the metabolic effect, 
including ' * that repeated administration of steroids 
may increase the sensitivityccf the central nervous 
system towards pentobarbitone. However, the same authors
found that chronic administration of medroxyprogesterone 
acetate significantly increased hepatic microsomal 
hydroxylation'of aniline, N-demethylation of aminopyrine 
and O-demethylation of p-nitroanisole. The doses used 
in these experiments and those of Juchau and Pouts (1966), 
however, were all very high indeed. Whether lower doses 
produce similar effects is not known.
The findings of this chapter, therefore, show that 
during the third:trimester of pregnancy in the rat the 
hexobarbitone sleeping time is increased. The total 
capacity of the pregnant rat to metabolize a given dose 
of hexobarbitone is not, however, any different from the 
non-pregnant. Although these effects of pregnancy may 
be due to the high levels of circulating steroids, 
pretreatment of rats with similar endogenous.steroids for 
various lengths of time does not alter the sleeping 
time. Pretreatment of female rats with certain synthetic 
steroids, however, decreases the hexobarbitone sleeping 
time, probably by increasing its metabolism in the liver.
GHAPTER VIII 
IN YIYO METABOLISM OP PHENAGETIN IN THE
RAT AND HUMAN
Introduction
Some in vivo studies on the effects of pregnancy 
and oral contraceptives on drug metabolism have been 3.
undertaken in this chapter. The drug chosen for study 
was phenacetin (p-ethoxyacetanilide or acetophenetidin) 
an analgesic which in recent years has fallen out of 
favour because of the toxic side effects of kidney 
.damage and methaemoglobinaemia produced by long-term 
administration. To some extent it has been superseded 
as an analgesic by paracetamol (N-acetyl-p-aminophenol), 
its major metabolite which has a similar analgesic 
action to phenacetin but Is reported to have less toxic effect
The metabolism of phenacetin has been well studied 
in man, dog, rabbit and cat. Brodie and Axelrod (1949) 
showed that in man the major route of metabolism is by 
O-dealkylation•to give N-acetyl-p-aminophenol which is 
then conjugated chiefly as the glucuronide; Smith and 
Williams (1949) found a similar picture in rabbits.
The cat, however, is unable to conjugate the N-acetyl- 
p-aminophenol as the glucuronide, but excretes the 
N-acetyl-p-aminophenol as an unknown conjugate (Welch 
et al 1966). Phenacetin is also metabolized to a 
lesser extent by deacetylation to p-phenetidine which, 
it has been suggested, is responsible either directly or 
indirectly for producing methaemoglobinaemia (Brodie 
and Axelrod 1949). More recently a cysteine conjugate 
S-(acetamido-4-hydroxyphenyl)-cysteine and the 
corresponding mercapturic acid have also been reported 
as minor metabolites of phenacetin in humans (Jagenburg 
and Toczko, 1964). Phenacetin is also hydroxylated to 
a minor extent in the position ortho to the N-acet .yl 
to give 2-hydroxyacetophenetidine (Klutch et al, 1966) 
and can also be hydroxylated at the amino group to give 
H-hydroxyacetophenetidine (Klutch and Bordun, 1968).
The pathways of phenacetin metabolism may be 
summarized as follows
NHCOCH. NHCOCH.
Hydroxylation
Phenacetin
OH
N-acetyl-jD-aminophenol
OC-H
2-Hydroxyphenacetin
Deacetylation
De-ethylatior\ GSH? 
(major route)
NHCOCH.
OC_H
£-Phenetidine
NHCOCH
NH
COOH
OH
S-(l-Acetamido-i+-hydroxy- 
phenyl)cysteine
Conjugation
Glucuronide
+
Sulphate
1-Acetamido-A-hydroxy- 
phenylmercapturic acid
Phenacetin is therefore an example of a drug 
that can be metabolized by several different pathways.
It can also be given in high doses so that a quantitative 
study of its metabolism is facilitated by the relatively 
high amounts of metabolites that are produced.
Brodie and Axelrod (1949) have described colorimetric 
methods for the determination of phenacetin and p- 
phenetidine, and also for H-acetyl-p-aminophenol (Brodie 
and Axelrod,1948). More recently Klutch and Bordun (1968) 
have developed selective thin-layer chromatographic 
methods for the estimation of the various possible 
transformation products of phenacetin present in urine 
or other biological material. The advantage of the 
chromatographic methods is their sensitivity and 
specificity for a compound present in a multi-component 
mixture, but they are not as quantitative as the chemical 
methods described. The same authors have briefly 
described gas chromatographic techniques for more 
accurate quantitative determinations of the metabolites 
of phenacetin.
In the present study it was at first envisaged that 
the metabolism of phenacetin would be studied with 
isotopically labelled material. ^C-ring labelled 
aniline was available, but the synthesis of ^C-phenacetin 
from ^C-aniline proved unsuccessful. The possibility of 
labelling either the acetyl or ethyl groups was considered 
but was not eventually carried out. The method finally 
adopted.was a gas-liquid chromatographic technique 
modified from that described by Klutch and Bordun (1968).
The investigations carried out included some aspects 
of the quantitative study of phenacetin metabolism in 
pregnant and non-pregnant rats and in human volunteers 
taking oral contraceptives.
Materials and Methods
Materials
Phenace.tin m.p. 135°C, p-phenetidine, H-acetyl-p- 
aminophenol m.p. 167°C, p-aminophenol m.p. 184°G? and 
diphenylamine m.p. 53°C, were all obtained from British 
Drug Houses and were used as supplied. The phenacetin
administered to human subjects was in tablet form 
complying with the specifications of "Phenacetin Tablets" 
in the British Pharmaceutical Codex, 1963. Each tablet 
contained 300 mg of phenacetin. 2-Hydroxyphenacetin 
was a gift from Dr. L.Prescott.
Silicone rubber (SE30) (Pye-Unicam Ltd.),
Celite 80-100 grade (Pye-Unicam Ltd), Carbowax 20M 
fc'(Hopkin & Williams) and ■ p-glucuronidase (Sigma, bovine 
liver) were all used as supplied.
All solvents used were of analytical grade (British 
Drug Houses).
Gas chromatography of phenacetin and its metabolites
The instrument used was a Pye Unicam Series 104 gas 
chromatograph fitted with a dual flame ionisation/electron . 
capture detector head. The splitter was removed from the 
detector so that the instrument was used as a flame 
ionisation detector. The recorder was a Honeywell model.
5 ft. glass coliimns, 5 mm. internal diameter (Pye 
Unicam Ltd.) were used, and -were packed as follows: the 
stationary phase was dissolved in methylene chloride 
(about 40 ml), and the required amount of supporting 
medium (Celite, 80-100 grade, abowit 10 g.) was added to 
the solution. After well mixing, the methylene chloride 
was removed under reduced pressure in a rotary evaporator 
using a very slow rate of rotation to minimize production 
of * fines1. When all of the solvent had been removed, 
the temperature of the water bath was raised to boiling 
and evaporation under reduced pressure continued for 30 
minutes to thoroughly dry the packing material. The 
packing material was then allowed to cool in a dessicator 
before sieving and packing the 80-100 mesh fraction into 
the column. To fill the column a small wad of glass 
fibre was placed in the shorter arm before attaching a 
connector. A vacuum line was then affixed to the 
connector and the glass fibre plug sucked to the end of
the column. A small amount of packing material was then 
fed into the other end of the column and, with assistance 
from continuous vibration from a "V/hirlimixer", was 
sucked along the tube. In this manner uniform packing 
was achieved. Each new column was conditioned in the 
chromatography oven at 25°C. above the proposed maximum 
operating temperature, with a small flow of nitrogen 
passing through it,for at least 24 hours before use.
The column packings used were based on those used 
by Klutch and Bordun (1968). Eor separating mixtures of 
phenacetin, p-phenetidine and p-aminophenol they used a 
6 ft. column packed with a mixture of SE.30 (1/0 - 
Carbowax 20 Ii (1$) coated on Anakrom AS, 80-90 mesh, 
while for separating phenacetin and E-acetyl-p-aminophenol 
they used a 4 ft. column packed with SE.30 (0.5$) - 
Carbowax 20 M (0.5$) on the same support material. The 
method used by these authors therefore required two 
columns. As I only had a single head flame ionisation 
detector such a method would have involved continual 
changing of columns. I therefore endeavoured to modify 
their method so. that separation and estimation of the 
metabolites of phenacetin could be achieved on one 
column. Three different packings were therefore tried, 
SE.30 and Carbowax 20 M mixed at the following concen­
trations - 1$ of each, 0.6$ of each and 0.3$ of each.
The columns were all 5 ft. in length and the support 
material was Celite.
In the initial investigations all work was carried 
out isothermally at various temperatures between 140°C 
and 200°C v/ith a detector oven temperature of 250°C 
(constant). However, in order to obtain separation of 
all the metabolites on the same column, temperature 
programming was used later. At some of the higher levels 
of sensitivity the base line tended to drift during
temperature programming. The carrier gas used for all 
determinations was' oxygen-free nitrogen at a flow rate 
of 60 ml/minute. Normally 1 yul volumes of solutions of 
the compounds in ethyl acetate were injected into the 
column* No flash heater was available for use so 11.5 cm 
long needles were used to inject the samples.
The retention times of phenacetin, p-phenetidine, 
p-aminophenol, N-acetyl-p- -aminophenol, 2 hydroxyaceto- 
phenetidine and diphenylamine are shown in Table 8.1*
Table 8. 1
G-as-Iiquid chromatography of phenacetin and its metabolites
Compound Retention time (mins) with the following stationary 
phases
A B 0 P
Phenacetin 18.0 5.0 2.5 5.5
p-Phenetidine 1.5 0.5 - 1.8
p-Aminophenol 8.5 2.0 0.5 4.0
2-Hydroxyacetophenetidine - - 12.0
N-acetyl-p-aminophenol - 37.0 17.0 16.0
Piphenylamine - — — 3.5
A: 1 $ w/w SE. 30 - Vfo w/w Carbowax 20M on Celite,5 ft.l80°G.
Bs 0.6$ ;^/w SET30 - 0. 6$*Vw Carbowax 20M on Celite,
5 ft. 200°C.
C: 0.3$ W/w SE.3 0 j - 0.3$ W/w Carbowax 20M on Celite, ^
5 ft. 200° C.
P: 0.3$ w/w SE. 30 - 0.3$ w/w Carbowax 20M on Celite,
5 ft. temperature programmed from 135°C to 205°C.
Initial period 1.0 mill. , rate of increase 32°C. 
per min. final period 20 min.
The column and conditions chosen for routine use 
was -P.
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Diphenylamine was used as an internal standard 
since it possessed a suitable retention time that did 
not interfere with the other components. The p-aminophenol 
had a retention time very close to that of the diphenyl- 
amine but was not detectable in the urine (see later) 
so that the closeness of retention times did not matter.
The retention time of N-hydroxyacetophenetidine could not 
be determined as none was available. Although Klutch 
and Bordun (1968) could not separate N-hydroxyacetophene- 
tidine from phenacetin they could only detect the 
N-hydroxy-metabolite after hydrolysis with ^B-glucuronidase, 
so it would not interfere with the estimation of phenacetin.
The retention times of the individual compounds were 
not affected by mixing with the other compounds. A 
chromatogram of a mixture is shown in Pig. 8.1. The peak 
for N-acetyl-p-aminophenol is seen to tail a little; 
however, the height of the peak was shown to be propor­
tional to amount, so its use is satisfactory. The 
sensitivity towards N-racetyl-p-aminophenol is not very 
great, but the amount to be detected in various urine 
samples is large so that again the method is satisfactory.
Extraction of phenacetin and its metabolites from urine
Known amounts of N-acetyl-p-aminophenol (200yug), 
phenacetin (20 jug) , phenetidine (20 /ig) and p-aminophenol 
(40 /ag) were dissolved in a portion of urine (4 ml).
The urine solution was then extracted as follows. To
4.0 ml. of urine, 2.5 g. of sodium chloride and 1.0 ml. 
of 0.2 M phosphate buffer pH 7.4 were added and the 
mixture was shaken for 15 minutes in 50 ml. stoppered 
tubes with 40 ml. of diethyl ether containing 1.5$ V/v 
isoamyl alcohol. A 20 ml. portion of the ether was 
removed an d 'evaporated to dryness under a stream of air 
in a conical tube immersed in a water-bath at 30°C. The 
residue was taken up in a 100 yul of ethyl acetate 
containing 5 yug of diphenylamine. 1 yul samples were
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'ig. 8. 1.
Gas, chromatogram of phenacetin and some of its
metabolites
Instrument: • Pye 104
Detector : Flame ionisation, 250°C.
Column : 5 {x 5mm. glass. 0.3^ SD30 plus 0.3^
Carbowax-20M on Celite.
Temperature: Programmed- 135°C.-205°C. Initial
period lmin. Rate of increase 32°C. 
per min. Final period 20min.
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then injected on to column D in the gas chromatograph 
using the conditions described above. The diphenylamine 
acts as an internal standard. Quantitative measurements 
made by comparison of peak heights with the heights of 
standard solutions indicated that the percentage 
recoveries were 88$ for N-acetyl-p-aminophenol, 75$ 
for phenacetin, 55$ for p-aminophenol and 16$ for p- 
phenetidine. The low recovery of p-phenetidine was found 
to be due to loss during evaporation of the solvent. By 
adding one drop of concentrated hydrochloric acid to the 
20 ml of ether extract before evaporation this loss was 
prevented. The p-phenetidine was then present as the 
hydrochloride (and so also was the p-aminophenol); the 
free base was released by passing a stream of NH^ over 
the residue for 15 seconds. This increased the 
recovery of phenetidine to 70$ and of p-aminbphenol to 
65$> while' the recoverjr of phenacetin and N-acetyl-p- 
aminophenol remained unaltered. These recoveries were 
considered satisfactory enough to use this method of 
extraction from the urines of animals and humans fed a 
dose of phenacetin. No 2-hydroxyacetophenetidine was 
available at this stage.
Thus, one single extraction with ether was found 
to give a satisfactory method of extracting phenacetin 
and its major metabolites from urine samples in the 
concentrations anticipated.
In rat experiments 4*0 ml of urine were taken 
through the procedure, but in human experiments 8.0 ml 
samples of urine were used, and all the quantities used 
in.the extraction procedure were doubled.
Analysis for total N-acetyl-p-aminophenol (i.e. 
free and conjugated) was carried out as follows: a 
0.2 ml portion of rat urine was buffered with 0c5 ml of 
0.1 N acetate buffer, pH 5.0,containing 1000 units of
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J3-glucuronidase, • and the mixture was incubated at 37°C 
for 24 hours. The mixture was then diluted to 4.0 ml 
with water, l.OwLof 0.2 M phosphate buffer pH 7*4 and 
2,5 g. of sodium chloride were added and the extraction 
was carried out as described above using 40 ml of ether 
containing 1.5$ V/v isoamyl alcohol. For human urine
1.0 ml was treated with 5000 units of J3-glucuronidase 
in 1.0 ml of acetate buffer, and the extraction carried 
out as for rat urine.
Bosage and collection or urine
Each human subject was instructed to collect a 
sample.of urine at 9.00 a.m. on the day of the experiment. 
This served as control urine. Each then took four 
tablets, each containing 300 mg. of phenacetin (1200 mg. 
total dose) and collected the urine for 24 hours.
Samples were kept in a cool place and refriger ated at 
the earliest opportunity. Two male subjects, three 
control female subjects and three female subjects 
taking oral contraceptives, two on "Minovlar” 
(norethisterone acetate and ethinyl oestradiol) and one 
on "Lyndiol" (lynestrenol and mestranol), took part in 
the experiments.
In the rat experiments phenacetin was administered 
as a suspension (10 mg/ml) in 10$ Tween 80, either 
intraperitoneally by injection or orally by intubation, 
at a dose of 100 mg/kg. The - animals were then placed
individually in metabolism cages and the urine collected 
for 24 hours. The cages were rinsed with water to 
remove adhering urine. Urine collected for the 24-hour . 
period prior to phenacetin administration was used as 
control urine. All rats used were female V/istar albinos, 
and pregnancy was established using the technique 
described in chapter five.
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Results and Discussion
Table 8.2 shows the pattern of urinary excretion 
of the major metabolites of phenacetin in control male 
and female human subjects and in females taking oral 
contraceptive agents. The results are expressed as a 
percentage of the dose given.
Table 8. 2
Pattern Of urinary excretion of phenacetin in humans
Percentage of dose excreted as:
Group Subject Phena­
cetin
p-Phene-
tidine
Free
N-acetyl-
p-arnino-
phenol
Conju­
gated
E-acetyl-
n-amino-
phenol
Males M.G.R. 0.27 0.02 2.5 69
W.B.L. 0.22 0.02 .4.1 42
Female
controls
L . E . F .
J.M.C.
0.26
0.20
0.01
0.01
3.5
2.8
73
70
E.D.1T. 0.39 0.10 5.8 12
On oral 
contra­
ceptives
L.B.*
J.W.*
a .ijA
0.48
0.52
0.47
0.40
0.05
0.05
19.5
4.4
2.5
30
40
68
* Minovlar / Lyndiol
It should be mentioned to begin with that obviously 
no firm conclusions can be drawn from the small number of 
subjects used. Results for the controls agree well with 
those obtained by Brodie and Axelrod (1949)> although the 
amount of p-phenetidine is lower than they found. The low 
recovery of conjugated IT-acetyl-p-aminophenol in one male 
subject could well be due to a sample being missed during
the 24 hours. The exceptionally low excretion of 
conjugated N-acetyl-p-aminophenol in one control female 
is unlikely to be due to this reason; it was learned 
after the experiment that this subject was suffering 
from amenorrhoea, but it is unlikely that this would 
produce such a difference. The urine was particularly 
dark and contained a lot of sediment. All three 
subjects taking oral contraceptives showed an increased 
excretion of unchanged phenacetin, and possibly also of 
p-phenetidine. In one case there was a large increase 
in the excretion of unconjugated N-acetyl-p-aminophenol. 
In the two subjects taking Minovlar there also appeared 
to be a decreased excretion of conjugated N-acetyl-p- 
aminophenol. This was not the case with the subject 
taking Lyndiol. No urine samples were collected after 
the first 24 hours so whether the remainder of the dose 
is excreted after this time or whether some other 
metabolite is produced is not known. One might suggest 
that the metabolism of phenacetin by dealkylation and 
the subsequent conjugation of N-acetyl-p-aminophenol 
with glucuronic acid is inhibited. These findings are 
thus similar to those described by Crawford and Rudofsky 
(1966) who found that the amount of unchanged pethidine 
and promazine in the urine of human subjects on the pill 
is greater than in controls. However, the number of 
findings described here is small, and confirmation or 
otherwise will have to await larger numbers of observa­
tions. Moreover, the effects described need not be due 
to alterations in metabolism, and could be attributable 
to altered excretion or absorption.
The pattern of urinary excretion of phenacetin and 
its metabolites by pregnant and non-pregnant rats has 
been determined in animals dosed both intraperitoneally 
and orally. The results are shown in Tables 8.3 and 8.4 
respectively.
Table 8, 3
Pattern of urinary excretion of phenacetin and its 
metabolites in pregnant and non-pregnant rats dosed
intraperitoneallv
Group
Percentage of dose excreted as:
. .. .. . ......  i .. . . .....- ...
Unchanged
Phenacetin
Pheneti-
dine
Pree
N-acetyl-
p-amino­
phenol
Conjug­
ated N- 
acetyl- 
p-amino- 
nhenol
Non-pregnant 0.25 0.06 4.5 2.4
0.33 0.21 14.9 0.9
0.28 0.50 2.5 22.6
0.15 0.05 1.3 11.2
Kean ± S.E.M. 0.25 £ 0.04 o.2i io.io 5.8^3.1 9* 3-5.0
20-day
pregnant
0.09
0.18
0.00
0.20
0.8
7.9
2.3
11.7
0.17 0.18 1.2 11.4 ,
Mean - S.E.M. 0.15 - 0.03 0.13^0.06 3.3 - 2 . 2 8.4-3.1
The results obtained after intraperitoneal admini­
stration were not very consistent, and only a small 
percentage of the total dose was recovered. This could 
be due to insufficient hydrolysis of conjugates of 
N-acetyl-p-aminophenol by the JB-glucuronidase, possibly 
due to the presence of an inhibitor of the JB-glucuronidase 
in the rat urine. Alternatively, since the recovery from 
human urine was good but from rat urine it was poor, 
it is possible that in the rat the phenacetin is excreted 
in the bile as rats are good biliary excreters. Tests 
for complete hydrolysis of the glucuronide could not be
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carried out as no reference N-acetyl-p-aminophenol 
glucuronide was available. A comparison between the 
amount of conjugated N-acetyl-p-aminophenol excreted by 
the pregnant and non-pregnant rats is, therefore, 
probably not justified, but nevertheless the ranges are 
approximately the same. As far as the unconjugated 
metabolites were concerned, there appeared to be little 
difference between the twenty-four hour excretion of 
p-phenetidine and N-acetyl-p-aminophenol in pregnant 
and non-pregnant rats. The amount of unchanged 
phenacetin excreted was slightly lower in the pregnant 
animals. No metabolites were detectable in the second 
twenty-four hour urine samples.
Table 8. 4
Pattern of urinary excretion of phenacetin and its 
.metabolites in pregnant and hou-pregnant rats
dosed orally
Group
Percentage of Dose excreted as:
Unchanged
Phenacetin
Pheneti-
dine
Pree N- 
acetyl- 
p-amino- 
phenol
Conjugated
N-acetyl-
p-amino-
phenol
Non-pregnant 0.06 0.76 2.9 4.7
0.10 0.28 2.8 6.7
0.07 0.17 •3.5 13.6
0.06 0.10 2.5 14.6
Mean - S.E.M. 0.07-0.01 0.33-0.15 2.9-0.2 9.9-2.4
20-day 0.10 0.00 2.2 12.0
pregnant 0.06 0.10 2.6 11.4
Mean 0.08 0.05 2.4 11.7
The results obtained after oral administration 
were rather more consistent, but the overall recovery was 
again low. There did not appear to be any difference 
between the pattern of excretion of the pregnant animals 
and the non-pregnants.
These results in pregnant rats do not indicate that 
the metabolism of phenacetin is significantly altered 
during pregnancy. Thus, there is certainly no evidence 
of inhibition of metabolism in vivo as one might expect 
from the in vitro studies. However, the rate of metabolism 
could be inhibited and the total metabolism still be 
completed within twenty-four hours. It would therefore 
be worthwhile measuring the concentration of phenacetin 
and its metabolites in the blood -and urine, at different 
time intervals after dosage to determine the rates of 
metabolism.
Conclusion
The method described by Klutch and Bordun (1968) 
for the extraction and gas chromatographic separation 
of phenacetin and its metabolites, which required the use 
of two separate‘columns, has been modified to give a 
simplified quantitative method for the estimation of these 
compounds in urine, which involves the use of a single 
column. Thus, phenacetin, p-phenetidine and N-acetyl- 
p-phenetidine and N-acetyl-p-aminophenol present 
together in a sample of urine can be extracted into ether, 
and separated on the same column. 2-Hydroxyphenacetin can 
be separated on this column, but its extraction has not 
been studied. p-Aminophenol can also be separated on the. 
column, but it is unstable and cannot be estimated in 
urine samples. The behaviour of N-hydroxyphenacetin under 
these conditions has not been investigated as none was 
available.
The method applied to humans and rats dosed with phena­
cetin has shown that women taking oral contraceptives may 
show a mild degree of inhibition of phenacetin metabolism, 
while pregnant rats do not show any difference to non-pregnant 
animals in their pattern of excretion of phenacetin and its 
metabolites.
CHAPTER IX.
GENERAL DISCUSSION
The object of this final chapter is to try to 
correlate the in vitro.results from Chapters five and 
six with the in vivo results from Chapters seven and 
eight, and also to suggest further work which would 
give a deeper insight into the effect of pregnancy and 
oral contraceptives on drug metabolism.
It was shown in Chapter five that drug-metabolizing 
enzymes responsible for aromatic hydroxylation and 
glucuronidation, but not for nitroreduction, are 
inhibited in the full-term pregnant rat liver when 
measured in vitro and expressed in terms of unit liver 
weight; similarly the microsomal cytochrome P450 is 
decreased. The in vivo demonstration that the duration 
of action of hexobarbitone is increased in full-term 
pregnant rats shows that there is agreement between 
the in vitro and in vivo results. Contrary to these 
findings, no evidence was found from the pattern of 
twenty-four hour urinary excretion of phenacetin and 
its metabolites that the metabolism of this drug was 
inhibited in the full-term pregnant rat. However, only 
the overall twenty-four hour picture was obtained during 
which time metabolism could have been delayed, yet still 
completed. It would be of interest to compare the rates 
of phenacetin metabolism in pregnant and non-pregnant 
rats by measuring the blood and urine levels of 
phenacetin and its metabolites at different time intervals 
after a single dose. An alternative explanation for the 
lack of effect of pregnancy on phenacetin metabolism 
could be that as with nitroreduction, the metabolism of 
phenacetin is, in fact, not altered by pregnancy.
However, the major route of metabolism is by dealkylation 
which takes place by a hydroxylation reaction and might 
be expected, therefore, to be similar to biphenyl and 
hexobarbit one.
The activity of the drug-metabolizing enzyme 
systems responsible for aromatic hydroxylation, nitro­
reduction and' glucuronidation together with cytochrome 
P450 and microsomal protein content of livers from 15-16 
day pregnant rats showed no significant difference from 
non-pregnant rats although the cytochrome P450 and the 
hydroxylase were slightly decreased. The duration of 
action of hexobarbitone was, though, significantly 
increased in 15-16 day pregnant rats, but the increase 
was not as great as with the full-term rats so that both 
in vitro and in vivo results agree qualitatively.
Although both in vitro and in vivo studies showed 
that pregnancy in the rat has an inhibitory effect on 
drug metabolism, it is important to note that there is 
also an increase in liver weight so that the total 
liver activity of drug-metabolizing enzymes in the 
pregnant rat is equal to the non-pregnant.- Hence, 
when the same total-dose of hexobarbitone is given to 
full-term pregnant rats there is no difference in 
sleeping time. With the 15-16 day pregnant rats, where 
the total liver cytochrome P450 is increased, the 
duration of action of the same total dose of hexobarbitone 
is decreased. Here again there is direct agreement 
between in vitro enzymic studies and in vivo studies.
In vitro studies demonstrated that there is no 
drug-metabolizing enzyme activity or cytochrome P450 
present in rat placentae and foetal livers. Although 
no direct in vivo experiments were carried out with 
these tissues, it would be expected that any activity in 
them might lead to a more rapid, breakdown of hexobarbitone 
and, therefore, a decreased duration of action,which is 
not the case. . It can be concluded that neither the 
placentae nor foetal livers supplement the drug- 
metabolizing activity of the maternal liver.
Previous studies (Hsia et al 1963) had suggested 
that the high levels of circulating hormones during 
pregnancy might be responsible for impaired conjugation 
reactions during pregnancy, and this idea was extended 
to cover metabolic transformations when it was shown 
that steroid hormones could competitively inhibit 
microsomal drug-metabolism,(Tephly and Mannering,1964;
1968; Juchau and Pouts, 1966; Wada et al 1968). The 
effect of in vitro addition of natural oestrogens and 
progestogens on the enzymes studied in the pregnant 
rat was investigated and it was shown that both types 
of steroid could inhibit these reactions, probably 
competitively, but only at relatively high concentra­
tions. In vivo studies involving pretreatment of 
female rats for varying lengths of time with progesterone 
and oestradiol, both alone and combined, did not, however, 
produce any inhibitory effects on microsomal drug 
metabolism, nor alter the duration of action of hexo­
barbitone, except one hour’s pretreatment with proges­
terone which increased significantly the hexobarbitone anaes­
thesia/' This could hhve been due to impaired: metabolism of th 
hexobarbitone but could also have been due to the anaesthetic 
action of progesterone itself. The pretreatment studies 
did not appear, therefore, to support the suggestion that 
the high levels of circulating steroid hormones in 
pregnancy are responsible for the inhibition of drug 
metabolism. However, only one dose level of the steroids 
was used and the dosage was -peridioc. rather than continuous 
so that a consistently high level of circulating steroid 
would not have been maintained as in pregnancy. This 
effect might be overcome by using liver perfusion 
techniques where a high level of steroid could be main­
tained in the perfusate.
Thus, the very high levels of steroid required to 
produce inhibition in vitro together with the failure of
pretreatment studies with steroids to demonstrate any 
inhibition of drug metabolism suggest that the inhibitory 
effect of pregnancy on drug metabolism may not be due 
directly to inhibition from steroids. This idea is 
given support by the fact that in late pregnancy in the 
rat there is a decrease in the cytochrome P450 concentra­
tion in the liver and this could account for the impaired 
drug metabolism.
A determination of the kinetic constants of the 
enzyme systems in pregnant and non-pregnant rats would 
shed some light on the cause of the inhibitory effect of 
pregnancy. If the apparent Michaelis constant (K^) for 
the enzyme reaction, differs between the pregnant and 
non-pregnant rat, it would show that a competitive 
mechanism of inhibition was operating and would suggest 
that the circulating steroids were responsible. If, on 
the other hand, K®. remained the same and T/max f°r the 
system decreased,this would indicate that the amount of 
enzyme present was limiting the reaction. Since the 
completion of this work Guarino et al (1969) have 
described the effect of pregnancy in rats on the kinetic 
constants for the hepatic microsomal hydroxylation of 
aniline and the demethylation of ethylmorphine. They 
showed that in 20-day pregnant rats there is a significant 
decrease in Vmax for both aniline hydroxylase and ethyl­
morphine, but the apparent Kms for both the enzymes did 
not differ between the 20-day pregnant and non-pregnant 
rat. Moreover, there is a decrease in microsomal 
cytochrome P450 in the 20-day pregnant rat liver and 
there is a quantitative correlation between this decrease 
and Vmax the two enzymes. These effects were not 
apparent in 6 and 14-day pregnant rats. These results, 
therefore, substantiate the findings of this thesis that 
the inhibitory effect of pregnancy on hepatic drug- 
metabolizing enzymes in the rat is probably .due to the
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decreased amount of cytochrome P450 in the liver and 
probably not due to competitive inhibition from steroid 
hormones.
It is still possible that the steroid hormones 
produced during pregnancy are responsible for the 
decrease in cytochrome P450. However, pretreatment of 
female rats for varying lengths of time with progesterone 
and oestradiol both alone and combined, albeit at only 
one dose level, did not produce any decrease in 
cytochrome P450 in the liver. Purther evidence that the 
steroid hormones are not responsible comes from the fact 
that the peak levels of these hormones during pregnancy 
in the rat do not correspond with the peak of the 
inhibitory effects, in fact steroid levels are raised 
throughout pregnancy, but the inhibitory effect on drug 
metabolism is only apparent during late pregnancy.
Impaired drug metabolism has been reported in many 
states characterized by rapid growth, and it is suggested 
that a common factor such as growth hormone may cause 
this effect. Such a factor may be responsible for the 
inhibitory effect of pregnancy on drug metabolism since 
this state is also characterized by rapid growth.
Moreover, it is only over the final few days of pregnancy 
that the inhibition develops, and it is over this time 
that the level of growth hormone increases most.
Recently Wilson (1969 a and 1969 b) has identified 
somatotropin (growth hormone) as the pituitary hormone 
responsible for decreasing liver metabolism of hexobarbitone, 
ethylmorphine and aminopyrine in rats. Porty-eight hours 
after a single subcutaneous injection of 1.73 units of 
somatotropin (but not after adrenocorticotropic hormone 
or prolactin) the metabolism of these three drugs is 
inhibited by approximately 2 5 c/° (Wilson 1969 a), which is 
similar to the degree of inhibition produced by pregnancy 
in the rat. Thus it seems possible that the increased
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level of growth hormone may he responsible for the 
inhibitory effect of pregnancy on drug metabolism. It 
will be interesting t o •determine, whether growth hormone 
causes a decrease in cytochrome P450 levels in the 
liver; it would seem most probable that it would act 
by interfering with protein synthesis in some way.
Since iron is a vital component of haemoproteins 
it is possible that a deficiency of this element during 
pregnancy may result in a decrease in liver cytochrome 
P450. It would, therefore, be of considerable interest 
to investigate the hepatic drug-metabolizing enzyme 
activities in pregnant and non-pregnant rats fed on 
diets containing a deficiency and an excess of iron.
What is the therapeutic significance of the finding 
that pregnancy in the rat has an inhibitory effect on 
drug metabolism? The first point is the question of 
extrapolating from one species to another. Indeed it 
has been shown here that the rabbit shows a different 
pattern of response in the effect of pregnancy on drug 
metabolism to the rat. It is naturally difficult to 
investigate drug metabolism in the pregnant human in 
view of possible adverse effects on the foetus, but 
where it is essential to administer drugs their 
metabolism could be studied and compared with controls. 
Secondly, with many drugs it is not the metabolism that 
is the rate limiting step in-determining the duration 
of action; other factors such as absorption, distribution 
and excretion may be more important in limiting drug 
action. Finally, even if the pregnant human does show, 
similar effects to the pregnant rat and the rate of 
metabolism does control the drug action, it should be 
remembered that the total ability of the pregnant rat 
to metabolize a drug was the same as the non-pregnant, 
so as long as the same total dose of drug is given to 
the pregnant human as the non-pregnant, there will 
probably be little difference•in therapeutic response.
The synthetic steroids used as oral contraceptive 
agents produced inhibition of microsomal hydroxylation 
in a similar manner to the natural steroids of pregnancy 
when added in vitro to rat liver preparations. Pre­
treatment studies with these steroids for three days 
showed no inhibitory or stimulatory effect on drug- 
metabolizing enzymes. Pretreatment one hour before with 
norethynodrel, however, did show an inhibitory effect on 
aromatic hydroxylation, -but no decrease in cytochrome P450. 
Eighteen days treatment with a mixture of progestogen and 
oestrogen caused an increase in aromatic hydroxylation 
and a decrease in duration of action of hexobarbitone but 
no increase in microsomal cytochrome P450. Prolonged 
oral treatment of rats with a low dose of two progestogens 
caused a decrease in aromatic hydroxylation, but had no 
effect on cytochrome P450; a third progestogen similarly 
studied did not produce the decrease. The duration of 
action of hexobarbitone did not always correlate with the 
in vitro findings. Thus, one hour’s pretreatment with 
norethynodrel did prolong the duration of action, but all 
other pretreatments decreased the duration of'action 
suggesting that the metabolism of hexobarbitone had been 
stimulated. The general trend of the effect of oral 
contraceptive steroids on drug metabolism appeared to be 
an initial inhibition followed by stimulation. The content 
of cytochrome P450, however, was not altered by any pre- 
treatment with oral contraceptive steroids.
As with the pretreatment studies with the natural 
steroids, the synthetic steroids were only given periodically 
and, therefore, high blood levels would not be maintained. 
However, this is how the oral contraceptive pill is normally 
taken, and it represents a major difference between the 
steroid picture during pregnancy and in women using the 
pill. The fact that one hour's pretreatment of rats with
norethynodrel caused inhibition of metabolism might 
suggest that its basic, action is inhibitory, and it 
would.,, therefore, be worth investigating its effect 
using the perfused liver.
The in vivo studies with phenacetin were only 
carried out on a small number of human subjects, but 
these gave an indication of slight impairment of 
metabolism. It may be that the effect of oral contra­
ceptives on drug metabolism depends on the rate of 
metabolism of the component steroids such that if a 
steroid is slowly metabolized it may exert its effect 
for longer. Since there is a large range of oral 
contraceptives on the market it is possible that some 
might produce inhibition, others no effect, and still 
others stimulation of drug metabolism. Further studies 
involving measuring rates of metabolism and excretion 
of phenacetin and other drugs and their metabolites 
need to be undertaken.
It is certainly apparent that the effect of oral 
contraceptive steroids on drug metabolism in the rat 
is not the same as the effect of pregnancy. This is 
best illustrated by the fact that there is no decrease 
in microsomal cytochrome P450 and that the duration of 
action of hexobarbitone is decreased in the steroid 
treated rat, whereas in the pregnant rat there is a 
decrease in the microsomal cytochrome P450 and an 
increase in the duration of action of hexobarbitone.
In conclusion it can be stated that during late 
pregnancy in the rat there is a decreased concentration 
of cytochrome P450 in the liver which is accompanied by 
a consequent decrease in the activity of some, but not 
all; drug-metabolizing enzymes; these decreases are 
compensated for by an increase in size of the liver, 
and are not supplemented by any activity in the placenta
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or foetal liver. These in vitro effects are reflected 
in vivo by the duration of action of hexobarbitone, 
but do not alter the pattern of metabolism of 
phenacetin. The effect of late pregnancy has not been 
* reproduced by pretreatment of rats with natural steroids 
nor by synthetic steroids used as oral contraceptive 
agents. The latter, in fact, seem to produce the opposite 
effect, i.e. a stimulation of drug metabolism, at least in 
the rat.
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